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The Involvement of Calpastatin in Myoblast Fusion 
by Matthew Peter Kent 
Myoblast fusion is adynamic event that can be recreated ill pitrousing tissue 
culture. Portions of eDNA encoding inhibitory and non-inhibitory domains of ovine 
calpastatin were expressed in murine C2C12 myoblasts as fusion proteins with 
enhanced green fluorescent protein (EGFP). The ability of these myoblasts to fuse 
into myotubes, the dynamics of particular indicator proteins, and the subcellular 
localisation of fluorescence were assessed. 
Formation of skeletal muscle is a multistage process characterised by the 
biochemical and morphological maturation of myoblasts (mononucleate) into 
myotubes (multinucleate). A key event in the transition from myoblast to myotube is 
fusion. Fusion is a dynamic event which can be induced and monitored by culturing 
muscle cells ill pi/roo An expanding body of evidence indicates that proteolytic activity 
from the ubiquitous calpains (~- and m-) is obligatory for fusion and myotube 
development. 
Calpastatin is the specific endogenous inhibitor of calpain. Domains 1, 2, 3 
and 4 are homologous and possess inhibitory potential. The N-terminal domain L 
may playa role in regulating calpastatin action and / or directing the localisation of 
calpastatin to the plasma membrane. Proteolytic activity is prevalent around the 
plasma membrane during fusion. It was decided to investigate domain L's potential 
role in targeting calpastatin to this region. 
The polymerase chain reaction (PCR) was used to amplify regions of ovine 
calpastatin eDNA corresponding to domains L, 1 and L1. The PCR reaction enabled 
the introduction of restriction enzyme sites to permit in-frame ligation of the 
ii 
amplimers into a prokaryotic expression vector. Using Eco;'; domains Land 1 of 
ovine calpastatin were expressed separately and together, in combination with 
glutathione S-transferase (GST). The GST tag enabled purification of the expressed 
product which was then characterised in terms of heat stability, molecular weight and 
activity. The proteins behaved normally in respect to their ability to inhibit calpain, 
and were used as antigens for the successful production of polyclonal anti-calpastatin 
antibodies. 
C2C12 myoblasts were cultured under proliferation conditions before being 
induced to fuse. The rate and extent of fusion in control cells was assessed by 
microscopic examination and by fluorescent automated cell sorting (F ACS). F ACS 
analysis was unable to accurately distinguish myotubes and significantly 
underestimated the percentage fusion at all times. Three proteins (myosin, desmin 
and troponin T) were reported to be indicators of biochemical differentiation while 
des min and troponin T are also potential substrates for calpain. Levels of these 
proteins and patterns of migration were determined using Western analysis. While 
the levels of all three proteins reflected biochemical differentiation, only troponin T 
Westerns exhibited truncation products. It could not be concluded if this truncation 
was associated with calpain activity. Levels and fragmentation patterns of ).l-calpain, 
m-calpain and calpastatin were also assessed. Both proteases were detected in C2C12 
extract in an active form. Despite one of the polyclonal anti-calpastatin antibodies 
demonstrating immunoreactivity against native murine calpastatin, no endogenous 
calpastatin was detected in C2C12 extract. 
The polymerase chain reaction (PCR) approach used to produce prokaryotic 
expression vectors was also used to produce eukaryotic expression vectors. 
Amplimers of domains L, 1 and Ll were ligated into a mammalian expression vector 
containing EGFP cDNA. Conditions for transfection of C2C12 myoblasts were 
optimised using a control EGFP expressing plasmid. Cells were transfected with one 
of four expression plasmids (three experimental plasmids and one control), 
encouraged to proliferate and induced to fuse. There were no differences in terms of 
fusion rate or extent attributable to the expression of calpastatin. FACS analysis did 
not reveal any qualitative differences in terms of fluorescence between treatments. 
ill 
Western blot analysis of myosin, desmin, troponin T, ~-calpain and m-calpain did 
not detect any qualitative or quantitative differences. Western analysis of the 
expressed calpastatin products revealed complex banding patterns which may reflect 
structural instability and / or proteolytic susceptibility. A schematic model is 
proposed which seeks to depict the truncation points. 
Finally, fluorescent microscopy and confocal microscopy were used to 
localise the fluorescent component of the recombinant calpastatin - EGFP hybrids. 
Examination of transfected cells indicated that the active component of the 
expressed calpastatin was localised, together with EGPF, within the nucleus. In 
contrast, domain L did not influence the subcellular localisation of EGFP, although 
this may be explained by the probable separation of domain L from EGFP suggested 
in the schematic model. 
KEYWORDS: myoblast fusion, C2C12, proteolysis, calpain, calpastatin 
domains, recombinant protein, glutathione S-transferase (GST), enhanced 
green fluorescent protein (EGFP), subcellular localisation, fluorescence, 
fluorescent automated cell sorting (F ACS). 
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Chapter 1 
Review of Literature 
1.1 Muscle and myoblast fusion 
Processes associated with muscle development have attracted considerable 
interest in recent years. One reason for this is that muscle represents a good example 
of specialised tissue differentiation and growth. Mature skeletal muscle cells are 
permanently multinuclear and non-mitotic, and form the foundation of the muscle 
fibre. These fibres are composed of many multinucleate myotubes which are formed 
during embryogenesis by the fusion of mononucleate myoblasts (see Figure 1.1). 
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Figure 1.1 Schematic diagram showing the general development of skeletal muscle. 
Precursor cells (myoblasts) arise from pluripotent stem cells (progenitor cells). Myoblasts proliferate 
until they reach a stage at which cell division ceases. Fusion is initiated and concurrenlly muscle 
specific proteins are produced (differentiation). Following the formation of multinucleate myotubes, 
further maturation occurs in the form of innervation, and relocation of nuclei to the tissue periphery 
(adapted from Huynen 1994). 
The process of myoblast fusion within a primary cell culture was first 
witnessed in the late 1950's (Holtzer ct al, 1958). Since this time several myoblast cell 
lines have become available exhibiting continuous multiplication while retaining the 
capacity to differentiate and fuse (Yaffe, 1968). These cultures are invaluable tools 
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for examining myogenesis, and have given rise to several excellent reviews describing 
aspects of this process (Wakelam 1985; Olsen 1992; Stockdale 1994). 
1.1.1 Embryonic development of muscle 
Muscle is derived from the lateral plate and paraxial somitic mesoderm during 
embryoni~ development (Goldspink 1974). The first discernible step in myogenesis is 
the accumulation of mitotically active cells at sites destined to later become muscle. 
These myogenic progenitor cells enter a phase of determination, become spindle 
shaped and proliferate. Mammalian muscles are variable with respect to their 
position, size, shape and contractile properties. Consequently it was recognised that 
myoblasts do not represent an homogeneous population, but rather one that is 
composed of distinct myogenic sub-lineages (Donoghue & Sanes 1994). Proliferation 
continues during embryogenesis up until a point at which myoblasts withdraw from 
the cell cycle and differentiate both biochemically and morphologically. The trigger 
for this transition is unknown. 
1.1.2 Biochemical differentiation 
The biochemical differentiation of a myogenic progenitor into a mature 
myoblast is characterised by the cell exiting the cell cycle, the expression of lineage 
determination genes, and the appearance of typical muscle proteins such as myosin 
and actin (Okazaki & Holtzer 1966). The differential expression of lineage 
determination genes is crucial for committing cells to a particular myogenic path 
(Olsen 1992). Members oEthe myogenic transcription factor gene family are 
important agents in this transmutation. This family includes MyoD1, myogenin, 
MRF4 and myf5 genes, all of which produce basic helix-loop-helix master regulatory 
nuclear proteins (Buckingham 1992). These genes appear to be pivotal in myogenic 
determination and their expression can even force cells of a different parentage into 
becoming myoblasts (Filvaroff & Derynck 1996). The complex interaction between 
genes and gene products makes the muscle development cascade an auto- and cross-
regulatory network where the activity of one member may influence its own activity 
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or the activity of others (Ii et aI., 1992; Rudnicki et al., 1992; Weintraub 1993; 
Kaushal et aI., 1994). 
1.1.3 Morphological differentiation 
A series of events characterise morphological differentiation. After 
withdrawing from the cell cycle, recognition takes place, cell-cell contact is 
established and adhesion occurs. The initial recognition step assists fusion between 
myoblasts, and precludes fusion between dissimilar cell types (Wakelam 1985). After 
cell-cell contact myoblasts elongate and align with each other, leading to parallel 
alignment along the long axis of the myoblast. Both recognition and alignment ar~ 
likely to involve muscle specific proteins, which may only appear at a specific stage of 
biochemical differentiation. Adhesion was recognised in experiments where 
myoblasts were cultured under fusion permissive conditions and progressively 
became undissociable before they were recognisably multinucleate (Wakelam 1985). 
1.1.3.1 Myoblast Fusion 
Fusion between two myoblasts or a myoblast and a myotube takes place after 
alignment. It is now generally accepted that fusion results from a series of distinct 
events. Doberstein et al. (1997) produced an excellent article which describes the 
morphological changes together with an analysis of gene expression. Although their 
work utilises the fruit fly (Drosophila melanogastei» as a model system, the process of 
myogenesis in this species shares many characteristics with myoblast fusion in 
vertebrates. Initially, in prefusion myoblasts, an intense concentration of vesicles 
appear touching the cytoplasmic face of the juxtaposed plasma membranes. The 
vesicles pair up across the membranes and an electron-dense material, associated 
with the plasma membrane and accumulating in the extracellular space, forms 
between paired vesicles. This morphology may cover 111m2 of the cell surface and is 
named a "prefusion complex". Other characteristic features include stretches of 
electron-dense material :=::500nm long which form along regions of membrane 
breakdown. These have also been reported in vertebrate myoblasts where they are 
called membrane plaques. Although they are rare relative to pre fusion complexes, the 
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authors suggest they result from vesicle pairing. Cytoplasmic continuity is established 
through multiple pores of local fusion between opposed plasma membranes. 
Membrane vesiculates along the zone of contact and forms sacs enclosing what was 
formerly extracellular space. These vesicles become progressively rounder as the 
membrane breaks up and are later recycled in a manner not clearly understood. 
These observations provide the foundation for the model of myoblast fusion shown 
in Figure 1.2 (Doberstein et al, 1997). 
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Figure 1.2 Diagram showing significant morphological changes occurring at the 
ultrastructural level during the fusion process (Doberstein et al,.1997). 
Myoblast fusion is specifically calcium dependent and other divalent cations 
cannot substitute for calcium, although they may playa supporting role (petrie et al, 
1996). The in vitro optimal calcium concentration for fusion is l.4mM. Reducing this 
to O.3mM inhibits fusion. Proliferation and alignment seem independent of calcium 
concentration. 
Wakelam (1985) has reviewed the research characterising myoblast surface 
biochemistry during fusion. Generally, there are no obvious changes in lipid 
composition of the plasma membrane correlating with transitions and phases in 
myoblast fusion. However, membrane fluidity appeared to be a critical factor in 
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fusion competence which stimulated interest in surface protein changes. Research 
has focused upon aspects of protein synthesis, accumulation, modification and 
degradation, and there is considerable information describing the fluctuations in 
specific surface proteins. Electrophoresis of surface proteins shows a general trend 
towards a decline in high molecular weight proteins and a greater amount of low 
molecular weight proteins, possibly indicating proteolytic involvement. 
1.2 The Calpain Protease 
Thirty-five years ago, Gurhoff (1964) reported the existence of a calcium-
dependent soluble protease that ~ould later be named "calpain" (Murachi 1989). 
Calcium-dependent proteolytic activity has since been detected in many different 
species and tissues, and several distinct members have been added to the family. 
Despite their ubiquitous nature, a clear physiological function for these enzymes 
remains elusive. However, substantial research has been carried out and a number of 
review papers have highlighted significant advances (Suzuki et aI., 1987; Croall & 
Demartino 1991; Melloni & Pontremoli 1991; Saido et aI., 1994b; ] ohnson & 
Guttmann 1997; Sorimachi et aI., 1997). 
1.2.1 Calpain Structure and Function 
Two ubiquitous calpains were the first members of this family to be 
described in detail. These are known as l1-calpain (or calpain I, calcium-dependent 
neutral protease (CANP-1)) and m-calpain (or calpain II, (CANP-2)). The distinction 
between them is based upon either a 11M or mM calcium requirement for half-
maximal activity in vitro (Mellgren 1980; Dayton et aI., 1981). Both proteins have been 
purified, and characterised as cysteine proteases. 
The native enzymes are found as heterodimers with subunit molecular 
weights of 80 kDa and 30 kDa (Suzuki 1990). Peptide mapping, cDNA sequence 
analysis and immunological techniques demonstrate that the small subunit originates 
from a single gene, while 11- and m-calpain large subunits arise from two separate 
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genes. Considerable cDNA sequence homology exists between /1- and m-calpain, 
with particularly high homology found in the proteolytic region. Comparing the 
peptide sequences from different species also reveals significant homology, indicating 
evolutionary conservation. The large subunit of /1- and m-calpain comprises four 
domains, while the smaller subunit is partitioned into two domains (see Figure 1.3). 
II III IV 
Ca2+ BindingProtease Domain Domain 80 kDa 
V VI 
Pro-peptide Region? 
30 kDa 
Hydrophobic 
Figure 1.3 Schematic diagram showing the domain structure or the ubiquitous ~- and m­
calpain. 
The role of each domain may be suggested by comparing it to other defined 
proteins. Domain II includes the active site, while domain IV contains EF - hand 
structures defining it as a calcium-bincling domain. Domains 1 and III remain 
functionally nondescript, although autoproteolytic modification of the N-terminus of 
domain 1 during protease activation may hint at a regulatory role. With respect to the 
small subunit, two domains 01 and VI) can be structurally defined. Domain V 
contains a predominance of hydrophobic residues, which may relate to the protease 
associating with the plasma membrane. Similarity between domains IV and VI, 
establish that the latter also functions as a calcium-binding domain. 
It is unclear if the two subunits remain associated during in vivo proteolysis. 
Co-immunoprecipitation studies have shown the subunits remain associated during 
substrate proteolysis (Zhang & Mellgren 1996), and reports of bacterially expressed 
large and small subunits show that formation of a heterodimer is obligatory for 
activity (Graham-Siegenthaler et a/., 1994; Eke et al., 1995; Simon et a/., 1995). 
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However, Yoshizawa et al.} (1995a) reported that the calpain subunits dissociate in 
the presence of calcium, and that this event is essential for enzymatic activity. 
Moreover, Meyer ct a/. (1996) expressed the large subunit of human Jl-calpain in 
insect cells and were able to detect high levels of proteolytic activity. It is possible 
that the subunit could associate with naturally expressed small subunit of Jl-calpain. 
This protein subunit has been detected in Drosophila (pinter ct a/., 1992), but not in 
bacteria. Furthermore, Y oshizawa ct a/. (1995b) demonstrated that under optimal 
refolding conditions the re-natured large subunit had full enzyme activity in vitro, 
even in the absence of the small subunit. With respect to Meyer's work (Meyer ct a/., 
1996) it should be noted that expression of active large subunit calpain has not been 
reproduced in other laboratories despite concerted efforts (Goll; personal 
communication 2001). 
1.2.2 Catalytic properties of calpain 
The calpain active site contains cysteine and histidine residues characteristic 
of cysteine proteases, and a conserved asparagine residue appears crucial in stabilising . 
this pairing (Simon ct a/., 1995). Calpains are inhibited by agents such leupeptin and 
E-64, which also inhibit other sulfhydryl proteases, and chelating agents such as 
EDTA and EGTA. The most obvious catalytic difference between the two 
ubiquitous enzymes is their dissimilar demand for calcium. At micromolar calcium 
concentrations (5 - 50 JlM) Jl-calpain reaches half-maximal activity, which contrasts 
with the millimolar calcium demands of m-calpain to attain the same degree of 
activity. The wide range of reported calcium requirements may be due to variations in 
experimental conditions, especially the ionic strength of in vitro preparations (Elce et 
a/., 1997). These requirements are intriguing because under normal conditions in vivo 
calcium concentrations range between 100 and 200 nM with transient increases up 
to 500 - 800 nM occurring at certain stages of cell division (poenie et a/., 1985; 1986; 
Bitar et a/., 1986), and with certain localised concentrations of calcium reaching 30 
JlM (Davies & Hallett 1998). The discrepancy between prevailing calcium 
concentrations and calcium concentrations required for calpain activity maybe 
associated with autolysis of both subunits. Specifically, while it is not uncommon for 
proteolytic enzymes to autolyse, autolysis of calpain reduces the calcium 
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concentration required for half-maximal activity (Suzulci et aI., 1981). This is one 
mechanism through which calpains may reduce prohibitive caldum demands. 
1.2.3 Autoproteolytic modification of calpain 
Autolytic conversion of calpain entails the removal ofN-terminal portions 
from both subunits. It is unclear, however, whether it is autolysis of the large or the 
small subunit that is responsible for increased calcium sensitivity and subsequent 
proteolysis, or indeed whether autolysis is obligatory for proteolysis. Kinetic studies 
show that autolysis of J.l- and m-calpain subunits occur at different rates (Saido et aI., 
1994a). In vitro, the large subunit of J.l-calpain degrades rapidly and is swiftly followed 
by small subunit degradation (Saido et aI., 1992a), whereas autolysis of m-calpains 
large subunit takes place more slowly than that of the small. 
Autolysis of J.l-calpain large subunit is a two stage process producing 78 kDa 
and 76 kDa products which result from the initial cleavage of 14 amino acids 
followed by a further 12 amino acids (Inomata et aI., 1988; Zimmerman & Schlaepfer 
1991). Autolysis of m-calpains large subunit is also a two-stage process involving an 
initial loss of 9 amino acid residues, followed by the loss of a further 11 (Brown & 
Crawford 1993). The slightly smaller truncation of m-calpain produces isoforms that 
are almost indiscernible by SDS-PAGE. Extensive autolysis of large subunits from 
both J.l- and m-calpain generates fragments ranging between 21 and 42 kDa 
(Nishimura & Gall 1991; Crawford et aI., 1993). Autolysis of the small subunit 
involves the complete removal of domain V and proceeds through 27 kDa and 23 
kDa intermediates before resulting in an 18 kDa product (McClelland et aI., 1989; 
Hathaway & McClelland 1990). 
Brown & Crawford (1993) observed that increased calcium sensitivity of m-
calpain correlated with the initial autolysis (9 residues) of the large subunit but not 
with truncation of the small subunit. Results from Saido et aI., (1994a) contradict this. 
By employing antibodies specific to either 8 or 18 N-terminal residues of m-calpains 
large subunit, these authors concluded that removal of these regions is not obligatory 
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for increased calcium sensitivity. In fact, truncation of the small subunit was the only 
detectable structural change associated with proteolytic activity. Recently, Elce et al. 
(1997) mutated recombinant rat m-calpain and established that removal of amino-
terminal fragments from the large subunit (and not small subunit autolysis) was 
responsible for enzyme sensitisation. These workers also observed significant effects 
of ionic strength and pH on in vitro enzyme activity and suggest that inconsistencies 
in the literature result from variations in experimental conditions. It has been 
suggested that the increased sensitivity displayed by autolysed calpain is a 
consequence of removal of a region blocking the active site of the proteins. 
However recent work by Hosfield et aI., (1999) has determined from crystallization 
studies that the first 20 - 28 amino acids are located some distance from the active 
site and their removal is not critical for "unblocking" the active site. Moreover, 
Crawford et al. (1993) reported that E64 could bind to the active site of unautolysed 
calpain, indicating this site is functional prior to autolysis. While not dependent upon 
autolysis, this binding does require calcium (Thompson et aI., 1990). 
While there is little doubt that autolysis increases the sensitivity to calcium, 
does calpain exist as an inactive pro-enzyme requiring autolysis for activation, or is it 
active in its native form and simply becomes more sensitive to calcium following 
truncation? The almost synchronous occurrence of autolysis and proteolysis has led 
to the hypothesis that autolytic conversion of a calpain pro-enzyme is the likely 
mechanism of activation. Saido et al. (1994a) reported that autolysis of both ~-calpain 
subunits preceded casein proteolysis, as did autolysis of m-calpains small subunit. 
Significantly autolysis of the large subunit of m-calpain lagged behind casein 
hydrolysis suggesting that truncation of the catalytic subunit is not required for 
activity. As noted, however, large subunit truncation of m-calpain can be difficult to 
detect by SDS-PAGE. In order to detect ~-calpain activity, microtubule-associated 
protein 2 (MAP2), was used as a highly sensitive calpain substrate (Baki et aI., 1996). 
The 76-kDa isoform of ~-calpain was generated in a linear manner in concert with 
the hydrolysis of MAP2, passing through origin. The hydrolytic proftle of MAP2 
exhibited a lag phase when incubated with native ~-calpain, but not when incubated 
with the autolysed enzyme. Thus, the autolytic removal of an N-terminal fragment, 
possibly including an auto-inhibitory region, appears obligatory for proteolysis. 
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This suggestion is challenged by other work which showed significant 
proteolytic activity of J.l-calpain at calcium concentrations (40 - 50 J.lM) which were 
insufficient to simulate autolysis (Cong et aI., 1989). Moreover, a monoclonal 
antibody specific for the calcium binding domain of the small subunit was found to 
increase the calcium demand for m-calpain autolysis without affecting the 
requirements for proteolysis (Cong et aI., 1993). The observation that the calcium 
concentrations required for J.l- and m-calpain autolysis are, or can be made, greater 
then those required for proteolytic action, strongly indicates that the protein does not 
exist as an inactive proenzyme. The lag phase which precedes substrate proteolysis by 
J.l-calpain has been thought to indicate an autolytic "activation" step. However, there 
is an alternative interpretation (Crawford et aI., 1993). Unautolysed J.l-calpain has a 
lower affinity for calcium and maybe the predominant form of the protease at the 
start of experiments exploring the temporal relationship between substrate 
proteolysis and autolysis. As a consequence, the rate of proteolysis will appear low 
initially compared to later stages when autolysis has generated truncated calpain with 
its greater affinity for calcium. More recently, Elce et al. (1997) expressed full length 
recombinant rat m-calpain large subunit containing a mutation which prohibited N-
terminal autolysis but found the mutated calpain was still capable of normal activity. 
One likely effect of J.l- and m-calpain truncation is a decrease in enzyme stability 
(fhompson et aI., 1990; Eke et aI., 1997), which may represent a self-regulation 
stratagem. 
Prolonged autolysis of purified bovine J.l- and m-calpain generates several 
fragments (Nishimura & Goll1991; Crawford et aI., 1993). The largest contains all 
domain II (catalytic domain) and a portion of domain I, but fails to exhibit 
proteolytic activity. Two intermediate fragments, between 20 kDa and 23 kDa, 
embrace domain N and a portion of domain III. The smallest fragment (18-kDa) 
contains the calmodulin-like domain of the small subunit (domain VI). Each 
intermediate fragment can non-covalently associate with the 18 kDa fragment 
(Crawford et aI., 1993). A similar proflle of fragments is seen when chicken calpain is 
allowed to autolyse to completion. Chicken calpain produces a large fragment (54-
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kDa) containing all of domain II, most of domain III and a portion of domain I, and 
degrades to a smaller fragment (37-kDa) with the loss of a portion of domain III. 
Finally, two smaller fragments are produced, a 32-kDa fragment containing domain 
N and some of domain III, and an 18-kDa fragment identical to that from bovine 
calpains. Again, the fragments containing domains N and VI associate non-
covalently. This probably reflects the manner in which the large and small subunits 
bind in the native enzyme, and mayor may not require the full domain sequences. 
Studies investigating calpain autolysis usually employ mM calcium 
concentrations to stimulate an autolytic response. Because supraphysiological 
concentrations of calcium appear to be required for activation of the cal pain system, 
scientists are investigating other in vivo calpain activation theories. 
1.2.4 Calpain activation theories 
Some interest has focused on the fact that 11- and m-calpain undergo 
autolysis, producing isoforms with diminished calcium requirements. In 1987, this 
observation was interpreted by two groups to represent a possible pro-enzyme 
activation mechanism (Mellgren 1987; Suzuki eta/., 1987). More recently, Tompa eta/. 
(1996) has suggested a m~chanism whereby Il-calpain, in the presence of 11M 
calcium, catalyses limited proteolysis of m-calpain alleviating its extreme calcium 
demands. He proposes that this heterolytic, intermolecular reaction represents a 
"calpain cascade" causing activation of 11- and m-calpain. However, a recent paper by 
Thompson et a/. (2000) refutes this hypothesis by demonstrating that after incubation 
of Il-calpain with m-calpain at a 1 : 50 ratio (in the presence of sufficient calcium to 
activate Il-calpain) m-calpain remained intact and its calcium requirements for activity 
remained unchanged. The ratio of m-calpain to Il-calpain is probably a significant 
contributor to this effect, since Tompa et a/. (1996) successfully demonstrated 
proteolysis of m-calpain by Il-calpain by employing a higher ratio of 1 : 5 (Il-calpain : 
m-calpain) in their experiments. While autolysed Il-calpain demonstrates half-
maximal activity at a physiological calcium concentrations (Edmunds et a/. , 1991), 
autolysed m-calpain still demands calcium concentrations in excess of physiological 
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levels despite a 20-50 fold increase in its sensitivity. Moreover, autolytic fragments of 
the calpains are not observed in cell extracts (Edmunds et aI., 1991; Saido et aI., 
1992a) and both /l- and m-calpain have demonstrated relatively long half lives in vivo 
(Zhang et aI., 1996). In strict molecular terms calpain must be active for proteolysis to 
take place and, coupled with the fact that not all available evidence supports the pro-
enzyme theory, autolysis remains an unsubstantiated mechanism of activation. 
In Vliro, calpains show weak calcium-independent hydrophobic associations, 
but strongly hydrophobic regions are exposed following calcium binding 
(Gopalakrishna & Barskey 1985). The hydrophobic nature of the small subunits N-
terminus has given rise to the membrane activation theory (Suzuki et aI., 1987; 
Mellgren 1987). This proposes that calpains activate after associating with plasma 
membrane phospholipids in a calcium dependent manner (Thompson et aI., 1990). 
Specifically, polyphosphoinositides have been shown to promote /l-calpain activity 
(Saido et aI., 1992b). After association take place, calpain undergoes autolysis 
(pontremoli et aI., 1985a; 1985b) and is released into the cytosol. This membrane 
activation theory remains incompletely tested in vivo, although in crude tissue 
preparations containing calcium, calpain has been shown to associate with subcellular 
organelles in a hydrophobic manner (Gopalakrishna & Barskey 1986), and calcium 
dependent binding to erythrocyte plasma membrane (pontremoli et aI., 1985a; 
Molinari et aI., 1994) and to insoluble fraction of rat lenses (Lampi et aI., 1992) has 
also been observed. Additional support for the theory is provided by Michetti et al. 
(1996) who found that erythrocyte calpain released from the membrane following 
autolysis. Interestingly, association appeared to be mediated through the large 
subunit and it may be that membrane affinity requires regions in both subunits 
(Melloni et aI., 1992). 
There is, however, significant doubt concerning the validity of the membrane 
activation theory. Several findings fail to support this theory (Goll et aI., 1989; Goll et 
aI., 1992). Goll suggests that the simplest mechanism for activation is the 
involvement of an "activator". This may be a kinase or phosphatase, whose activity is 
dependent on calcium fluxes, which phosphorylate or dephosphorlyate calpain. This 
modification to calpain increases the calpain binding affinity for calcium. 
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Alternatively, a calmodulin-like protein may bind calcium, deliver it to calpain, and 
have the additional effect of reducing the calcium demands of calpain. Researchers in 
Italy have also proposed the existence of an activator protein which binds calpain 
with a high specificity (pontremoli ef aI., 1990b; Melloni ef aI., 1992; Melloni ef aI., 
2000b). In erythrocytes, the protein (40 kDa) is associated with the plasma 
membrane, possibly through another membrane bound protein, where it promotes 
autolysis of calpain (Salamino cf aI., 1993). An analogous activator has been purified 
from rat skeletal muscle and shows specificity for m-calpain (Melloni cf aI., 1992). 
This 35 - 45 kDa protein is associated with the cytoskeleton and after 
autoproteolytic conversion of the bound m-calpain, the active calpain enzyme is 
freed into the cytoplasm. In a recent paper, the same researchers isolated a protein 
from rat skeletal muscle called acyl-CoA-binding protein (Melloni ef aI., 2000a). This 
20 kDa protein reduces the calcium concentration required for optimum m-calpain 
activity from 300 J.lM to 10 J.lM. This result, coupled to the discovery of a 30 kDa 
protein in bovine brain tissue which specifically decreases the calcium requirement 
for J.l-calpain and accelerates autolysis (Melloni et aI., 1998b; Melloni ef aI., 1998c), 
may represent an enzyme specific regulatory system. 
All these observations underscore the elusive nature of the activation 
mechanism(s) of calpains. It is not surprising to find that attempts to reconcile the 
evidence have produced different models. 
1.2.5 Calpain Substrates 
As the ubiquitous nature of the calpains became apparent, the nature of the 
endogenous substrates was actively investigated. Many cellular proteins have been 
reported as being susceptible to calpain hydrolysis (Wang ef aI., 1989; Carillo ef aI., 
1994). They can be grouped into three broad categories; enzymes, cytoskeletal / 
membrane proteins, and receptor proteins. Interestingly, the relatively large 
proportion of membrane associated substrates is consistent with the calpain 
activation proposals. There are many synthetic peptides which are susceptible to 
calpains but will not be discussed here. 
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Calpains display strict substrate specificity with few differences existing 
between the specificity of the two calpain isoforms and the fragment patterns they 
generate (Sasaki et aI., 1984; Croall et aI., 1996). It has been reasoned that if calpain 
recognises a specific residue pattern or peptide bond then this would be present at 
the region removed through autoproteolysis. This was investigated and a general 
calpain cleavage sequence was suggested (McClelland et al. 1989). The P2 position is 
typically hydrophobic (eg. leucine or isoleucine) the PI is a non-specific residue, PI' is 
a neutral residue and P2' residue is either hydrophobic or neutral. These conclusions 
are comparable to those of Sasaki et al. (1984) who suggested a preference for 
residues such as tyrosine, methionine and arginine at the PI position, preceded by 
leucine or valine at Pz. These guidelines are often transcended although 
inconsistencies may be due to calpain recognising higher order 2° and 3° structures 
such as hydrophobic-hydrophilic boundaries rather than linear structures (Wang et aI., 
1989; Stabach et aI., 1997). If proteolysis is dependent upon the gross structure of 
substrates then this could explain why proteolysis often results in relatively large 
protein fragments which contain sequences that are not subject to cleavage. 
One potential higher order candidate structure is the calmodulin-binding 
domain which is manifest in several calpain substrates. Calmodulin is a calcium-
binding protein that interacts with other proteins regulating their physiological 
processes. It has been reported that the calmodulin-like domains within calpain 
interacts with calmodulin-binding proteins (Molinari et aI., 1995b) which then 
become susceptible to calpain proteolysis. However, calmodulin-binding proteins 
lacking the binding domain are still susceptible to proteolysis (Croall et aI., 1996). 
Thus an alternative mechanism for substrate recognition must exist. Rogers et al. 
(1986) were the first to recognise that proteins containing sequences rich in proline 
(P), glutamine (E), serine (S) and threonine (I) residues were relatively short lived. 
PEST sequences have the potential to sequester Ca2+ ions and may consequently 
enable calpain to overcome its calcium restrictions. An examination of calmodulin-
binding proteins has revealed several strong PEST sequences (Wang et aI., 1989). It 
has been suggested that calpain is primarily driven to proteolysis by recognising 
PEST sequences and that the association of the calmodulin - binding and calmodulin 
-like domains enhance the substrate/protease coalition which gives the appearance 
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of a functional requirement for these regions. While some substrates display a 
positive correlation between PEST content and calpain susceptibility (Smith et aI., 
1993; Noguchi et aI., 1997) several substrates do not obey the rule (Molinari et aI., 
1995a; Carillo et aI., 1996). This prompted some investigators to suggest PEST 
sequences are not necessary for calpain proteolysis Oohnson & Guttmann 1997) and 
that the propensity for a substrate to be susceptible to calpain action is multifactorial. 
Post-translational modification of substrates may influence the proteolytic 
potential of calpains. For example the phosphorylation of some connexin molecules 
protects them from calpain degradation and presumably, dephosphorylation has the 
opposite effect (Elvira et aI., 1994). The relationship between this modification and 
proteolysis is possibly more complex than this study implies. The phosphorylated 
state of the insulin receptor substrate-1 does not, for example, influence its 
susceptibility to calpain (Smith et aI., 1993). In contrast, phosphorylation of troponin 
I with protein kinase A confers protection whilst protein kinase C (PKC) 
phosphorylation appears to increase substrate susceptibility (Di Lisa et aI., 1995). 
With respect to the latter, these effects are only observed with Il-calpain and not m-
calpains (Di Lisa et aI., 1995). In addition, kinases are themselves calpain substrates, 
and degradation of PKC to co-factor independent PKM is catalysed by both Il- and 
m-calpain. While m-calpain continues to degrade PKM making its appearance 
transitory, the kinase is unaffected by Il-calpain and is theoretically able to act on 
substrates inaccessible to its parent enzyme (Cressman et aI., 1995). These 
observations indicate the complex interrelationships which influence the 
functionality of calpain. 
1.2.6 Other members of the calpain family 
The large subunit of calpain was cloned for the first time in 1984 from 
chicken calpain (Ohno et aI., 1984). It is now recognised that this calpain isoform 
represents an intermediate type known as III m-calpain (Sorimachi ct aI., 1995b). 
Since then, various calpain isoforms have been identified and their structures 
determined through cDNA cloning (Sorimachi et aI., 1997). The large subunit of m-
calpain has been sequenced in humans (Imajoh et aI., 1988), and a novel large subunit 
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(nCL) isoform has been cloned from C. elegans (Barnes & Hodgkin 1996). In 
mammals the ubiquitous calpains Ql- and m-) have been joined by tissue specific 
isoforms. This distinction now forms the basis of calpain classification (Sorimachi et 
al.,1997). 
The tissue specific division includes the skeletal muscle specific p94, also 
known as calpain 3 and nCL-1 (Kinbara et aI., 1998b), the stomach specific isoforms 
known as nCL-2 and nCL-2' (Sorimachi et aI., 1993a), and the new rodent lens 
specific isoforms Lp82 (Ma et aI., 1998; Ma et aI., 1999) and Lp85 (Ma et aI., 2000). 
p94 is a monomeric protein whose structure is similar to that of the large subunit of 
~- and m-calpain except for the inclusion of 3 short sequences (Sorimachi et aI., 
1993b). The mRNA levels of p94 exceed those of the ubiquitous calpains, and while 
the protein is relatively stable in skeletal muscle (Spencer et aI., 1997) it undergoes 
rapid autolysis following extraction (Sorimachi et aI., 1993c; Kinbara et aI., 1998a). 
nCL-2 is homologous to other large subunits containing a cysteine protease domain 
and calcium binding domain, while nCL-2' is composed of the protease domain only 
and lacks the calcium binding domain (Sorimachi et aI., 1993a). Lens protein 82 
(Lp82) represents a splice variant of p94 and is the most abundant calpain isoform in 
young mouse and rat lens (Ma et aI., 1998; Ma et a4 1999). Lp82 demonstrates a 
reduced sensitivity to calpastatin inhibition (Nakamura et aI., 1999) and, in alliance 
with Lp85, may form ~ system involved in lens specific proteolysis. Other atypical 
homologues of calpain have been reported in mammals, insects, nematodes, fungi 
and yeast (Sorimachi et aI., 1997). 
1.2.7 Functions of the calpains 
The physiological function(s) of the members of the calpain family remains 
unclear although several suggestions have been forwarded. The ubiquitous nature of 
~- and m-calpain has suggested they are involved in cell signalling. As already 
mentioned, protein kinase C maybe converted by calpain proteolysis to an active, 
cofactor-independent protein kinase M (Nishizuka 1985). In addition, however, 
hormonal polypeptides can induce PKC down-regulation by stimulating calpain to 
proteolyse this membrane associated signalling molecule (Eto et aI., 1995). A model 
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showing the possible role of calpains in signal transduction has been presented by 
Suzuki et a/. (1987). Alternatively, Emori & Saigo (1994) reported that calpain 
localises in a manner suggesting an involvement with cytoskeletal remodelling, 
especially of actin structures, during Drosophila embryogenesis. A similar report was 
presented by Schollmeyer (1988) who suggested that m-calpain is involved in critical 
spindle disassembly during mitosis. The possibility that calpain is involved in cell 
cycle progression has led to an investigation of the proteolysis of nuclear proteins 
(Gilchrist et aI., 1994). Several nuclear proteins are substrates for calpain, and nuclear 
kinase activity can be solubilized by calpain (Mellgren 1991). In particular m-calpain 
has been shown to proteolyse nuclear proteins at concentrations of calcium normally 
required by Jl-calpain, suggesting that m-calpain is sensitised to calcium in the 
presence of DNA (Mellgren et aI., 1993). These observations may be significant in 
light of a report that ,calpain regulates adipocyte differentiation, possibly through the 
degradation of a transcriptional activator gene product (patel & Lane 1999). 
Differentiation of neurites also appears to be regulated by calpain (pinter et aI., 1994) 
although this is probably mediated through structural protein turnover rather than 
changes in gene expression. A well-established function of calpains is their 
involvement in post-mortem myofibrillar protein degradation (Koohmaraie 1988) 
which has been expanded to include regulation of the turnover of the myofibrillar 
proteins in vivo (Huang & Forsberg 1998). Finally, calpain may be involved in 
apoptosis. Evidence suggests calpains participate in an escalation of proteolytic 
activity during the final stages of a cell's life cycle (Martin & Green 1995; Chan & 
Mattson 1999). 
Calpains have been associated with several pathological conditions (Wang & 
Yuen 1994; Johnson & Guttmann 1997). An elevated level of m-calpain is a feature 
of cataracts, a condition that can be alleviated by administering the calpain inhibitor, 
E64 (Shearer et aI., 1991). Similarly, neurodegenerative symptoms during ischaemic 
myocardial infarction and cerebral ischaemia can be reduced through application of 
calpain inhibitors (Wang et a/., 1996). Dystrophic muscle from hamsters are 
characterised by elevated m-calpain levels and heightened activity compared to 
normal muscle Oohnson & Hammer 1988). The gene responsible for Limb-Girdle-
Muscular-Dystrophy-type-2A (LGMD2A) has been mapped 'and found to be the 
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gene encoding for p94 (Sorimachi et aI., 1995a). Evidence also suggests an 
involvement of the calpains in Alzheimers Disease (Nixon ct aI., 1995). Finally, 
damage to the bone joint extracellular matrix by externalised calpain may contribute 
to the inflammation seen in arthritis (Menard & EI-Amine 1996). 
In summary it is apparent that over-action of calpains is probably an 
important component of several metabolic disorders, but the cause of the 
perturbation is not always clear. It may be from elevated calpain levels or from a 
reduction in calpastatin, the naturally occurring endogenous inhibitor of calpains. 
While calpain inhibition by synthetic inhibitors is a promising pharmacological 
avenue for disease prevention (Wang & Yuen 1994), much of the understanding of 
calpain inhibition to date is based upon an understanding of the natural inhibitor. 
1.3 Calpastatin 
Calpastatin was first described and partially purified by Drummond & 
Duncan (1966) who noted it was an inhibitor of cardiac phosphorylase b kinase. 
Twelve years later two papers related its potential to inhibit calpain (Nishiura ct aI., 
1978; Waxman & Krebs 1978). Since then various papers have described primary and 
tertiary structures of calpastatin, its functional relationships, the mechanism of 
calpain inhibition, and its regulation. Initial reports of chromatographically isolated 
erythrocyte calpain suggested a molecular weight of 300 kDa (Murakami ct aI., 1981). 
However, subsequent SDS-PAGE analysis revealed a variety of sizes (parkes 1986). 
Several theories have explained the size discrepancies including the formation of 
calpastatin tetramers (fakano & Murachi 1982) and undefined post-translational 
modifications (Emori ct aI., 1987; Imajoh et aI., 1987). Amino acid sequencing and 
eDNA analysis have revealed that calpastatin contains an unusually high proportion 
of charged amino acids (fakano ct aI., 1988) which may result in anomalous 
electrophoretic migration. Western blotting has revealed two predominant isoforms 
by employing antibodies specific to the native monomeric proteins; a 110 - 120 kDa 
protein found in all tissues examined, and a 70 kDa form in erythrocytes. These two 
forms show a strong amino acid similarity and immunological cross reactivity. The 40 
kDa difference is due to the absence of domains Land 1 in the erythrocyte isoform, 
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and are probably a result of specific proteolytic processing afLtr translation (Lee el ai, 
1992). Recently, Cong e/ 01. (1998) reported that bovine heart calpastatin eDNA 
possesses a translation initiation codon (AUG) 204 nucleotides upstream of the 
previously designated start point. Translation from this point results in the addition 
of 68 amino acids to ca lpastatin creating a region termed "XL". An antibody raised 
against "XL" recognises a 145 kDa band, which is evidence for the upstream AUG 
being uti lised, and u,e 145 kDa band representing fu ll -length calpastatin IiI vivo. 
Geesink e/ 01. (1998) purified heart and skeletal muscle calpastatin from several 
species. Western blotti ng demonstrated the presence of a higher molecular weight 
calpastatin isofo rm (145 kDa) in heart tissue only. In contrast, skeletal muscle 
appeared to contain the 125 kDa calpastatin iso fo rm only. Some heart ex tracts 
contained the ') 25 kDa isofonn. It remain s to be established if the difference in size 
is caused by the inclusion of domain XL in lhc: 145 kDa isoform. 
A nalys is o f complementary DNA (cDNA) st.:llllcnces has demons trated that 
numerous calpastatin variants exist in ti ssues from differenL suurces (Lee el aI., 1992j 
Servadio & Casan 1993; D e TulJio e/ aI., 1998; Tabno et 01., 2000). Many Ji fferenccs 
are attributable to ex on skipping during transcription and may lead to proteins with 
different susceplibiliries to post-translational modjfications. Examination of cDNA's 
revealed the presence o f four ho mologous domains o f approximately 120 - 140 
amino acids sharing roughly 30 % sequence homology ( f akano e/ aI., 198Gb, Emori e/ 
aI., 1987). These repetitive sequences were called domains 1-4 and in full size 
calpastalin are joined by an N-terminalleader region, of similar size, referred to as 
domain L. D omains I - 4 represent inhibitory domains. Each contain three 
conserved sequences named regions A, B and C. 
Domain L Domain 1 Domain 2 Domain 3 Domain 4 
Figure 1.4 Schematic diagram 01 calpastatin. The lypical110 - 120 kDa calpastatin isolorm is 
composed of four homologous lnhibitOfY domains (1 · 4), and an N-terminal domain l. Within each 
inhibitory domain three regions (A.B.C) are conserved. 
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1.3.1 Structure and function relationships 
In 1987, a 130 amino acid fragment of calpastatin was isolated and found to 
have inhibitory activity (Maki et al, 1987a). Later studies on cell extracts from E. coli 
containing recombinant plasmids showed that each of the four domains possessed 
inhibitory activity against both ~- and m-calpain (Maki et a/.) 1987b; Emori et al, 
1988). No inhibitory potential was observed when incubating recombinant domain L 
with calpain. These observations led Maki et al (1987a) to conclude that the repetitive 
region is the functional unit of the protease inhibitor. The comparison of amino acid 
sequence of calpastatin with other known sequences revealed there was homology 
with the calcium-binding domain of calmodulin. However the characteristic EF hand 
structure was not found (Takano et al, 1986b). 
The physical arrangement of calpastatin's amino acid residues was 
determined and revealed that conserved regions A and C, at the Nand C terminal 
ends of each domain respectively, were likely to be internalised and possessed a 
hydrophobic profile. Region B displayed a predominantly hydrophilic profile and 
probably presents itself on the surface of the folded protein where it is able to 
interact with calpain (Maki et al, 1988). The A and C conserved regions form u-
helical structures which may be important in stabilising the tertiary structure of the 
whole domain. The removal of regions A and C through restriction digestion or site-
directed mutagenesis of eDNA generated pruned peptides with significantly lower 
inhibitory potential than whole inhibitory domains (Emori et al, 1988; Maki et 
al,1988). Further deletions towards the central region B caused inhibitory activities to 
fall below detectable levels. A detailed structure of the region B was presented by 
Maki et al (1989). They synthesised a 27 amino acid peptide based on this region 
which displayed strong inhibitory potential. The oligopeptide embraced a 12 residue 
region known as the central consensus sequence (CCS). This region is common to all 
four inhibitory domains and is exposed on the surface of the calpastatin molecule 
where it can interact with calpain. More recently, several low molecular weight 
inhibitors have been shown to effectively inhibit calpain (Li eta/., 1996). While no 
function is clearly ascribed to the remaining bulk of the inhibitor there is evidence to 
suggest that some regions associate with calpain but not for the purpose of 
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inhibition. Kawasaki et 01. (1993) investigated effects of calpastatin on the ability of 
calpain to bind to the plasma membrane and found that a region which was not 
associated with calpain inhibition, interacted with a non-catalytic region of calpain. 
The effect of this association was to prevent calpain from binding phospholipid but 
it did not reduce calpains activity. 
1.3.2 Mechanism of calpain inhibition by calpastatin 
The mechanism by which calpastatin inhibits calpain has attracted a lot of 
attention. It appears that calpastatin does not inhibit calpain by sequestering free 
calcium since increasing calcium concentrations do not reverse the inhibition 
(Nishiura etal., 1978). However, calpastatin has an absolute requirement for calcium 
to bind calpain. The binding and inhibition can be reversed by calcium chela tors 
(Melloni et aI., 1982). Calcium has the effect of changing the conformation of the 
calpain (Tsuji et aI., 1981) possibly by altering its structure into a form that allows 
calpastatin to bind. Following removal of calcium, the physical association between 
calpain and calpastatin is reversed. The central consensus sequence does not contain 
the preferred proteolytic site of calpain, which indicates that calpastatin does not 
operate as a suicide substrate despite the fact that it is substrate both in vivo and in 
vitro (Doumit & Koohmaraie 1999). 
Kapprell & Goll (1989) reported that autolysed 11-, autolysed m- and 
unautolysed m-calpain require more calcium for half-maximal activity than was 
required for their half-maximal binding to calpastatin. These enzymes could not 
activate in vivo unless; 1) calpastatin is relocated and removed from calpain, 2) 
calpains are localised at a region where calcium concentrations are high enough to 
permit activity, 3) some factor regulating the interaction between calpain and 
calpastatin increases the calcium requirement for inhibition over activation, 4) the 
calcium requirement for calpain activation is lowered to enable activation. 
Unautolysed Il-calpain, however, requires less calcium for activation than is required 
for calpastatin binding. This suggests that under certain circumstances Il-calpain 
could be active in the presence of calpastatin. 
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Nishimura & Goll (1991) found that autolytic fragments of calpain, which 
contain the calmodulin-like domains but not the proteolytic domain, bind to a 
calpastatin affinity column in a calcium dependent manner. The fact that the 
proteolytic domain failed to bind to the column is difficult to reconcile since 
calpastatin is the competitive inhibitor of calpain. Experiments by Ma cl a/. (1993) 
established, however, that the binding of calpain to calpastatin is not correlated to its 
inhibition. This was determined by exploring the associations between various 
recombinant calpastatins and an immobilised recombinant calmodulin-like domain 
(CaMLD) engineered from ~-calpain. Ma showed that only calpastatin domains 1 
and 4 could bind to immobilised CaMLD. After removal of region B (the inhibitory 
region), regions A and C of domain 1 associated with CaMLD, displayed no 
inhibitory potential and yet were susceptible to hydrolysis by calpain. In contrast, 
recombinant domain B failed to bind to the column but inhibited calpain. 
Interestingly, substituting region A from domain 1 into domain 3 enabled this 
domain to associate with CaMLD. Thus, it would appear that region A is critical for 
CaMLD association but not for inhibition. The latter function is fulfilled by region B. 
Furthermore, calpastatin binding to CaMLD's is not directly involved in calpain 
inhibition. Further work revealed that mutating conserved residues in regions A and 
C reduced the binding of calpastatin to the calpain calmodulin-like domain as well as 
the ability of calpastatin to inhibit calpain. This observation, coupled with the fact 
that region B is solely responsible for inhibition of calpain, lead Ma cl a/. (1994) to 
conclude that regions A and C potentiate the inhibitory activity of calpastatin by 
interacting with calpains calmodulin-like domain which allows region B to form a 
tighter complex and, as a consequence, exert its inhibitory influence. It would appear 
that the interaction of region A with the CaMLD of calpain is based upon the 
hydrophobic properties of the CaMLD which appear after exposure to calcium 
(Yang cl aI., 1994). Calcium has been shown to lead to calmodulin developing a 
hydrophobic surface (Tanaka & Hidaka 1980). This may be the mechanism of 
interaction between calmodulin-binding peptides and calmodulin. 
Calpastatin can be degraded by calpain after the two have associated in the 
presence of calcium (Mellgren cl aI., 1986; Doumit & Koohmaraie 1999). This 
degradation requires a relatively high ratio of calpain to calpastatin. The degree of 
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calpastatin degradation increases with the addition of more calpain (Mellgren & Lane 
1990). Furthermore, the degradation of calpastatin by calpain is a relatively slow 
process compared to the degradation of casein (Mellgren ct aI., 1986). It is important 
to recognise that the degradation of calpastatin by calpain does not lead to a loss of 
inhibitory function and calpastatin fragments resulting from extensive proteolysis still 
retain inhibitory potential (DeMartino ct aI., 1988; Nakamura ct aI., 1989). This 
observation indicates that the inhibitory region is resistant to cleavage and/or that 
the structural arrangement of calpain and calpastatin precludes its degradation. 
However, a considerable body of evidence has described a gradual decline in 
detectable calpastatin activity during post-mortem storage of skeletal muscle 
(Koohmaraie ct aI., 1987; Morton c/ aI., 1999). 
1.3.3 Regulation of calpastatin 
The mechanisms regulating calpastatin inhibitory activity are not completely 
understood. Protein and mRNA abundance and post-translational modifications are 
all points at which regulation may occur. 
The existence of multiple calpastatin isoforms has been reported in rat 
skeletal muscle and brain tissue (pontremoli c/ aI., 1991; Averna c/ al., 1999) and 
human haematopoietic cell lines (Adachi c/ aI., 1991). In some instances the isoforms 
are different with respect to their domain composition. For example, the classical 
calpastatin is composed of one N-terminal domain (domain L) and four similar 
inhibitory domains (domains 1-4). However, in the instance of rat brain tissue, 
isoforms were discovered which comprised of only domain L and another of 
domains Land 1 only (Averna c/ al.,1999). In contrast, other isoforms are less easily 
distinguished. Pontremoli separated two forms of calpastatin on a DE32 
chromatography column which displayed similar molecular weights. However 
calpastatin I, which eluted first, exhibited greater inhibitory potential over J.1-calpain 
than m-calpain, whereas the less prevalent calpastatin II was more effective against 
m-calpain. The same laboratory later discovered that calpastatin I and II are 
reversibly dephosphorylated and phosphorylated (respectively) forms of the same 
calpastatin isofbrm (pontremoli c/ aI., 1992). More recently, these researchers 
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identified calpastatins I and II in rat brain tissue and found that calpastatin I had 
inhibitory potential against J.l- and m-calpain, while calpastatin II displayed an overall 
poor inhibitory potential (Salamino et aI., 1997). In this instance it is speculated that 
the calpastatin II isoform comprises a reservoir of low activity inhibitor whose 
behaviour is utilised under specific cell conditions. For example, conversion of the 
less active calpastatin II to calpastatin I followed by the elevation of intracellular 
calcium levels (Salami no et aI., 1994a). This possible mechanism of differential calpain 
regulation represents post-translational control. 
It is not clear which cellular enzyme system is responsible for calpastatin 
phosphorylation. Both cAMP-dependent protein lcinase A (PKA) and protein lcinase 
C (PKC) have the ability to phosphorylate calpastatin (Mellgren & Carr 1983; Adachi 
et aI., 1991; Salamino et aI., 1994a; Averna et aI., 1999) although details about their 
efficiencies vary. Phosphorylation occurs at the serine and threonine residues (Adachi 
et aI., 1991) and has been specifically seen at a single domain L serine residue in some 
rat brain isoforms (Averna et aI., 1999). Serine and threonine residues are strongly 
represented in the recently revealed domain XL malcing it a potential substrate for 
phosphorylation. Cong et al. (1998) suggest that the absence of region XL, by 
proteolysis or alternative start site selection, may playa regulatory role by altering the 
phosphorylation patterns of the protein. These authors also revealed the existence of 
a calpastatin promoter susceptible to PKA phosphorylation, and demonstrated that a 
constitutive activator ofPKA could cause a 7-20 fold increase in promoter activity. 
Thus calpastatin may be regulated at the transcriptional level. 
1.3.4 Calpastatin membrane associations 
Using immunostaining, calpastatin has been detected at the sarcoplasmic 
reticulum and sarcolemma, as well as displaying a granular/ fibrillar localisation in 
thyroid epithelial cells (Karlsson & Nilsson 1997). Bovine sarcolemmal vesicles were 
extracted and calpastatin was found associated with the cytoplasmic face (Mellgren et 
aI., 1987a; Mellgren et aI., 1987b). Therefore, in an intact myofibril the inhibitor 
would exist on the intracellular side where it would be able to interact with calpains. 
Calpastatin is a hydrophilic protein containing relatively few hydrophobic residues. 
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Hydrophobic association with membranes is, therefore, unlikely. The high 
proportion of charged residues, the fact that soluble calpastatin can associate with 
biological membranes in low ionic strength buffers, and the effect of pH and ionic 
strength all suggest that ionic interactions are important in this process of membrane 
binding (Mellgren 1987). All phospholipid species possess a polar nature and the 
affinity of various phospholipids to calpastatin was examined. Purified myocardial 
calpastatin bound to two acidic phospholipids; phosphatidylserine and 
phosphotidylinositol. There was no binding between the neutral phospholipids and 
calpastatin (Mellgren ct aI., 1989). In contrast, purified erythrocyte calpastatin did not 
bind to phosphatidylserine or phosphotidylinositol under the same experimental 
conditions (Mellgren 1987). As noted previously, erythrocyte calpastatin lacks 
domains Land 1. Digestion of purified myocardial calpastatin with cyanogen 
bromide produced a 20 kDa fragment which binds to phosphotidylinositol but does 
not exhibit any inhibitory activity (Mellgren ct aI., 1989). Sequence analysis revealed 
there was significant homology with porcine calpastatin domain L. The amino acid 
composition of domain L is strongly basic and has a high isoelectric point relative to 
domains 1 - 4 (Lee ct aI., 1992). The net charge of this region could, therefore, 
facilitate an association with acidic charged groups as in phospholipids. Finally, 
Adachi ct 01. (1991) showed using 32p - lab~lled calpastatin that 30 % of the 
calpastatin was membrane bound, compared to 6 % using 3sS-methionine labelled 
calpastatin. The authors suggest that membrane associated calpastatin is either 
preferentially phosphorylated or phosphorylated calpastatin migrates to membranes. 
These alternatives represent possible mechanisms of regulating calpastatin. 
1.4 Calpains and calpastatin as regulators of myoblast fusion 
Studies indicate that the plasma membrane region is an important site of 
calpain activity where there are many potential calpain substrates. The disruption of 
structural proteins can increase membrane fluidity and may represent a precursor 
step in membrane fusion. More specifically, the degradation of membrane 
cytoskeletal proteins from membrane patches and / or the removal of intrinsic 
proteins from membranes, may increase the local lipid concentration and prepare the 
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region for fusion. Several laboratories have investigated the role of calpain 
proteolysis in myoblast fusion. 
It has been established that myoblast fusion is strictly calcium dependent and 
is accompanied by significant changes in the surface protein composition (Wakelam 
1985). This prompted researchers to search for an association between protease 
activity and fusion. One of the earliest reports observed that myoblast extracts 
contain calcium-dependent protease activity whose activity correlated to fusion but 
was undetectable in undifferentiated myoblasts (Kaur & Sanwal1981). However, an 
increase in activity was also observed in non-fusing myoblast variants suggesting that 
the level of activity was not dependent upon, or sufficient to ensure fusion. 
However, by investigating the fusion of L6 myoblasts Schollmeyer (1986a) was able 
to determine that EGTA prevented fusion while treatment with A23178 promoted 
precocious fusion. This evidence has been repeated (Hayashi ct aI., 1996; Barnoy ct 
aI., 1997) and underscores the importance of calcium and its effectors in fusion. 
Schollmeyer's research into myoblast fusion continued and using 
immunocytochemistry she was able to report that the distribution of m-calpain 
changed from a predominantly diffuse distribution to a more peripheral distribution 
in pre-fusion myoblasts (Schollmeyer 1986b). In non-fusing variants, m-calpain 
distribution did not change following treatment to induce fusion. The localisation of 
Jl-calpain didn't change in either normal or non-fusing variants, leading the authors 
to suggest that it was the extracellular distribution of m-calpain that is responsible for 
myoblast fusion. More recently, Kwak ct al. (1993a) determined that an increase in m-
calpain expression and activity, and not Jl-calpain, correlated with myoblast fusion. 
These results are reinforced by quantification of Jl- and m-calpain mRNA (poussard 
ct aI., 1993). In this study the mRNA level of m-calpain was seen to increase over the 
fusion period whilst Jl-calpain mRNA only increased after fusion. The authors 
suggest that this supports the involvement of m-calpain in fusion and that the 
delayed elevation of Jl-calpain may hint at its involvement in the control of other 
biological activities. The measurement of mRNA levels was repeated in 1994 by the 
same laboratory (Cottin ct aI., 1994) together with the quantification of calpain 
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activity. They found that m-calpain activity was detectable at 2 and 4 days, and 
maximal at 6 days, which is concurrent with maximum fusion. At 8 days, the rate of 
fusion declined in accord with m-calpain activity, however, /1-calpain was maximal at 
8 days after b~coming measurable at 6 days. These results differ from those reported 
by Ebisui ct al. (1994) who found that both /1- and m-calpain activity increased very 
slightly up to day 6 beyond which, m-calpain activity stabilised and /1-calpain 
escalated rapidly. While cell fusion was most rapid between 2 and 4 days the 
"percentage cells fused" value was still increasing at 10 days. 
In support of m-calpains involvement, Brustis ct al. (1994) observed a drastic 
increase in fusion when m-calpain was added to the growth media surrounding cells. 
Furthermore, these workers used monoclonal antibodies specific to m-calpain to 
reduce fusion by 76 %. The cells had not been made permeable so the binding 
effects of the antibodies are thought to have been occurring at the exterior surface. 
The inhibitory effect of anti-m-calpain antibody appears to be reversible and to 
diminish over time suggesting the degradation or internalisation of the antibodies 
(Dourdin ct aI., 1997). No similar impediment to fusion was apparent when dosing 
the media with monoclonal anti-/1-calpain antibodies. Balcerzak ct al. (1995) 
employed an 18-mer antisense oligodeoxyribonucleotide targeting a region of m-
calpain mRNA to reduce calpain synthesis by 48% and myoblast fusion by 70%. No 
effect was observed on fusion when antisense oligonucleotides against /1-calpain or 
p94 were used. 
Numerous experiments have sought to modify fusion using inhibitors or 
promoters of proteases. Kumar et al. (1992) used the cysteine protease inhibitors, 
leupeptin and E64, to block the fusion of C2C12 myoblasts as has Dourdin ct al. 
(1997). While Ebisui ct 01. (1994) and Barnoy ct al. (1998) have used calpeptin to 
disrupt this process. Poussard ct al. (1993) reports that insulin ,which elevates calpain 
mRNA levels, stimulates fusion, while transforming growth factor-p (fGF-P) 
suppressed fusion (Barnoy ct aI., 1997). Cottin ct al. (1994) expanded this list to 
include IGF-1 and corticosterone as stimulators of fusion. Both were also found to 
increase calpain mRNA levels. However, Hayashi ct al. (1996) cautioned that 
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myoblast fusion is a complex, multifactorial process and those agents which 
influence fusion could be operating though a mechanism other than the up- or 
down-regulation of calpain. 
More compelling evidence for the involvement of calpains in fusion may be 
provided by discovering its location during fusion. Initial work revealed that m-
calpains distribution changed from being diffuse throughout the cytoplasm to being 
predominantly associated with the plasma membrane (Schollmeyer 1986b). Brustis ef 
al. (1994) also witnessed a surface distribution of m-calpain, although these authors 
considered that its association was more with the extracellular matrix surrounding 
myoblasts. While these experiments used monoc:lonal antibodies to localise calpain, 
less precise methodology has also indicated an involvement of exteriorised calpain. 
Leupeptin is able to inhibit calpain but is not cell permeable. Myoblasts cultured in 
media containing leupeptin fail to fuse, which suggests that the leupeptin's anti-
fusion effects are manifesting at the exterior of the cells (Brustis ef aI., 1994). Cell 
penetrating calpain inhibitors such as calpeptin also inhibited fusion. However, since 
these inhibitors are usually included in the culture media there is no evidence to 
suggest that their effects are occurring intracellularly (Kwak ef aI., 1993b; Ebisui ef aI., 
1994; Barnoy ef aI., 1998). 
The peripheral relocation of m-calpain during myoblast fusion was 
challenged by Moraczewski ef al. (1996) who observed the distribution of the 
ubiquitous calpains during in vitro fusion of human satellite cells. These workers 
reported that Jl-calpain is predominantly localised in the nuclei, but as myoblasts fuse 
to become young myotubes (2-3 nuclei) and then older myotubes (12+ nuclei) it 
moves towards a more cytoplasmic distribution. Irrespective of the differentiation 
stage, m-calpain was detected in punctuated peri-nuclear regions, which possibly 
hints at its localisation in the endoplasmic reticulum. 
As a regulator of calpain activity, it is logical to expect that calpastatin may 
playa role in regulating the fusion process. Recent work by Temm-Grove ef al. 
(1999) demonstrated that microinjection of calpastatin into myoblasts completely 
abolished fusion, in contrast to microinjection of m-calpain which accelerated the 
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process. Moreover, Kosower & Barnoy (2000) reported that calcium dependent 
protease activity is only detectable once calpain is separated from calpastatin. The 
authors concluded that calpains and calpastatin are associated during proliferation 
and at the beginning of fusion. Accordingly, the relationship between the enzyme 
and its inhibitor must change for calpain to be active during fusion. Kaur and Sanwal 
(1981) found that in rat myoblasts, the levels of an inhibitor of calcium-dependent 
protease activity declined during fusion. More recently Barnoy et 01. (1996) reported 
that calpastatin levels (protein and activity) decrease by a factor of 10 during 
differentiation which may allow calpain activity to become apparent. Other research 
indicates the decrease in calpastatin is due to diminished mRNA levels and that 
artificially reproducing this with antisense oligodeoxyribonucleotides will stimulate 
fusion (Balcerzak et 01., 1998). The authors concluded that acute "hyperactivity" of 
m-calpain from reduced calpastatin is directly correlated to the onset of the fusion 
process. Not surprisingly, the addition of calpastatin to cultures containing 
myoblasts, reduced fusion by 70% (Brustis et 01., 1994). Some reports do not support 
the idea of a calpastatin decline (Kwak et 01., 1993a). While it is difficult to ascribe a 
reason, Balcerzak et 01. (1998) has attributed dissimilar results to differences in the 
experimental cell lines. 
1.5 Summary and experimental proposal 
Mature muscle tissue arises from embryonic stem cells via a distinct series of 
steps. This involves the proliferation of mononucleate myoblasts followed by their 
biochemical and morphological differentiation into multinucleate myotubes which 
form the basis of higher order muscle structures. Fundamentally, biochemical and 
morphological differentiation are represented by the expression of muscle specific 
proteins and the fusion of myoblasts respectively. Myoblast fusion is accompanied by 
significant cell surface restructuring and controlled proteolysis. 
The calpains (~- and m-) are members of an expanding family of calcium 
dependent proteases and have been the subject of intensive investigation over the 
last three decades. In structural and functional terms, the proteases and their 
endogenous inhibitor calpastatin have been well defmed. Despite this, however, 
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many details concerning in vivo activation and the specific functions of the ubiquitous 
proteases remain unknown. Several aspects of myoblast fusion, notably, the reliance 
upon calcium and proteolysis have inspired several researchers to search for an 
involvement of calpains in the fusion process. 
A variety of approaches have been used to investigate this involvement 
although the majority of work employs myoblasts grown in tissue culture as a model 
system. Unfortunately, differences between culture systems (eg. cell type and media 
composition) have sometimes resulted in diverging results. Nevertheless, a 
compelling body of evidence has demonstrated that calpain, especially the m-calpain 
isoform, is of crucial importance in the normal fusion process. 
This work seeks to investigate the role calpastatin plays in regulating fusion. 
Calpastatin is the endogenous inhibitor of the calpains and its levels can be 
manipulated to produce dramatic impacts upon fusion. Moreover, aspects of the 
structure of calpastatin suggest possible mechanisms by which the protein may be 
able to perturb events at specific cellular locations. For example, the N-terminal 
"domain L" of calpastatin may be responsible for directing the protein to the plasma 
membrane; a location where calpain activity is thought to occur. Consequently this 
thesis aims to: 
(i) Manipulate the ovine calpastatin eDNA to create vectors containing 
specific regions of calpastatin. The regions will be selected on their 
inhibitory activity and putative subcellular localisation signals. 
(ii) Express the proteins encoded by the vectors in bacteria and assess 
the basic aspects of their structure and function. 
(ill) Use the expressed proteins as antigens with which to produce 
antibodies for subsequent usage. 
(iv) Characterise the fusion of myoblasts grown in tissue culture, and 
assess whether calpain and calpastatin activities are useful indicators 
of the process. 
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(v) Generate vectors encoding regions of calpastatin which will be 
suitable for expression in myoblasts and which will enable detection 
of the expressed product. 
(vi) Optimise the methodology for the introduction of plasmid DNA into 
myoblasts. 
(vii) Introduce expression vectors into myoblasts and monitor the effect 
of expression of calpastatin regions on the fusion process. Specific 
attention will be given to the subcellular localisation of the expressed 
product. 
It is expected that this thesis will contribute to the understanding of the 
involvement of calpastatin in myoblast fusion and to an appreciation of the structure 
and function of calpastatin. 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Solutions 
The most commonly used solutions were: 
TBE (1 X): 
45 mM Tris base, 45 mM boric acid, 1 mM EDTA (PH 8.2) 
Tris Buffered Saline (1 X TBS): 
20 mM Tris-HCI pH 7.5, 0.5 M NaCI 
DNA Loading buffer (5 X): 
0.25 % bromophenol blue, 40 % (w Iv) sucrose 
PBS (1 X): 
0.8 % NaCl, 0.02 % KCl, 0.14 % Na2HP04, 0.024 % KH2P04 (PH 
7.3) 
Protein Denaturing Buffer (6 X PDB): 
0.35 M Tris-HCl pH 6.8, 10 % SDS, 30 % glycerol,S % ~-MCE, 
0.012 % bromophenol blue 
Running Buffer (10 X): 
0.25 M Tris-HCI, 2.0 M glycine and 10 % SDS 
Transfer Buffer (1 X): 
25 mM Tris-HCI pH 8.3, 192 mM Glycine, 20 % Methanol (v Iv), 
1 %SDS 
CaCl2 Buffer (1 X): 
60mM CaCI2, 15 % glycerol, 10mM PIPES (PH 7.0) 
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2.1.2 Antibiotics 
Ampicillin (Amp) interferes with a terminal reaction in bacterial cell wall 
synthesis. A stock solution was made as a 100 mg/ml in water, ftlter sterilised, and 
used at a final concentration of 50 /lg/ml for broth cultures and at 100 /lg/ml for 
agar plates. 
Kanamycin (Kana) binds to the 70S ribosomes and causes misreading of 
messenger RNA. A stock solution was prepared by dissolving the solid at 60 mg/ ml, 
and used at a working concentration of 30 /lg/ml for broth cultures and 50 /lg/ml 
for agar plates. 
Geneticin is also known as Neomycin or G418 and blocks protein synthesis 
by interfering with ribosomal functions. It was purchased as a stock solution of 50 
mg/ml, working concentration for selection was 800 /lg/ml and 100 /lg/ml for 
maintenance. 
2.1.3 Antibodies 
Table 2.1 list of primary (1°) antibodies. Antibody dilutions are noted in individual Figure 
legends. 
[A!'Jtisera - l,Host : Antigen 'lyRe - Reference .-
-
- -
D3 Mouse Desmin Monoclonal Danto & Fischman (1984) 
cn Mouse Troponin T Monoclonal Jin et al. (1989) 
MF20 Mouse Myosin Monoclonal Bader et al (1982) 
Anti-GFP Mouse GFP Monoclonal Roche (Cat # 1814 460) 
Anti-GST Goat GST Polyclonal APB (Cat # 27-4577) 
551 Rabbit Domain L Polyclonal This Thesis 
552 Rabbit Domain 1 Polyclonal This Thesis 
566 Rabbit Domain L Polyclonal This Thesis 
567 Rabbit Domain 1 Polyclonal This Thesis 
107-82 Mouse m-calpain Monoclonal ABR Geesink & Goll (1995) 
1F7E3D10 Mouse Calpastatin Monoclonal ABR Thompson & Goll (Unpublished) 
2H2A7C2 Mouse Il-calpain Monoclonal ABR Thompson & Goll (Unpublished) 
3B9 Mouse Calpastatin Monoclonal Doumit & Koohmaraie (1999) 
B2F9 Mouse Il-calpain Monoclonal Geesink & Koohmaraie (1999) 
Forsberg Rabbit m-calpain Polyclonal Huang & Forsberg (1998) 
Forsber!l Rabbit Il-calpain Polyclonal Forsberg (Unpublished) 
, 
j 
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Table 2.2 list of secondary (2°) antibodies and the appropriate dilutions. 
-
~ -
Antisera Host Antigen Type Conjugate Dilution Source 
-
A-3688 Goat Mouse IgG Polyclonal Alkaline Phosphatase 1:2000 Sigma 
A-0418 Goat Rabbit IgG Polyclonal Alkaline Phosphatase 1:2000 Sigma 
A-2168 Rabbit Goat IgG Polyclonal Alkaline Phosphatase 1:2000 Sigma 
2.1.4 Oligonucleotides 
Oligonucleotides used in this work were all "guaranteed oligos" synthesised 
by GENSET. They were used without further purification. 
Table 2.3 Oligonucleotides used in this work. 
PGEXS 5' -GGGCTGGCAAGCCACGnTGGTG-3' Chapter 4 
PGEX3 5' -CCGGGAGCTGCATGTGTCAGAGG-3' Chapter 4 
DLGFps 5' -TGCCGGAA nCGCCACCATGAA TCCCACAGAAGCCAAGGCT-3' Chapter 5 
DLGFp3 5' -CAGCCGGTCGACTGCAGAAGGTn ACnGGCnGG-3' Chapter 5 
D1GFps 5'CAGCCGGAA nCGCCACCATGGCAAAGTCAGACATGGATACTGCT-3' Chapter 5 
D1GFp3 5' -CTGCCGGTCGACCTCnCCACnnCnCnnC-3' Chapter 5 
DLGSP 5' -CTGCCGGAA nCAA TCCCACAGAAGCCAAGGCT-3' Chapter 4 
DLGSP 5' -CAGCCGGTCGACn ATGCAGAAGGnTACnGGCnG G-3' Chapter 4 
D1GSP 5-'CTGCCGGAAnCAAGTCAGACATGGATACTGCT-3' Chapter 4 
D1GSP 5-'CTGCCGGTCGACn ACTCnCCACnnCnCnnC-3' Chajller 4 
2.1.5 Bacterial culture media 
Bacterial cells were grown at 37°C with aeration using the following media: 
Luria-Bertani Medium (LB) 
(1 % Bacto-tryptone, 0.5 % yeast extract, 170 mM NaCl) 
pH 7.5 with 4M NaOH, make to 1L with ddH20, autoclave to 
sterilize. 
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2 x Tryptone and Yeast Broth (2 x TY) 
(1.6 % Bacto-tryptone, 1 % yeast extract, 280 mM NaCl) 
Make to 1L with ddH20, autoclave to sterilize 
Terrific Broth (TB) 
1.2 % Bacto-tryptone, 2.4 % yeast extract, 0.4 % v Iv glycerol 
supplemented with 17 mM KH2P04 and 72 mM K zHP04 
Agar plates for supporting solid bacterial growth consisted of 2 x TY broth 
or LB broth supplemented with 1.6 % agar. After sterilisation, broth and broth 
containing agar are cooled to 50°C before the addition of antibiotic. 
2.1.6 Plasmids, bacterial strains and mammalian cell lines 
2.1.6.1 Plasmids 
Table 2.4 Plasmids used in this thesis. Diagrams of vector maps are provided in Appendices 
A.1, A.2, A.3 and A.4. 
pBSCalstn 
pBluescript II KS+ 
pGEX-4T-l 
pEGFP-N3 
Bluescript plasmid containing ovine calpastatin cDNA 
Ampicillin resistant cloning vector 
Prokaryotic GST protein fusion vector 
Eukaryotic GFP protein fusion vector 
2.1.6.2 Bacterial strains 
Collingwood (1994) 
Stratagene 
APB (Smith & Johnson 
1988) 
Clontech 
Table 2.5 Bacterial strains. Both f.colistrains are gram negative, non-conjugative and non-
pathogenic. DH5a is a K12 f. coli derivative, while BL21 originate from B strain £. coli. 
- ~ - ~ . 
Genotype Supplier Reference , 
Strain I 
BL21 F' ompT gal Idem] lIon] hsdSB (rB-mB-) 
F' <l>80dlaeUM15 LJ(laeZYA-argF )U169 deaR reeA 1 
DH5a endA1 hscR17&K-,mK+)phoAsupE44A;th~1 gyrA96 
relA1 
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APB 
NEB 
Wood (1966); Studier & 
Moffatt (1986) 
Grant et at (1990) 
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2.1.6.3 Mammalian cell lines 
Table 2.6 Mammalian cells used in this work. 
C2C12 Mouse (strain C3H) skeletal 
muscle myoblast 
2.2 Methods 
ATCC Yaffe and Saxel (1977): Blau et al (1985) 
2.2.1 Preparation of competent E.coli cells and transformation 
Fresh competent E.coli cells were prepared according to a modified protocol 
based upon that described by Sambrook et al. (1989). A loop-full of frozen E.coli 
stock was streaked onto pre-warmed LB plates and grown overnight at 37°C. The 
following day a single colony was used to inoculate 10 ml LB broth which was 
incubated overnight at 37°C with shaking. The following day 1 ml of the overnight 
culture was added to 100 ml pre-warmed 2 x TY broth and incubated at 37°C with 
shaking. Growth was monitored by measuring A600 of the culture against an 
uninoculated 2 x TY reference. When the culture A600 was 0.40 (approximately 2 - 4 
hours) the culture was cooled on ice to inhibit any further growth. 
Bacteria were transferred to 2 chilled sterile 50 ml centrifuge tubes (Falcon), 
stored on ice for 10 minutes and pelleted by centrifugation at 500 g for 10 minutes at 
4°C (varifuge). The supernatant was decanted and replaced with 10 ml CaClz buffer. 
The pellet was resuspended by gently swirling the centrifuge tubes until cell clumps 
could no longer be seen. Bacteria were recovered by repeating the centrifugation 
step, then resuspended in 10 ml CaClz buffer, swirled and held on ice for 30 minutes. 
Finally, the cells were collected by centrifugation and resuspended in 2 ml CaClz 
buffer. Aliquots of 100 J..ll were pipetted into sterile 1.5 ml eppendorf tubes and 
stored upright at -80°C. 
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For each transformation, a 100 Jll aliquot of cells was thawed on ice and a 14 
ml polypropylene tube was similarly chilled. The competent cells were gently pipetted 
into the chilled tubes, and plasmid DNA (10 - 100 ng) was added by moving the 
pipette through the cells while dispensing. The cells were flick-mixed and incubated 
on ice for 30 minutes. In all cases a negative control, which received no plasmid 
DNA, was included. Bacteria were given a heat shock by rapid transfer from ice into 
a 42°C water bath for 45 seconds, before being returned to the ice for a further 2 
minutes. After adding 900 Jll room temperature SOC broth (2 % casein hydrolysate, 
0.5 % yeast extract, 8.5 mM NaCl, 2.5 mM KC1, 10 mM MgC12' 20 mM MgS04, 20 
mM glucose; pH 7.0) to each tube, the cells were incubated with shaking at 37°C for 
1 hour to allow expression of antibiotic resistance. Agar plates made from LB broth 
and including selective antibiotic were prepared. Aliquots of the bacterial cultures 
(between 50 and 200 Jll) were pipetted onto the plates and spread with a glass rod. 
The control competent cells were plated onto agar plates in the presence and absence 
of antibiotic. The plates were incubated upside-down at 37°C overnight and the 
number of transformants counted the next day. 
2.2.1.1 a-complementation detection 
Plasmids used in this work all contain the N-terminal146 amino acids of the 
~-galactosidase gene containing a non-disruptive multiple cloning site. When 
transformed into host cells that code for the C-terminal portion of the protein only 
(Lac- bacteria), the two gene products combine through a-complementation to 
produce an active protein. Lac+ bacteria are easily distinguished because they form 
blue colonies in the presence of the chromogenic substrate 5-bromo-4-chromo-3-
indolyl-~-D-galactosidase (X-gal). 
When DNA is inserted into the plasmid's multiple cloning site, the gene is 
disrupted and expression of active ~-galactosidase is prevented. Agar plates, 
containing the appropriate antibiotic, were prepared for testing transfection success 
by spreading with 40 Jll stock X-gal solution (20 mg/ ml in dimethylformamide) and 
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4 ~l IPTG (200 mg/ml). The plates were incubated at 37°C until all the fluid had 
evaporated (approximately 3 - 4 hours), and an aliquot (100 ~l) of the transformed 
bacteria was evenly spread with a glass rod. The plates were incubated upside-down 
at 37°C overnight and the number of successful transform ants (white colonies) 
counted the next day. The percentage of successfully transfected bacteria was 
calculated according to the following calculation: 
Number White Colonies 
Number White + Blue Colonies 
2.2.1.2 Preservation of bacteria 
x 
100 
1 
Bacterial stock solutions and transformed bacteria may be frozen and stored 
for indefinite periods at -80°C. LB broth (5 ml) containing the appropriate antibiotic 
(where required) was aseptically inoculated with a single colony of bacteria, and 
incubated at 37°C overnight with constant shaking. The following day bacteria were 
harvested by centrifugation (microfuge; 12 000 rpm, 2 minutes) and supernatant 
removed by aspiration. The pellet was resuspended in 2 ml LB containing 15 % (v Iv) 
sterile glycerol. Volumes of 100 ~l were aseptically transferred into sterile 1.5 ml 
cryovials and incubated at RT for 1 hour to allow the glycerol to penetrate the cells. 
Aliquots were stored frozen in an upright position at -80°C. 
2.2.2 Plasmid DNA extraction 
For the rapid and small scale isolation of plasmid DNA a modification of the 
alkaline lysis method of Sambrook et al. (1989) was used. Plasmid DNA obtained in 
this way was used for the purposes of checking ligation experiments, and confirming 
the identity of plasmids by restriction digestion. 
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2.2.2.1 Small scale preparation of plasmid DNA 
Single transform ant colonies were aseptically transferred to separate 14 ml 
polypropylene tubes containing 5 m1 LB broth and the appropriate antibiotic. The 
cultures were incubated at 37°C overnight with constant shaking (180 rpm). Three 
ml of stationary phase bacteria were harvested and resuspended in 100 ~l of solution 
I (50 mM glucose, 10 mM EDTA , 25 mM Tris-HCI; pH 8.0), then incubated at RT 
for 5 minutes. The cells were lysed and the DNA denatured following the addition of 
200 ~l of fresh solution II (1 % SDS, 0.2 M NaOH) and then gently mixed by 
inverting the tube 5 times before incubating on ice for 5 minutes. Protein and 
chromosomal DNA was precipitated by the addition of 150 ~ of solution III (3.0 M 
sodium acetate; pH 4.8) and gentle mixing before incubating on ice for 5 minutes. 
Cell debris and chromosomal DNA was pelleted by centrifugation (microfuge; 12 
000 rpm, 10 minutes). Plasmid DNA and RNA was recovered from the supernatant 
by the addition of 2 volumes (v Iv) absolute ethanol, incubation at RT for 5 minutes 
and centrifugation (microfuge; 12 000 rpm, 10 minutes). After removing the 
supernatant the pellet was vortexed in 1 ml ice-cold 70 % ethanol. DNA was 
repelleted by centrifugation and the supernatant removed. The pellet was dried under 
a centrifugal vacuum using a SpeedVac Concentrator, before being resuspended in 
sterile ddHzO containing 0.01 volume 0.5 ~g/ml Dnase-free Rnase. 
2.2.2.2 Mid-scale preparation of high purity plasmid DNA 
For extraction of very high purity plasmid DNA, such as that used for 
transfection, a Plasmid Midi-Kit was employed. This plasmid purification kit uses a 
modified alkaline lysis procedure, followed by the binding of DNA to anion-
exchange resin, from which impurities are eluted by successive wash steps. DNA is 
eluted with a high-salt buffer, and concentrated and desalted by isopropanol 
precipitation. The manufacturers instructions were followed, and high purity DNA (1 
~g/~l) was obtained. 
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2.2.2.3 Extraction and ethanol precipitation of plasmid DNA 
Following isolation, nucleic acids may be purified from contaminating 
protein by sequential extractions with phenol:chloroform:isoamyl alcohol (25:24:1) 
and then by chloroform. Nucleic acids were precipitated with 0.1 volume (v/v) 
sodium acetate (NaOAc: 3 M; pH 5.2) or 0.25 volume (v/v) ammonium acetate 
(NH40Ac: 10 M) followed by the addition of2.5 (v/v) volumes of absolute ethanol. 
Tubes were inverted to ensure complete mixing and incubated on ice for 10 minutes. 
Following centrifugation (microfuge; 12000 rpm, 10 minutes) the supernatant was 
removed and the pellet was vortexed in 1 ml 70 % ethanol. The DNA was repelleted 
by centrifugation and the supernatant removed. The pellet was dried by spinning in a 
SpeedVac Concentrator and redissolved in sterile ddHzO. 
2.2.3 Protein extraction and quantification 
2.2.3.1 Rapid, small scale extraction of bacterial protein 
Protein from small samples of bacterial culture could be rapidly extracted 
using a freeze/ thaw protocol. Cells from 1 ml samples were harvested by 
centrifugation and washed once with ice-cold PBS. The cells were then pelleted and 
resuspended in Lysis Buffer (100 mM NaCI, 1 mM EDTA, 1 mM PMSF, 1 mg/ml 
lysozyme, 50 mM Tris-HCI; pH 8.0) to an AS90 of 0.7. After incubation at 4°C for 30 
minutes, the cells were ruptured by freeze-thawing, once at -20°C and twice at -80°C, 
with thawing performed at RT. Soluble protein was obtained as the supernatant after 
centrifugation oflysed cells (microfuge; 12000 rpm, 15 minutes). The pellet, 
containing cell debris and inclusion bodies, was washed once with ice-cold PBS and 
solubilized by boiling in 1 X PDB using the same volume as for lysis buffer. 
2.2.3.2 Large scale soluble bacterial protein extraction 
Cells harvested from 1 litre of 2 x TY bacterial broth culture, grown under 
shake flask conditions, were collected by centrifugation (Beckman JA 10; 5000 g, 10 
minutes, 4°q. The supernatant was decanted and the tubes inverted onto absorbent 
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towels to remove as much of the supernatant as possible. The pelle ted cells were 
resuspended in 100 ml of ice-cold PBS containing 1 mM PMSF. Cells were lysed by 
sonication on ice (10 x 30 seconds, 40 % power) and Triton X-l00 was added to the 
crude bacterial lysate to a final concentration of 1 %. Clarification of the lysate was 
performed by centrifugation (Beckman JA20, 12000 g, 15 minutes, 4°C) and the 
soluble protein containing supernatant was collected and frozen at -20°C for no 
longer than 24 hours. 
2.2.3.3 Small scale extraction of soluble protein from skeletal muscle 
Soluble protein from small amounts of skeletal muscle were required for 
SDS-PAGE and Western Blot analysis. Samples (5 gm) from sheep Longissimus dorsi 
and mouse hind limb (1 gm) were trimmed of connective tissue and minced with 
scissors before being homogenised on ice in 5 volumes extraction buffer (5 mM 
EDTA, 0.05 % ~-MCE, 100 mM Tris-HCI, pH 8.3, 4°C) using a polytron (3000 
rpm). The homogenate was centrifuged (Beckman ]A20, 27 000 g, 30 minutes, 4°C) 
after which the soluble protein containing supernatant was collected and filtered 
through glass wool to remove any lipid. An aliquot was removed from the "total 
soluble protein fraction" and heated to 100°C for 5 minutes. The heated solution was 
then centrifuged in a microfuge at maximum speed and the supernatant removed and 
labelled "boiled soluble protein fraction". The protein content from both fractions 
was determined as described in section 2.2.3.4. 
2.2.3.4 Protein quantification 
Protein quantification was performed using either the Bio-Rad Protein Assay 
"Microassay Procedure" (BioRad), or the BCA Protein Assay "Micro titer Plate 
Assay" (pierce) according to the manufacturers instructions. Standards covered a 
range of concentrations from 0.025 mg/ml to 0.5 mg/ml, and were prepared from 
Bovine Serum Albumin (pierce). The standard curves typically displayed an I- value 
greater than 0.95, and both standards and samples were analysed in quadruplicate. 
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2.2.4 Gel electrophoresis 
2.2.4.1 DNA 
Fractionation of DNA electrophoresis using a Mini-Sub Cell gel tank 
provided satisfactory resolution for this study. The agarose concentrations selected 
were based upon the recommendations of Sam brook ct 01. (1989). The gel was 
prepared by melting the appropriate percentage (w Iv) of SeaKem agarose in 1 X 
TBE, and casting into a "minigel" mold. The DNA samples were coloured and 
weighted by the addition of 0.2 volumes of 5 X DNA loading buffer before being 
loaded onto the gel. The electrophoresis buffer used was 1 X TBE containing 
ethidium bromide (0.5 f!g/ml), and gels were typically electrophoresed at 5 V Icm for 
1 hour. DNA was visualised by viewing the gel over an UV transilluminator. 
2.2.4.2 Protein 
Proteins were separated using discontinuous denaturing SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) according to the method of Laemmli (1970). The 
Mini-Protean II apparatus enabled sufficient resolution for this work. Resolving gels 
were composed of 10 % or 12.5 % acrylamide, 375 mMTris-HCl (PH 8.8) and 0.1 
% SDS. The stacking gels were composed from 4 % acrylamide, 125 mM Tris-HCl 
(PH 6.8) and 0.1 % SDS. The 30 % stock acryJamide solution had a ratio of 37.5:1 
acrylamide :N,N'-methylenebisacrylamide. Polymerisation of the gels was initiated by 
the addition of 1 % (v Iv) freshly prepared 10 % ammonium persulphate and 0.1 % 
(v/v) N,N,N',N'-tetramethylethylenediamine (TEMED). Samples to be loaded were 
denatured at 100°C for 3 minutes in 1 X PDB. Gels were pre-run for 10 minutes at 
100 V in Running Buffer before loading the samples and electrophoresis was 
continued at 100 V until the dye front had migrated from the gel. Following 
electrophoresis, proteins were fixed and stained with a solution containing 50 % 
methanol, 10 % glacial acetic acid and 0.25 % Coomassie Brilliant Blue R250~ Gels 
were then destained by repeated washes with a solution of 50 % methanol and 10 % 
acetic acid, and were allowed to reswell in ddH20. Stained gels were preserved by 
drying between two sheets of cellophane using a GelAir Drying System. 
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2.2.4.3 Gel Documentation and densitometry 
A permanent record of agarose and PAGE gels was captured using a Ultra 
Violet Products (UVP) ImageStore 5000 gel documentation system. Using a dual 
white-light and UV-C transilluminator, SDS-PAGE and agarose gels were 
illuminated and images were captured using the incorporated digital camera 
(resolution set at 752 x 582 pixel's). Images were initially saved as *.BMP files which 
could be studied using GelBase/GelBlot Pro image analysis software (UPV). Alkaline 
phosphatase developed Western blots were similarly analysed after being scanned 
using a MicroTek Scan Maker X6el and stored as computer files. 
2.2.5 Purification of DNA fragments with DEAE membrane 
Fragments of DNA produced by restriction digestion or PCR were extracted 
from agarose gels using diethylaminoethyl (DEAE) membrane. Following 
electrophoresis through an appropriate percentage TBE agarose gel in the presence 
of ethidium bromide, the DNA fragment of interest was located with a hand-held, 
long-wavelength ultraviolet lamp and an incision was made directly in front of its 
leading edge. A piece ofDEAE membrane (Schleicher and Schuell NA-45) was cut 
that was same width but slightly deeper than the gel incision. This was prepared by 
soaking in 10 mM EDTA (PH 8.0) for 5 minutes, then replacing this solution with 
0.5 M NaOH and soaking for a further 5 minutes. The membrane was washed 
extensively with ddHzO before being inserted into the gel incision, care was taken to 
exclude air bubbles. Electrophoresis was resumed at 5 V / em until the band of 
interest had migrated onto the membrane. The membrane was removed from the gel 
and washed with 10 mllow-salt wash buffer (50 mM Tris-HCI, 0.15 M NaCl, 10 mM 
EDTA; pH 8.0). The membrane was transferred to a microfuge tube, and the DNA 
eluted by completely immersing the membrane in the least possible volume of high-
salt elution buffer (50 mM Tris-HCI, 1 M NaCl, 10 mM EDTA; pH 8.0), and 
incubating at 65°C for 30 minutes. After removing the fluid to a new microfuge tube, 
the membrane was incubated for a further 15 minutes in a second aliquot of high-salt 
elution buffer. The two aliquots of elution buffer were combined and nucleic acid 
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was extracted using phenol:chloroform and ethanol precipitation as described in 
section 2.2.2.3. 
2.2.6 Assessment of DNA concentration and purity 
The yield and quality of plasmid DNA was determined 
spectrophotometrically. The absorbance at wavelengths 260 and 280 nm were read 
on a DNA sample which was first diluted (as much as 1000 fold) in ddHzO. An A z60 : 
A z80 ratio of 1.8 indicates that the DNA is free from RNA and protein 
contamination. A solution containing 50 Jlg/ml double-stranded DNA has an 
absorbance of 1 at 260 nm. Thus the DNA concentration was calculated froni the 
following equation: 
DNA Concentration {J1g/ mO = A 260 x 50 x dilution factor 
Where required, DNA purity and quantity was further assessed by 
electrophoresis of the sample and standards through an agarose gel and staining with 
ethidium bromide. Subjective comparisons between the fluorescent intensity of the 
unknown sample and a known DNA standard were made. Typically, a titration of 
samples would be compared to a titration of Hind III restriction enzyme digested A 
DNA. Knowing the fragment sizes in base pairs and total concentration of the 
standard DNA enables calculation of the DNA concen"tration for each fragment 
(usually encompassing a range from 0.3 - 238.0 ng). By titrating both the sample and 
the standard it is possible to assess which standard fragments fluorescence most 
closely resembles that of the sample, and thus estimates the concentration of the 
sample. 
2.2.7 DNA manipulation 
2.2.7.1 Restriction enzyme digestion 
Restriction enzyme digests of DNA were performed according to the 
manufacturers recommendations of incubation buffer, temperature, time and 
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addition of other reagents such as BSA. Where two restriction enzymes with 
differing optimal salt concentration requirements were used in a single reaction, the 
buffer conferring the greatest predicted activity to both enzymes was used. Each 
digest typically contained DNA, endonuclease, buffer and water. 
2.2.7.2. Ligation 
Ligation was used to introduce purified PCR products into expression 
vectors. DNAs were ligated in a reaction volume of 10 III reaction buffer (66 mM 
Tris-HCl pH 7.5, 5 mM MgC12' 1 mM DTT, 1 mM ATP) containing 1 unit T4 DNA 
Ligase. The concentrations of vector to insert were chosen based upon the protocol 
described by Sam brook et al. (1989). The mixture was incubated at RT for 3 hours. 
Ligations were terminated by heating to 65°C for 10 minutes. The efficacy of the 
ligation was confirmed by agarose gel electrophoresis of 0.1 volume of the ligation 
mixture. 
2.2.8 Nucleotide sequencing 
PCR products were purified from agarose using DEAE paper and ethanol 
precipitation. The DNA was sequenced by dideoxy-dye chain-termination chemistry 
using PCR primers described in Table 2.1.4. Termination products were analysed on 
an Applied Biosystems Automated Sequencer at the Centre for Gene Technology, 
School of Biological Sciences, University of Auckland (NZ). Sequence analysis was 
carried out at Lincoln University using DNAMAN (ver 4.0a). 
2.2.9 The polymerase chain reaction 
The polymerase chain reaction (PCR) was used to amplify particular 
sequences of DNA fragments and to introduce restriction enzyme recognition 
sequences at critical points of the amplimer. DEAE membrane purified DNA 
fragments (50 ng) were amplified in a reaction volume of 100 J.1l consisting of 1.5 
mM MgC12' 1.0 mM dNTP's, 2 11M oligonucleotide primers, and 1 U Taq 
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polymerase, the reaction volume was overlaid with 50 J.1l sterile mineral oil. Samples 
were amplified using a Perkin Elmer GeneAmp PCR System 2400 thermal cycler. 
The program consisted of 30 cycles of 95°C for 1 minute, 56°C for 2 minutes and 
78°C for 2 minutes, cycling was completed with a 10 minute incubation at 78°C 
before maintenance at 4°C, Nucleic acids were isolated by adding 1 volume of 
chloroform (150 J.lI) to the PCR reaction, vortexing and centrifuged (microfuge; 12 
000 rpm, 10 minutes). After removing the nucleic acid containing supernatant, PCR 
products were purified free from amplification primers and reagents with agarose gel 
electrophoresis and DEAE membrane purification as described in section 2.2.5. 
2.2.10 Preparation and purification of GST-fusion proteins 
An aliquot of frozen transformed bacteria was thawed on ice before being 
added to 5 ml LB broth (containing appropriate antibiotic). The inoculated LB 
culture was grown at 37°C overnight with constant shaking. The following day 1 ml 
of the stationary phase culture was used to inoculate 1 litre of 2 x TY broth 
containing appropriate antibiotic which was incubated at 3rC with constant shaking. 
The absorbance of the culture at 590 nm was monitored by removing 1 ml aliquots 
at 1 hour intervals and measuring in a spectrophotometer. When the culture reached 
an absorbance density of 0.8, the bacteria were induced to transcribe the GST 
plasmid by the addition of 0.5 ml 500 mM IPTG. Samples of bacteria (1 ml) were 
taken immediately prior to addition of IPTG and at 1 hour intervals. Protein was 
extracted as described in section 2.2.3.1, and electrophoresis enabled the appearance 
of the target protein to be monitored. 
Once suitable quantities of the desired protein had been expressed, soluble 
bacterial protein was extracted as described in section 2.2.3.1. The soluble protein 
containing supernatant was thawed on ice and mixed with 10 ml50 % (v/v) slurry of 
glutathione-agarose beads. Binding took place overnight at 4°C with gentle 
revolution (15 rpm) using a Hybaid oven. GST fusion proteins bound to glutathione-
agarose beads were collected by centrifugation (varifuge; 1000 rpm, 15 minutes, 4°C), 
the supernatant was decanted and replaced with 100 ml of 0.1 % Tween-20. Beads 
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were mixed by rotation for 20 minutes. Centrifugation and washing steps were 
repeated twice more with 100 ml of 0.1 % Tween-20, and three times with 100 m1 
PBS. Finally, the beads (5 m1 bed volume) were pelleted by centrifuging (varifuge; 
1000 rpm, 10 minute, 4°q and resuspended in 10 ml of PBS containing 100 cleavage 
units of thrombin. This mixture was gently rotated at RT for 4 hours. While'the GST 
fragment remained immobilised on the beads, the calpastatin fragments were released 
and could be recovered from the supernatant. In parallel experiments, the equivalent 
supernatant fraction from bacteria expressing GST alone from pGEX-4T-l was also 
recovered and used as negative controls in calpain inhibition assays. Yields of 
purified calpastatin fragments were calculated with the BCA protein assay. 
2.2.10.1 CBND assay for GST activity 
The detection and quantification of GST was accomplished through 
measuring the appearance of a conjugate which arises from the interaction between 
GST and l-chloro-2,4-dinitrobenzene (CBND). A CBND assay solution was freshly 
prepared (100 mM KHZP04 / KzHP04 pH 6.5, 1 mM CBND, ImM reduced 
glutathione) from 100 mM CBND stock dissolved in absolute ethanol. Sufficient 
volumes were transferred to UV-transparent cuvettes, and sample aliquots of 
between 1/10 and 1/100 volume were added, volumes in non-sample cuvettes were 
made to equivalent volume with water. The mixtures were well mixed and placed in a 
twin-beam spectrophotometer measuring at 340 nm. The reaction is constant within 
the limits of sensitivity of the spectrophotometer, and quantification of GST is 
achieved by measuring reaction rate according to the following equation: 
MHO / minule / ml sample MHO (td - M)4o (ttl 
(12 - I/)(ml sample added) 
It is necessary to include a control assay solution (lacking sample) to account 
for any background increases in absorbance. Pure, recombinant GST was used for 
quantification after determining its protein concentration. A selection of 
concentrations were assayed and the rate increase plotted, thus allowing the 
determination of approximate GST concentration in samples. 
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2.2.11 Recombinant protein activity assay 
2.2.11.1 Calprun protease assay 
The activity of the calprun proteases was determined by measudng the 
hydrolysis of a substrate protein (Koohmarrue., 1990). Briefly, aliquots of calpain 
(made to 1.0 ml with ddHzO) were incubated at 25°C with 1.0 ml Assay Buffer (100 
mMTris-HCI pH 7.5, 0.7 % casein, 50 mM ~-MCE, 1 mMNaN3) and 100 fll of 0.1 
M CaClz or 0.2 M EDTA. The reaction was stopped after 30 minutes with 2 ml ice-
cold 5 % TCA and the mixture was centrifuged (vadfuge; 2 500 rpm, 15 minutes, 
20°C). The absorbance of the supernatant was read at 278 nm, after blanking against 
ddHzO. One unit of calprun was defined as the amount that gave a calcium 
dependent increase of 1.0 unit of absorption in 1 hour. 
2.2.11.2 Calpastatin assay 
Quantification of calpastatin activity is achieved through measuring its ability 
to reduce the activity of calprun. Aliquots of purified calpastatin were preincubated 
for 10 minutes at 4°C with a fixed amount of bovine m-calpain (0.2 units) extracted 
as previously described (Edmunds et aI., 1991). The volume was made to 1.0 ml with 
ddHzO, and followed with a further 1.0 ml of Assay Buffer. Inclusion of CaClz, or 
EDTA, reaction incubation and termination, and the measurement of activity was 
performed as described for calprun (section 2.2.11.1). The absorbance of samples not 
contruning calpastatin aliquots were calibrated to represent 100 % m-calprun activity, 
and were used as a comparison for the samples. Activity of calpastatin was expressed 
either as percentage reduction in calprun activity or Units activity, wher~ 1.0 Unit was 
defined as the amount of calpastatin which completely eliminated 1.0 Unit calprun. 
2.2.12 Amino acid sequencing 
For N-terminal amino acid determination, thrombin-treated calpastatin 
fragments were separated on SDS-PAGE and electroblotted onto polyvinylidine 
difluoride membrane (PVDF) using 3-[cyclohexylamino]-1-propanesulphonic acid 
Chapter 2 : Materials and Methods 48 
(CAPS) buffer (10 mM CAPS pH 11, 10 % methanol (v Iv)). The positions of the 
protein bands were ascertained by Coomassie staining and automated Edman 
degradation was performed using an Applied Biosystems Model 476A sequencer at 
the Bioprocessing Technology Centre, National University of Singapore, Singapore. 
2.2.13 Generation of polyclonal antibodies 
Recombinant domain L and domain 1 were purified as described in section 
2.2.10. Four 6 week old New Zealand White rabbits were selected for generating 
antibodies. These were divided into two pairs, one animal (A) within each pair would 
receive a total of 780 Ilg protein from 4 immunisations, the other (B) would receive 
900 Ilg protein over 3 immunisations. The two pairs would be exposed to either 
domain L or domain 1 antigen, resulting in four different immunisation regimes 
referred to as L(A), L(B), 1 (A), and 1 (B). 
The first immunisation was performed at 6 weeks of age. Antigen (1.2 
mg/ ml) was emulsified with an equal volume of Freund's Complete Adjuvant, and 
100 III was subcutaneously injected over 4 (A) or 6 (B) sites across the animals back. 
Boosters were at 4 week intervals, and differed in respect to the volume (75 Ill) 
injected, but not the number of injections or the sites. 
Immediately preceding the first immunisation, and 10 days after each booster, 
5 ml blood samples were collected by making a small incision in the marginal 
auricular vein. Prior to the incision being made, the vein region was shaved, bathed 
in ethanol, rubbed and swabbed with d-limonene. This has a vasodilative effect and 
ensures swift and simple blood collection. Blood samples taken after the first 
immunisation were examined for immunogenic response, while the sample taken 
prior to the first immunisation served as a control. 
One month after the second booster, B animals were anaesthetised using 
Ketamine HCI (100 mg/ml) and Xylazine HCI (22.8 mg/ml) at a 3: 2 ratio and a 
final volume of 2.5 ml / 4 kg body weight. A heart puncture was used to 
exsanguinate the animals, and blood was collected into non-heparinised centrifuge 
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tubes. The blood was allowed to coagulate and the serum was collected after gentle 
centrifugation. Animals belonging to the A group were administered a third booster, 
and 1 month later were sacrificed as described above. 
2.2.14 Western analysis 
Western blotting uses chromogenic immunological techniques to identify 
specific proteins within a complex mixture. Protein preparations were first resolved 
by SDS-PAGE and then electro blotted to Nitrocellulose Membrane using a 
Transblot Apparatus immersed in Transfer Buffer. Proteins were transferred at RT 
for 1 hour using a constant supply of 100 V. Upon completion, the membrane was 
immersed in Blocking Solution I (1 X TTBS containing 5 % (w/v) non-fat dry milk 
powder) for 1 hour at RT with gentle rocking. The membrane was similarly 
incubated with Blocking Solution II (1 X TTBS containing 3 % (w/v) non-fat dry 
milk powder) containing the primary antibody (Table 2.1). After removing the 
primary antibody solution the membrane was washed 3 times for 5 minutes with 
TTBS. Secondary antibodies (Table 2.2) were all conjugated to alkaline phosphatase 
and were added in Blocking Solution II. The membrane was incubated and washed 
as previously described. Finally, the blot was developed using the Alkaline 
Phosphatase Conjugate Substrate kit according to manufacture's instructions. 
Typically blots would be allowed to develop for 5 - 20 minutes before the membrane 
was washed with copious amounts of ddH20 and air dried. 
2.2.15 Cell culture 
2.2.15.1 Maintenance 
Skeletal myoblasts (C2CI2, ATCC) were grown on either 100 mm culture 
plates or T175 Culture Flasks with 10 ml or 40 ml, respectively, "complete growth 
media" (Dulbecco's Modified Eagle Medium supplemented with 10 % Foetal Calf 
Serum and 0.1 % (v Iv) each of Fungizone and Penicillin-Streptomycin). Plates were 
incubated at 37°C in a moisture saturated 5 % CO2 in air atmosphere. 
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2.2.15.2 Passaging 
Immediately prior to cells reaching confluence they were passaged. Media 
was removed and the plates were washed with 1 X PBS pre-warmed to 37°C, this 
was then replaced with 2.0 ml pre-warmed 4 % Trypsin/EDTA and the plates were 
returned to the incubator for 10 minutes or until all cells had released from the plate 
surface. At this time the solution was removed to a sterile 15 ml centrifuge tube, 
combined with 8.0 m1 complete growth media and centrifuged (varifuge; 400 rpm, 10 
minutes, 25°C). Media was decanted and the cell pellet resuspended in fresh 
complete growth media. Aliquots of suspension were seeded into new culture vessels 
to produce a cell density of 20 %. 
2.2.15.3 Cryopreservation 
For cryopreservation of cells after passaging, the pellet was resuspended in 
complete growth media supplemented with 5 % (v Iv) DMSO. The suspension was 
then aliquoted as 1.0 ml volumes into cryovials and frozen to -80°C at a rate of -1°C 
per minute. Any subsequent thawing of cells was performed rapidly to 37°C. 
2.2.15.4 Fusion induction 
Cells grown in complete growth media could be made to undergo fusion 
upon reaching confluence. Complete growth media was removed, the plate washed 
with 1 X PBS pre-warmed to 37°C, and the media was replacing with "differentiation 
media" (Dulbecco's Modified Eagle Medium supplemented with 2 % Horse Serum 
and 0.1 % (v Iv) each of Fungizone and Penicillin-Streptomycin). For extended 
growth periods, plates were washed with PBS and supplied with fresh differentiation 
media every other day. 
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2.2.15.5 Protein extraction 
Total protein was extracted from C2C12s following the release of cells from 
their support using trypsin/EDTA digestion. After washing with PBS to remove 
trypsin, cells from a 100 mm plate were pelleted by gentle centrifugation in a 1.5 ml 
microfuge tube. Excess solution was decanted and 200 JlI Lysis Solution (20 mM 
Tris-HCI pH 7.4, 150 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 0.1 mM AEBSF 
(4-(2-aminoethyl)-benzenesulphonyl fluoride), 10 Jlg/ml Aprotonin) was added. The 
pellet was then disrupted by sonication on ice for 10 seconds at 25 % maximum 
power. Finally, Triton X-1 00 was added to a final concentration of 1 %, and the 
homogenised solution inverted 5 times before being incubated on ice for 20 minutes. 
Protein concentration was determined as described in section 2.2.3.2 and samples 
were immediately prepared for SDS-PAGE analysis by dissolving them in an 
appropriate volume ofPDB. 
2.2.15.6 Cell staining and microscopy 
Where examination using a light microscope was desired, cells were cultured 
on flame sterilised coverslips in 35 mm plates under whatever conditions were 
demanded. At appropriate times, the media would be removed and the coverslip 
washed by bathing the plate three times with pre-warmed 1 X PBS. While still in 
solution, the coverslip would be gently levered from the plate and placed into 100 % 
methanol for 5 minutes to fix the sample. After air drying, the cells were stained with 
Giemsa Solution according to manufacturers instructions. Coverslips with stained 
cells were mounted cell-side down onto glass slides using a drop of DPX mountant. 
Routine examination of slides was carried out using an Olympus CH2 light 
microscope. Photography used Fujichrome Sensia II 400 fIlm in a Pentax Asahi 35 
mm reflex camera attached to a Zeiss Standard Microscope with a Zeiss MC63 
photomicrographic regulator. 
Fluorescent microscopy followed similar lines, cells were grown directly on 
coverslips and washed with PBS. Fixation was performed by incubating the cells for 
30 minutes at RT in 4 % paraformaldehyde dissolved in PBS. Cells were washed 
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twice with PBS and mounted cell-side down into glass slides with a drop of 50 % 
glycerol dissolved in ddH20. The coverslip was sealed with 10 % molten agarose, 
dried at RT for 30 minutes, and stored at -20°C until required. Fluorescence was 
very stable under these conditions and could still be detected after 3 - 4 months. 
Microscopy and photography was performed as described above with the inclusion 
of a Zeiss 450~490 - 510 nm block ftlter, and a Xenon lamp. 
For obtaining confocal microscope images, paraformaldehyde fixed samples 
were examined with a BioRad Microradiance confocal system linked to an Olympus 
IX -70 inverted microscope and viewed under oil emersion. The blue line of the 
argon laser was used for excitation and a 510 nm emission ftlter was used for 
observing GFP fluorescence. This work was performed at the Plant and Microbial 
Sciences Department, University of Canterbury, NZ. 
2.2.16 Zymographic PAGE analysis 
Zymographic gels enable detection of proteolytic activity in protein samples 
fractionated by non-denaturing PAGE (Raser ct aI., 1995). Acrylamide resolving gels 
were prepared from 375 mM Tris-HCl pH 8.8, 12.5 % acrylamide, 0.5 mg/ml casein 
solution (7 mg/ml casein in 100 mM Tris-HCl pH 8.8), 0.05 % TEMED and 0.5 % 
APS. The stacking gel was prepared as described in section 2.2.4.2, with the 
exception that it did not contain SDS. The gel was pre-run at 100 V for 15 minutes. 
The protein sample was mixed with Non-Denaturing Sample Buffer (4X; 150 mM 
Tris-HCI pH 6.8, 20 % glycerol (v/v), 0.75 % ~-MCE, 0.1 mg/ml bromophenol 
blue) and loaded. Electrophoresis was performed at 4°C in Non-Denaturing Running 
Buffer (25 mM Tris-HCl pH 8.3, 192 mM glycine, 1 mM EDTA, 0.5 % ~-MCE) for 
8 hours at 100 V. The gel was removed and incubated in CaCl2 solution (50 mM 
Tris-HCI pH 7.5, 4 mM CaCI2, 0.05% ~-MCE) three times for 20 minutes and finally 
left overnight at RT. The gel was then stained with Coomassie and destained as 
usual. 
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2.2.17 F ACS analysis 
Cells suspended in PBS were analysed using a fluorescence activated cell 
sorting (FACS) vantage flow cytometer (Becton Dickinson San Jose, CA) equipped 
with a 488 nm argon ion laser with fluorescence emission detected at 525 nm using a 
Dichroic Filter (DF) 530/30. This work was performed at the Christchurch Medical 
School, Christchurch, NZ. 
Chapter 2 : Materials and Methods 54 
Chapter 3 
Expression and purification of ovine calpastatin domains 
Land 1 in Escherichia coli, and the generation of specific 
polyc1onal antibodies 
3.1 Introduction 
As outlined in Chapter 1, there is evidence that the primary role of the 
calpains in myoblast fusion is the proteolytic disassembly of membrane proteins 
which allows fusion to take place. Microscopic examination and 
immunocytochemical evidence suggests that this proteolysis predominantly occurs at 
or around the plasma membrane during fusion. This observation would indicate that 
calpain is preferentially directed to the plasma membrane. However, the mechanism 
responsible for this localisation remains unknown. 
Previously, calpastatin has been found to localise with membrane 
preparations from sarcolemma and sarcoplasmic reticulum vesicles (Mellgren et aI., 
1987a; Mellgren et aI., 1987b). A proposed mechanism to account for the facts is that 
the basic amino acids of calpastatin associate with the acidic membrane 
phospholipids (Mellgren 1988; Mellgren et aI., 1989). It has been noted that domain L 
is relatively rich in basic amino acid residues which contributes to the high isoelectric 
point (Lee et al., 1992). Domain L of calpastatin is thought, therefore, to be 
responsible for targeting the protein to areas of the plasma membrane. The 
functional in vivo significance of domain L is explored in Chapter 4. 
Crucially, for calpain to be responsible for proteolysis it must avoid inhibition 
by calpastatin. Some data suggests that a down regulation of calpastatin mRNA 
expression and protein levels might accomplish this. At this point in time, 
information regarding the involvement of calpastatin in the fusion process remains 
incomplete. This chapter reports on the attempt to express large quantities of 
recombinant calpastatin variants encoding domain 1, domain L or domains Land 1 
combined. The physical characteristics and activities of these variants will then be 
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compared and contrasted. Purification of the three calpastatin variants will be 
described, together with their subsequent use in the generation of polyclonal 
antibodies for use in later experiments. 
3.2 Cloning strategy to generate recombinant calpastatin from E. coli 
The ability to obtain pure protein samples is critical when examining protein 
structure and function in vitro. It is also important in the production of good quality 
antisera. Traditional chromatographic techniques to separate calpastatin from tissue 
samples are elaborate (Mellgren & Carr 1983) while more compact methodologies do 
not generate a pure product (Koohmaraie 1990). Furthermore, despite the 
improvements in extraction techniques (Geesink et aI., 1998), the isolation of pure, 
native calpastatin with a high specific activity remains laborious. 
An alternative strategy is to produce synthetic oligopeptides based upon 
active calpastatin (Maki et aI., 1989). This approach is especially useful when 
developing therapies demanding extremely pure protein, or investigating specific 
structure and function relationships, or producing affinity columns (Anagli et al., 
1996). This technology, however, is not suited for larger or more complex proteins 
because of the inability to introduce the appropriate post-translational modifications 
and the accumulation of errors inherent in the production process. 
E. coli and some cell culture systems represent successful vehicles for the 
over-expression of both prokaryotic and eukaryotic protein Several systems are 
commercially available which permit the researcher to express a cDNA of interest. 
Such recombinant DNA techniques, while revolutionary, are not completely free of 
challenge. Host contamination, product solubility, structural integrity and biological 
activity are all potential problems. 
An early example of expression of calpastatin domains in E.coli was provided 
byMaki etal. (1987a; 1987b). In these studies, however, no attempt was made to 
quantify expression or to purify the recombinant product. Subsequent experiments 
by the same researchers used boiling, ammonium sulphate precipitation, ion-
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exchange and gel f.t1tration chromatography to purify the expressed recombinants 
(Malci ct aI., 1988; Ma ct aI., 1993; Ma ct a4. 1994) using standard extraction practices 
applied to tissue samples. 
As biotechnology develops, more powerful expression systems have become 
available. One particularly useful tool is to "tag" distinctive residues to the 
recombinant product, thus resulting in fusion hybrids. Following expression, the 
target protein may be purified though relatively simple affinity chromatography. In 
recent work, recombinant calpastatin was "tagged" with an N-terminal hexahistidine 
and expressed in E.coli and insect cells (Hitomi ct aI., 1998). The nature of the 
additional sequence was exploited to facilitate purification via affinity 
chromatography. However, this system did not permit isolation of calpastatin alone 
without additional residues. One system which has been used for the purification of 
many proteins employs the pGEX series of plasmids. These were created by Smith 
and Johnson (1988) to direct the synthesis of foreign polypeptides in E.coli as fusions 
with a 26 kDa Glutathione S-Transferase (GS1) encoded by the helminth Schistosoma 
japonicllm. This system has been used successfully to express active regions of 
calpastatin in bacteria (Doumit ct aI., 1996; Melloni ct aI., 1998a), and is particularly 
attractive since it allows the separation of the tag from its fusion partner via specific 
proteolytic cleavage. This is often important, because tags can be highly 
immunogenic and hamper immunodetection of target antigens \i oussoufian 1998). 
The vector encoding GST contains a protein sequence sensitive to thrombin 
proteolysis at a point between GST and its fusion partner. Cleavage at this point 
enables isolation of the fusion partner from GST following its immobilisation onto 
glutathione affinity agarose beads. 
Knowledge of the ovine calpastatin cDNA sequence (see Appendix B) 
permitted the design of peR primers that would amplify domains Land 1 separately, 
or in combination. The primer sequences were chosen to contain restriction enzyme 
sites that matched those of the GST vector's multiple cloning site. After digestion, 
these permit sticky-ended ligation of the insert into the vector in the correct 
orientation and reading frame with respect to the N-terminal GST start codon. An 
examination of the cDNA sequence also confirmed the absence of stop codons 
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(fAA) that would cause premature cessation of transcription. Figure 3. 1 provides a 
schematic overview of the process. 
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Figure 3.1 Construction of GST ..calpastatin plasmids. Ovine calpastatin cDNA contained within 
pBluescript II KS. (pBSCalstn) was extracted from translormed bacteria, and purified. Digestion 
with Xbal and Sacl released a fragment containing domains l -l : this was used as templ. te ONA 
in peR reactions. Three reactions were performed using primer combinations of OL s· & DL 3", D1 s· & 
0"· and Ol' · & OF, generating amplimers 01 domains L 1 and l-l respectively. The PCR products 
were gel purified and digested with restriction enzymes to generate sticky.ended products. These 
could then be ligated into a similarly digested pGEX-4T-l vector. The resultant construct is then 
suitable for introduction into E. coli and expression of recombinant fusion protein. 
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3.2.1 T emplate preparatio n 
Generation o f GST-ca1pastatin constructs began with a double diges tio n of 
pBSCalstn using the restrictio n enzymes Xba 1 and Sac1 , as described in seelio n 
2.2.7. 1. Digestion with Xba l releases th e insert from pBSKS, while Sac! cleaves at a 
point wi thin the insert (specifically 71 bp in to domain 2, see Appendix il) producing 
two fragments. The largest o f th e three fragments produced in this digestion 
represents the pBSKS vector (see Append ix A.I) while the former two represent the 
totali ty o f the calpastatin insert. E lectrophoresis thro ugh an agarose gel separated the 
products o f this diges tion (see Figm e 3.2). The smaller 862 bp fragment containing 
domains Land 1 and a sho rt sequence o f domain 2 was extracted from the gel using 
D EAE membrane as described in section 2.2.5. Following purifica tion, band 
homogenejty and size was co nfirmed by gel electrophoresis. 
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Figure 3.2 Extraction and purification of cDNA encoding domains Land 1. Agarose gel 
electtophoresis of pBSCalsln digesled wilh Xbal and Sail . producing 3 1ragmenls embracing 
pBSKS veclor (2958 bp). calpaslatin domains 2 - 4 (1425 bp) and calpaslalin domains l - l • 71 bp 
domain 2 (862 bp). 
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The quantity and purity of the DNA template was determined by measuring 
its absorbance at 260 and 280 nm. 
3.2.2 Amplification of calpastatin domains 
Three peR reactions were performed as described in section 2.2.9 using the 
862 bp fragment as template DNA and the primers shown in Figure 3.3. For suitable 
translation, the product of transcription must contain an initiation codon (usually 
AUG) and stop codon CUAA, UGA or UAG). The GST cDNA contained in the 
pGEX-4T-l plasmid contains an initiation codon upstream of the multiple cloning 
site, which is suitable for directing translation of the GST fusion proteins. However, 
there are no stop codons contained within domain L and domain 1 sequences. Thus 
TTA codons were included in both 3' primers, equating with ATT sequence in the 5' 
~ 3' strand, and a UAA triplet (stop codon) in the consequent mRNA. 
A 
B 
c 
D 
5' CTGCCGGAATTCATTCCCACAGAAGCCAAGGCT3' 
• EcoRl 
5' CAGCCGGTCGAcfiT!ijrGCAGAAGGTTTACTTGGCTTG<i' 
• SaIl 
5'CTGCCGGAATTCAAGTCAGACATGGATACTGCT3' 
+ EcoRl 
5' CTGCCGGTCGA<fiTPJCTCTTCCACTTTTCTTCTTTTC3' 
+ SaIl 
Figure 3.3 peR primer sequences used for the amplification of domains Land 1. Primer A is 
the 5' primer for Domain L (DLGSTS~, primer B is the 3' primer for Domain L (DLGSP1, primers C 
and Dare 5' and 3' primers for domain 1 (D1GSTS' and DlGSP' respectively). Bold nucleotide 
sequence is homologous to ovine cDNA, stop codons (boxed) were introduced to downstream 
primers and restriction enzyme locations are noted together with cut points (arrowed). Remaining 
nucleotides are non-homologous to ovine cDNA but are included to provide an "overhang" region. 
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The amplimer products from this pe R include the desired eDNA fragment 
and an additional 27 base pairs. This ex tension is composed of the restriction site (6 
bp) and a non-homologous overhang (6 bp) cnnmined in both primers, and stop 
cede ns (3 bp) in both 3' primers. Accordingly, the resultant amptimcr sizes are 357 
bp for the leader domain fragment, 432 bp for the domain 1 fragment, and 762 bp 
fragment combining both leader and I (see Figure 3.4). 
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Figure 3.4 Amplimer products resulting from peR. An 862 bp Iragment containing calpas{atin 
domains Land 1 (together with 71 bp of domain 2) was used as template to produce amplimers 
containing domain l, 1 and l T 1 only. 
After pe R, these fragments were gel electrophoresed, extracted using DEAE 
membrane, ethanul precipitated, and digested with Eco R 1 and Sail to produce 
sticky-ends. The pGEX-4T-l expression vector (see Appendix A.3) was similarly 
digested befo re ge.l frac tio natiun ,lI1d ethanol precipitated. After precipitatio n aU 
products (peR amptimers and digested pGEX-4T-l ) were subjected to phenol / 
chloro form extraction (see sectio n 2.2.2.3) and quantifit:d priur LO liga t..ion. 
3.2.3 Ligation and transformation 
peR products were ligated separately into digested pGEX-4T- 1 and the 
resultant product used to transform competent BL21 E. (o/i (see section 2.2.1). 
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Transformed bacteria were selected through their resist:lncc to ::I.mpicillin antibio tic. 
After 24 hours the plates were examjned, and based upon "blue-wh ite" selection the 
procedure appeared to have been 100% success ful in producing plasmids con tain ing 
inserts (sec section 2.2. 1.1) . By digesting the vecto r to completion with russ imiJar 
restriction enzymes it is possible to produce different sticky-end profiles. \'(Iith the 
use uf gel fractionation to isolate the desired fragme nt, the prospect o f the digestion 
products reuniting is eliminated and incorporatio n of insert is the only way to 
produce a construct with the potential for replicat ion. The DNA from 10 colonies, 
peculiar to each transformation treatment, was harvested fo llowi ng the miniprep 
protocol (section 2.2.2. 1) and subjected to a double restriction enzyme digestion 
designed to remove the insert. The nature of the insert was assessed by examination 
after gel e1ectrophoresis (see Figure 3.5) 
lOOObp-
8OObp-
6OObp-
SOObp -
'OObp-
3OObp-
200bp-
lOObp-
Figure 3.5 EcoRl and Sal1 digestion of miniprep DNA from successfully transfonned 
bacterial colonies. Gel shows pGEX-4T-1 vector and inserted domains L, 1 and L + 1, with 
predicted sizes 014959 bp, 343 bp, 418 bp, and 748 bp respectively. 
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3.2.4 Sequencing data 
As a final confirmation, the plasmids generated by this work (pGEX-DL, 
pGEX-D1 and pGEX-DLl ) were sequenced using the primers o riginally used for 
the amplification o f respective inserts. The sequences were almost identical to the 
repo rted ovine calpastatin eDNA sequence (Collingwood 1994) and to other 
cal pasta tin sequences when submitted to GenBank for analysis. Moreover, there was 
no evidence of unexpected stop codons that can sometimes arise during peR. 
Ovlne Calpaslatin Domain l 
3' pGEX-Dl sequence 
5' pGEX-DL sequence 
5' pGEX-DL1 sequence 
DlGSP ') 
Ol1GSTS,) 
=::::J1-"99:.;.:%-----, 
________ -,~ 91% 
Ovine Calpastatin Domain 1 ~ 
98% 91 ~ J' pGEX-D1 sequence ~,,,,OO'--'%'-----____ ..J_ _ . 
J' pGEX-DL 1 sequence 1-"'-=------
5' pGEX-D1 sequence 
A 
B 
Figure 3_6_ Homology trees comparing sequences contained within pGEX-DL, pGEX-Dl and 
pGEX-DL 1 constructs, with domain Land 1 sequence from ovine calpastatin. A. Ovine 
calpastatin domain L compared to 5' sequence of inserts encoding domain l and domains L ... '. 
and Ihe reverse complementary sequence of J' sequenced domain L B_ Ovine calpastatin domain 
1 compared 10 inserts encoding reverse complementary sequences of J' sequenced domain 1 and 
domain L + 1, and 5' sequenced domain 1. Schemalic diagrams show the application of primers 
used in the sequencing reactions_ Percenlage homology belween closest pairings is displayed. 
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3.2.5 Summary 
Regions of the ovine calpastatin cDNA sequence corresponding to domains 
Land 1 have been PCR amplified separately and in combination producing cDNA 
for domain L, 1 and L+ 1. Separately, the three sequences have been controllably 
incorporated into a GST expression vector ready for protein expression. 
3.3 Expression and purification of GST - calpastatin fusion proteins 
E coliBL21 bacteria harbouring pGEX-4T-1, pGEX-DL, pGEX-D1 or 
pGEX-DLl were used to produce GST - fusion proteins GST-DL, GST-D1 and 
GST-DL1 respectively. BL21 E coli are excellent host bacteria for protein expression 
(Studier & Moffatt 1986) because they lack both the Ion and OmpT proteases 
(Phillips ct aI., 1984; Grodberg & Dunn 1988). Cells deficient in these proteases 
accumulate recombinant proteins more quickly and are less likely to degrade some 
proteins during purification. BL21 Ecoli have been previously used successfully for 
the expression of a variety of recombinant proteins including active calpastatin (Ma ct 
aI., 1993; Ma ct al, 1994; Hitomi ct aI., 1998; Kato ct aI., 2000). 
3.3.1 Induction of recombinant fusion proteins 
Transformed bacteria were grown to log phase and induced to express 
protein using IPTG as described in section 2.2.10. There were no differences in 
growth rates or final density between untransformed and transformed bacteria (data 
not shown). A difficulty sometimes experienced with expression of large amounts of 
recombinant protein is the accumulation of inclusion bodies and resultant 
insolubility. A variety of approaches have been tried to obtain greater solubility 
through lower induction temperatures and IPTG concentrations, and longer 
induction periods. However, although protocols exist to retrieve insoluble protein 
(Frangioni & Neel 1993; Thatcher & Hitchcock 1994) there are some benefits from 
producing a protein that forms inclusion bodies. Target proteins are often protected 
from proteolytic breakdown and inclusion bodies are easy to isolate as a first step in a 
purification scheme. A comparison between the total insoluble and soluble protein 
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fractions was made and it was apparent that the majority of the fusion protei n was 
expressed in a soluble form (see Figure 3.7). 
Insoluble Protein 
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Figure 3.7 SOS·PAGE gel separating components of 10lal soluble and insoluble protein 
fractions Intense bands of recombinant protein appearing 5 hours after induction of expression 
occur more prominently in the soluble fraction. 
Af'"er centrifuhTtltion to remove the insoluble protein fraccion, the 
recombinant protein was easi ly scparalctl fro In the crude bacterial soluble fraction 
using affinity chromatography. G lutathiuno-agarosc beads spccificaUy bind GST and 
in so doing, separate the fu sion protcin from unbuuntl proteins. Samples of protein 
supernatant taken before and after incubation with glulaLltionc:-agarose beads were 
e lectrophoresed and stained. These samples revealed, from subjective ouservation, 
that less than half o f the expressed protein was being retained on the beads. A more 
precise measurement was obtained by exploiting the measurable activiry of GST 
upon its chromogenic substrate; l -chloro-2,4-dinitrobcnzene (CBND). The reaction 
resulting from GST's action upon CHND produces a conjugate whose absorbance 
can be measured at 340 nm (see sectio n 2.2. 10.1). I f required, this technique provides 
a way to estimate concentration (by weight) of expressed GST. Results from this 
analys is revealed that only 29 % of GST-DL was retained bound to the beads, 3 1 % 
of GST-Dl and 35 % of GST-DLl. Thus, two-thirds of the expressed protein was 
not recovered. Increasing the bead volume would be the simple solution to resolve 
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this hut the o bjective o f this work was to obtain sufficient pure protein for raising 
antibodies. Additional binding was therefo re no t performed. 
Beads from the purificatio n o f each recombinant pro tein were washed 
repcatt;: lU y with PBS until unbound protein was eliminated from the liguid frac lion. 
To test the purity uf each GST fusion pro tein prior to Lhrombin treatment, an aliquot 
o f beads from each purificatio n was incubated with 10mM reduced glut:Hhione 
(GS H) to elute bound pro tei ns. In aU cases SDS-PACE analys is of the eluant 
revealed one major pro tein product corresponding to CST, CST-DL, GST-Dl or 
GST-DLl . 
2 2 2 3': 
'" 
~ 
::J 
'" '" ;s: Qj ::J ::J 2 1il 1il 0 ~ 
'" 
--' 
--' ~ --' ::J 
"0 D D D Qj 
'" ...:. ...:. ...:. f- lY(/) (/) (/) (/) 0 
<.::> <.::> <.::> <.::> a; 
- 97.4kDa 
- 66.2 kDa 
- 45 .0 kDa 
- 31 .0 kDa 
-
- 25.5 kDa 
Figure 3.8 SOS·PAGE analysis of recombinant expression products. Fusion proteins. 
calpastatin domain + G5T. have been eluted from glutathione agarose with G511. 
The expecte<1 <ize< ate 26.0 kDa GST protein, 37.4 kDa GST·DL, 40.6 kDa 
GST·Dl and 52. 1 kDa GST·DLl protein. These molecular weights are derived from 
the expected protei n sequences, however the size calculated from PAGE analysis 
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indicates anomalous migration of the recombinant calpastatin. The molecular weights 
calculated from the migration of fusion proteins through the PAGE gel is 43.5 kDa, 
54.5 kDa, and 70.0 kDa for GST-DL, GST-D1 and GST-DLl respectively. GST 
alone migrated at 25.2 kDa which approximates its expected migration at 26.0 kDa, 
suggesting that the deviation from predicted size is due to the calpastatin component. 
This aberrant migration has been reported before and is thought to be due to an 
amino acid composition which is rich in Asp, Glu, Ser and Pro. 
3.3.2 Purification of calpastatin domains 
The pGEX GST expression vector encodes a thrombin protease specific site 
between GST and the multiple cloning site. Thrombin is a highly specific serine 
protease which, in vivo, is involved in the blood clotting cascade. Notably, thrombin is 
shown to be unable to cleave GST (Smith and Johnson 1988) which simplifies the 
extraction of the fusion partner. When GST-DL immobilised on GSH-agarose was 
incubated at 25°C in PBS containing thrombin, SDS-PAGE analysis showed a single 
major protein band released in the supernatant with an observed size of 16.6 kDa. 
On the other hand, immobilised GST-DLl and GST-D1 treated with thrombin 
under similar conditions resulted in the appearance of two protein bands in each 
samples supernatant larger than would have been predicted (Figure 3.9). 
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Figure 3.9 Protein extract after digestion of immobilised GST fusion proteins with thrombin. 
Thrombin digesled retombinanl calpaslalin proleins domain L. domain 1 and domains L 1. Doublel 
arrows emphasise original and truncated protein bands. 
The sizes of the fragments in the GST-Dl supernata nt are 22.7 kDa and 25.2 
kDa, while those in GST-DU 's supernatant are 42.3 kDa and 44.8 kDa, note that in 
both cases the size difference is 2.5 kDa which appro xima tes to 23 amino acid 
residues. TI,e expected sizes (disregarding the unexpected 2.5 kDa differences) were 
11 .4 kDa for domain L, 14.6 kDa for domain 1 and 26 kDa for domains U . The 
ratio u f o bserved size Qargcst fragment) [ 0 predicted size is 1.72 fo r domain 1, 1.46 
fo r domain L and '!. 72 fo r the do main L and 1 combinauon. O n average these are 
higher than the previously repo rted migralio n aberratio n ratios uf 1.48 and 1.25 
(Maki el al., I987a, Maki el aI., 1988) , and 1.53 (fakano et 01. , 1988). 
\'qith incubation time, the intensity o f the larger molecuJar weight band in 
bo th GST-l and GST -L1 decreased with concomitant incrcasc o f the smaller 
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molecular weight band until only the smaller protein moiety remained after 8 hours 
of exposure to thrombin. Furthermore, when using 5 units of thrombin, the larger 
molecular weight band was eradicated after only three hours of incubation (data not 
shown). This observation was consistent with specific degradation of full-length DLl 
and Dl into truncated derivatives. To eliminate the possibility that there is a 
contaminating protease in the thrombin solution, enzymes from two suppliers (APB 
and Roche) were tested, however the outcomes from digestion were identical. 
These derivatives were purified from an SDS-PAGE gel and subjected to N-
terminal amino acid sequencing over six residues as described in section 2.2.12. The 
resultant sequences showed 100 % homology to the predicted residues of domains L 
and 1 respectively up to six residues. These observations strongly suggest the 
presence of a proteolytically labile site at the C-terminus ofDl resulting in DL1 and 
Dl polypeptides lacking carboxyl residues. It is unknown whether the proteolysis 
was due to secondary site recognition by thrombin or contaminating proteases that 
co-purify with the protease. Despite the observed dose dependent response to 
increasing concentrations of thrombin, the preferred thrombin cleavage site (Arg-X 
or the less common Lys-X, with Pro preceding Arg or Lys; Voet & Voet 1995) is not 
represented in domain 1. It maybe worth noting that the C terminal sequence 
contains a high number of PEST (proline, glutamic acid, serine and threonine) 
residues, which may form the basis of the recognition site. Thus truncation of 
calpastatin fragments containing Dl may be PEST-associated degradation 
attributable to a protease other than thrombin. Indeed, the cleavage of recombinant 
GST fusion proteins by unidentified proteases has been observed in BL21 E.coli 
(Hengen 1996). In future, it may be advisable to precipitate crude bacterial proteins 
with TCA and heat denature immediately upon rupturing the cells. This will eliminate 
any problematic proteases, while leaving calpastatin intact (Geesink ct aI., 1998), and 
would represent a useful preliminary purification step. 
3.4 Activity of recombinant calpastatin on calpain in vitro 
Calpastatin is a constituent of the calpain proteolytic system and 
measurement of its activity is reflected through a decline in calpain mediated 
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proteolysis of a substrate protein. By employing such an assay system, it has been 
reported that recombinant proteins representing domains Land 1 - 4 show different 
inhibitory potential (Maki et aI., 1987b). No inhibition is witnessed from domain L, 
however domains 1 - 4 show comparable inhibitory action. In addition, other 
properties reported for native calpastatin were maintained, including inhibitory 
specificity and heat stability. Calpastatin is an unusually stable protein, and accurately 
assayable activity is preserved even after boiling for several minutes (Shackelford et 
aI., 1994). The activity and stability of recombinant calpastatin are two properties 
which were investigated to assess whether the expressed protein product was 
functionally active in a manner typical of native calpastatin. 
3.4.1 Determination of recombinant calpastatin activities 
Calpastatin activity is determined through its ability to inhibit calpain. The 
standard calpastatin assay used in this work is based on that described by 
Koohmaraie (1990) and is presented in section 2.2.11.2. In brief, "controls" measure 
calpain activity before addition of calpastatin. These values are compared with a 
series of "experimental values" which measure calpain activity following the addition 
of differing amounts of calpastatin. Figure 3.10 shows the effect of addition of 
recombinant calpastatin upon native purified m-calpain. Furthermore, the graph 
contrasts GSH eluted GST-fusions and thrombin digested calpastatin to assess 
whether the GST partner has any affect on inhibitory potential. 
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Figure 3.10 Graph showing the effect of different concentrations of recombinant calpastatin 
on m-calpain activity. Graph showing the effect of increasing molar concentrations of calpastatin 
on calpain activity. Represented are GSH eluted domains still partnered to GST (GST-L, GST-1, 
and GST-L 1) as well as GST alone (GST), and thrombin digested domains lacking the GST tag (L, 
1 and L 1). 
The assays were equalised on the basis of molarity, after calculating the 
molecular weights of the different samples and protein concentrations, and after 
performing preliminary assays to determine the range of sensitivities. This ensures 
that between assays, identical amounts of protein on a molecular basis are being 
compared, rather than total protein concentration which would see larger proteins 
under-represented. As expected, recombinant proteins containing the inhibitory 
domain 1 reduced the proteolytic activity of m-calpain, while domain Land GST 
failed to impact upon activity by themselves. 
GST fusions with 1 and L1 have notably less inhibitory potential than their 
digested counterparts. This may indicate that the GST tag constrains the competitive 
binding between calpain and calpastatin through steric inhibition. Further 
examination of the data demonstrates that GST-DLl has a greater inhibitory 
potential than GST-D1. When compared to GST-Dl, the inhibitory domain of GST-
DLl is presumably more distant from the N-terminal GST due to the presence of 
the intervening L domain, which may result in easier coupling to calpain. 
Interestingly, an enhanced inhibitory potential correlating to the presence of domain 
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L is also suggested after removal of GST (Figure 3.10). This implies that domain L 
may improve domain 1 's efficacy directly, as well as acting as a buffer region between 
GST and domain 1. The augmented inhibition attributed to domain L has also been 
reported by Melloni et a/. (1998a). These authors observed that the addition of 
recombinant domain L to calpastatin assays reduced the inhibitory potential of active 
recombinant calpastatin isoforms. They suggest that domain L assists calpastatin in 
its recognition of calpain by binding to the protease. 
To eliminate the possibility that the different inhibitions are due simply to 
inaccurate protein determinations western blot titrations were performed. Four SDS-
Page gels were loaded with samples of GST-DLl, GST-D1, DLl and D1 (two-fold 
serial dilutions from 0.025 nM to 0.049 pM). Gels were electrophoresed, transferred 
and western blotted identically with an antibody recognising domain 1 (Figure 3.11). 
Chapter 3:Expression and purification of ovine calpastatin domains Land 1 in Escherichia coli, and the 72 
generation of specific polyclonal antibodies 
iii i i 
~ ~ ~ ~ ~ 
o 0 0 0 0 
-- -- --
A ""=====- •
--~ "" =­-.. ~ ,. -
B 
, i! ! > , i i i i i • ~ " " ~ § ~ ~ m ~ ~ ~ g ;; N ~ ~ 0 
0 0 
-
0 0 0 
-------
1J=--
- -~ --
- - -
Figure 3.11 Western blot detecting recombinant calpaslatin at a range of concentrations. 
Proteins possessing calpain inhibitory pctential were assayed using the BioRad protein assay 
described in section 2.2.3 .4, titrated to concentrations ranging from 0.025 nM· 0.049 pM, and 
loaded onto a 10 % SOS-PAGE gel. Specifica lly. domain 1 (A). domain 1 + GST (B). domains L + 1 
(C), and domains L + 1 + GST (0) were loaded. These were transferred and plObed with anti-domain 
1 antibody (552) at 1 :500 dilution. 
Examination of the developed western blot shows relatively equal loading of 
all samples. The detection limit for both domain I (A) and domain L+ 1 (C) is at 
0.195 pM and, consequently, these proteins are accurately quantified wilh respect ro 
each other. Domain 1 + GST (B) is detectable at 0.098 pM which indicates that it 
may be present at sljghtly higher levels in relation to the other active calpas tatin 
recombinants. Finally, domain L1 + GST (0) is undetectable below 0.391 pM and is 
probably under-represented in the inhjbitory assay shown in Figure 3.10. However, 
since GST-DLl already demonstrates more potency than GST-Ol. this resuh 
strcnglhens the argument that domain L augments domain l 's activity. 
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Calculating the units of inhibition shows that the specific activity of Dl and 
DL1 was 27 units/mg total protein. Following thrombin digestion and boiling (10 
minutes 95°C), calpastatin specific activity increased to approximately 7100 units/mg 
for domain 1 and 5000 units/mg for domain Ll. This is a significant amount of 
activity. Bacteria are, therefore, a feasible vehicle to obtain large quantities of pure 
active protein which calpastatin characteristics. Furthermore, the results indicate that 
both active calpastatin fragments (D-l & D-Ll) exhibit the thermal stability 
previously reported for both full-length and derivative protein fragments of 
calpastatin. Consequently, in this work affinity-purified calpastatin fragments were 
subjected to heat treatment as a final purification step before being used as antigens 
for antibody production. 
3.5 Generation of poly clonal antibodies 
Polyclonal antibodies were generated by hyperimmunising rabbits with 
antigenic recombinant calpastatin as described in section 2.2.13. Briefly, two pairs of 
rabbits were injected over an 8-10 week period with either purified domain L or 1 
recombinant protein emulsified with Freund's complete adjuvant. To confirm that a 
polyclonal antigenic response was occurring, blood samples were taken after 4 weeks, 
serum was collected and used as primary antibody in a Western analysis of antigen. 
In all instances an antigenic response was noted (data not shown). At the conclusion 
of the immunisation routine the animals were anaesthetised, sacrificed and bled out. 
Approximately 100-150 ml blood was collected. From this 70-100 ml serum was 
harvested and used without further purification as the primary antibody for Western 
analysis. 
Immunological cross-reactivity of domain L and domain 1 polyclonal 
antibodies was assessed by Western Blotting (see section 2.2.14). Samples of antigen 
(ie. purified domain Land 1) were applied to an SDS-PAGE gel together with 
purified domain Ll, the soluble protein fraction from untransformed E. coll~ and 
GSH eluted GST, GST-L, GST-l and GST-L1. After electrophoresis and transfer, 
membranes from four similar gels were blotted with serum from the four rabbits (see 
Figure 3.12). 
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Figure 3.12 Western blots of cross-reactivity between the polyclonal antibody response from 
immunised rabbits. lanes contain crude bacterial exuact el), GSH eluted GST (2). GSH eluted 
GST·L (3), GST·1 (4), GST·L 1 (5), and thrombin digested domains L (6), 1 (7) and L 1 (8). Serum 
(1 :500 dilution) was used trom rabbits 551 and 556 (A, 5) immunised with pUle domain L, and 
rabbits 552 and 557 (C, 0) immunised with pure domain 1. 
The affini ty tag appeared to confer added stabil ity to the recombinant 
protein. High product homogeneity in the GST fusion proteins is indicated by the 
presence o f a sing le expressed band following extraction using a lysozyme/ freeze-
thawing approach (Figure 3.9). Previously, Takano , / of. (1988) direccly expressed fuU· 
length and partial fragments o f pig calpastaun in E. (oli and reported severe 
proteolytic degradation o f the translation products during extraction using the 
lysozyme/ freeze-thaw method. More recencly, Hilomi , / al. (1998) noted a significant 
degradation of recombinant caJpas tatin extracted through hypo tonic disruption or 
sonication. In this work, the method o f ex traction did not appear to signHicant1y 
disturb CST - fu sion pro teins although a degree o f cli sntption might he indicated by 
the smear o f reactivity seen in Figure 3.12. 
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Serum was valjdated for immunoreactivity against native calpastatin from 
sheep skeletal muscle prepared as described in section 2.2.3.3. Four duplicate gels 
were electrophoresed, protein was transferred and probed with one of the fOlIr 
serum preparations. Tile results from these western blots arc shown in Figure 3.13. 
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Figure 3.13 Western blots of demonstrating immunoreactivity of polyclonal anti-domain L and 1 
antibodies against native ovine ca lpastatin. Soluble total protein was extracted from fresh ovine 
skeletal muscle as described in section 2.2.3.3 An aliquot was removed and heated at 100 °C for 5 
minutes before being centrifuged at maximum speed in a bench top microfuge. The supernate was 
collected and. together with the unboiled soluble protein fraction. its protein concentration was 
determined. Samples were electrophoresed through a 10 % 50S-PAGE gel and transfened to 
nitrocellulose before being probed with either anti-domain 1 antibody 567 (A) and 522 (C). or anti-
domain L antibody 566 (B) and 551 (0) at 1:100. 
Figure 3.13 demunstrates that the fOLlr ant.ibodies raised in these experiments 
specifically recognised a large protein in Loth boiled and unboilcd ovine soluble 
protein extracts. Although the ideal confirmation would be from purified native 
calpastatin, the migration distance and the fact that the immunoreactive product is 
heat stable strongly indicates the band is calpastatin. Tn a similar experiment, Doumit 
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ef al.(1996) used recombinant bovine calpastatin domains 2 - 4 expressed with GST 
to produce antibodies. When assessing immunoreactivity, he observed cross 
reactions with samples of muscle from beef, sheep and pigs. This serves to 
demonstrate the high degree of homology between calpastatin protein from different 
species. 
3.6 Discussion 
In order to cater for certain structural and biochemical analyses, sufficient 
quantities of purified calpastatin are required. This is also required in the instance 
when quantification of calpain or calpastatin is required in total protein units. 
Previously, native calpastatin has been isolated from various target tissues of different 
species using conventional techniques, specifically·chromatography. Such techniques 
yield only small quantities from substantial starting raw material, requiring tedious 
processing. For example, Mellgren (1988) reported yields of 1 milligram purified 
calpastatin per kilogram of bovine heart. The methodology described in this chapter 
provides a useful and efficient approach for the production of large quantities of 
target calpastatin fragments in E. coli with yields of a few milligrams of purified 
recombinant protein per litre of bacteria culture. 
Amplification and incorporation of ovine calpastatin cDNA sequences 
encoding domains L, 1 and L1 was successful. The three fragments of ovine 
calpastatin were efficiently expressed in E. coli strain BL21 as fusions together with 
GST using the highly efficient pGEX-4T-1 vector. Under the control of the IPTG-
inducible tac promoter present in this vector, large quantities of soluble GST-fused 
calpastatin fragments were generated. After removal of the insoluble protein 
component, the recombinant fusion proteins were purified by affinity 
chromatography using glutathione-agarose. 
Minor contamination of all three fusion proteins with a 70 kDa protein was 
observed. This contaminant was likely to be the E. coli chaperone DnaK which has 
been identified as a common impurity co-purifying with recombinant proteins 
(Hellebust ef aI., 1990). 
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All three calpastatin fragments: DL, D1 and DU, exhibited aberrant 
mobilities on SDS-PAGE. This is in agreement with previous reports of anomalous 
electrophoretic behaviour of calpastatin and its deletion derivatives (fakano et at.) 
1988; Emori et at.} 1988). Examination of the primary amino acid sequence of DL, 
D1 and DU revealed a high proportion of charged residues and proline. Such 
unusual amino acid composition has been previously noted by other researchers to 
be characteristic of calpastatin in other species (fakano et at. 1988). It has been 
proposed that the abundance of charged residues and/or proline was responsible for 
the discrepancy between the calculated and observed molecular weight. The question 
of whether thrombin is responsible for the non-specific proteolysis of C-terminal 
domain 1 is unanswered. While the rate of appearance of truncated product is dose 
dependent upon thrombin concentration, there is no simple structure in the 
approximate region of cleavage that corresponds to thrombin's recognition site. In 
future, this problem may be avoided by using an alternative GST vector utilising an 
alternative protease recognition site, such as those recognised by Factor X (Smith & 
Johnson 1988) or protease 3C (Walker et at., 1994). 
There are several significant advantages of the GST fusion system. Firstly, 
consistent high yields of all three recombinant calpastatin fragments were obtained 
from a procedure that can be easily scaled up or down. Secondly, some stability may 
be provided by the GST tag, which serves to protect calpastatin during the extraction 
process. The inclusion of the lacI" gene within the plasmid ensures tight repression of 
the tac promoter. Previously BL21 have been seen to perish due to strong protein 
expression (Miroux & Walker 1996). However, this self inhibition allows normal, 
unimpeded growth of bacteria until they reach the desired density, when addition of 
IPTG alleviates this restraint and permits expression. Finally, the immobilisation of 
calpastatin on an agarose column via the GST tag essentially provides a calpastatin 
affinity column. This could then be used to examine calpastatins interaction with 
other agents (eg. calpain) in a manner that has been successfully employed previously 
(Ma dal, 1993). 
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Biological activity of recombinant calpastatin fragments was tested in calpain 
assays. Calpain was inhibited in a dose-dependent manner by DL1 and D1 
fragments, whereas no inhibitory potential was apparent in the case of DL and 
control GST incubations. This agrees with numerous studies in which activity is 
ascribed to particular regions within domains 1 - 4, but no activity is attributed to the 
N-terminal domain L (Maki et al, 1987a; Maki et al, 1987b; Maki et al, 1988; Ma et al, 
1993; Ma et al, 1994). The relative activities before and after removal of the GST 
handle were compared. It was found that the attachment of GST reduced the 
potential activity of the calpastatin partner. The inhibitor activity of DL1 and D1 
was not lost after heat treatment at 94°C for 20 minutes. In fact, this procedure 
appeared to increase the specific activity of these calpastatin fragments. Thus, heat 
treatment was found to be a useful ancillary step for purification of active calpastatin 
polypeptides produced in E. coli. This underscores the heat stability of calpastatin. A 
further advantage of the GST gene fusion approach is that GST activity can be 
assayed. This provides yet another tool for normalising the absolute amount of 
calpastatin added in calpain inhibition assays. 
The immunoreactivity and specificity of the polyclonal antibodies was good. 
There was no cross reactivity between domain Land 1 antibodies with their 
respective antigen, nor was there any reactivity with GST or soluble bacterial protein. 
This indicates the procedure to prepare antigen free of contamination was highly 
successful. Part of this success is probably due to the boiling step which removes 
non-heat stable proteins. Finally, all four antibodies display specific immunoreactivity 
against ovine calpastatin. 
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4.1 Introduction 
Chapter 4 
Characterisation of C2C12 fusion 
and transfection optimisation 
A growing body of evidence indicates the active involvement of calpains in 
fusion permissive events occurring at the plasma membrane (Cottin ct a/.J 1994; 
Hayashi ct a/.J 1996; Dourdin ct a/.J 1997). Calpastatin has the potential to influence 
the fusion process, through its action on calpain but there is relatively little 
information on the role of calpastatin in the fusion process. It is has been established 
that: (i) calpastatin mRNA and protein levels are down-regulated during fusion 
(Balcerzak ct a/. J 1998), (ii) calpain is associated with calpastatin during proliferation 
and fusion (Barnoy ct a/.J 1999) and (iii) microinjection of excess calpastatin prevents 
fusion (Temm-Grove ct a/.J 1999). 
Several approaches are available to investigate the influence of calpastatin on 
fusion. A researcher may choose to examine the effects of agents that mimic 
calpastatin and inhibit calpain (Barnoy ct a/.J 1997; Barnoy ct a/.J 1998) or calpastatin 
may be introduced mechanically into an experimental system through microinjection 
(Temm-Grove ct a/.J 1999). A third approach is to manipulate calpain activity by 
introducing into cells expression plasmids encoding calpastatin (Huang & Forsberg 
1998). This is arguably the least intrusive technique and provides the closest 
approximation to in vivo manipulation. 
Since its early use as a marker for gene expression (Chalfie ct a/.J 1994), Green 
Fluorescent Protein (GFP) has been used as a cellular probe to monitor the 
expression and localisation of proteins in vivo. For excellent reviews of the properties, 
protocols and applications of GFP see Tsein (1998) and Chalfie & Kain (1998). GFP 
was discovered in its native form in the bioluminescent jellyfish Acquorea victoria and 
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converts blue light (emitted by the photoprotein aequorin) into green fluorescence 
(Morise et al.) 1974). GFP has been well characterised structurally (Ormo et al.) 1996; 
Yang et al.} 1996; Brejc et al.} 1997). The mechanism of its fluorescence has also been 
established (Boxer 1996; Youvan & Michel-Beyerle 1996). 
The cDNA encoding GFP is commercially available and may be combined 
with cDNA's of interest to produce hybrid proteins (Rizzuto et al.) 1995). There are 
examples of GFP being introduced into plants (Haseloff & Amos 1995) Drosophila 
(Brand 1995) and mammalian cells (pines 1995). A unique quality of GFP is that it 
only requires oxygen as a cofactor to generate its brilliant fluorescence. This has 
made it particularly versatile for use in vivo to monitor the movements of individual 
proteins (pelham 1997; Presley ct al.) 1997) and protein interactions (Ma et al.) 1996). 
Moreover, the proteins structure and chromophore has been carefully manipulated to 
generate several variants on the wild-type GFP including Red Fluorescent Protein 
(Matz et al.) 1999), Blue Fluorescent Protein (Heim & Tsein 1996), Yellow 
Fluorescent Protein (Ormo ct al.) 1996) and the Enhanced Green Fluorescent Protein 
(EGFP) used in these experiments (Cormack et al.) 1996). 
Chapter 4 reports two issues. Firstly, this chapter characterises "normal" 
myoblast behaviour. Specifically, it investigates the percentage of cells fused after 
induction of fusion and the typical changes in the level of distinctive proteins using 
Western Blotting. Secondly, in preparation for the experiments performed in Chapter 
5 this chapter reports the construction of expression plasmids containing regions of 
calpastatin cDNA fused to EGFP. Chapter 4 also investigates the transfection of 
C2C12 myoblasts and the expression of a EGPF coding plasmid. 
4.2 Characterisation of myoblast fusion 
Myoblast fusion represents a useful model with which to examine 
developmental processes. It is possible to either purchase immortalised myoblasts 
such as C2C12, L6 and L8 cell lines or to extract a population of myoblasts from an 
embryonic source and construct a primary culture. The main advantages of using 
myoblast cell lines is that: (i) the populations are homogeneous, (ii) they may undergo 
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a significant number of mitotic cycles before perishing, and (iii) are usually well 
represented in the literature. The advantages of primary culture are the reduced cost, 
ease of access and, most importantly, the close physiological approximation to in situ 
myoblasts. 
In the literature, both types of culture have been used to replicate fusion 
events using similar methods. Myoblast are usually propagated in a growth factor rich 
environment until they attain a density of 50 -100 % confluence, then the media is 
changed to one containing lower concentrations of growth factors. This reduction in 
growth factors means that the myoblasts are no longer being forced to enter mitotic 
cycles and transcription of the myogenic regulatory genes can begin (Ludolph & 
Konieczny 1995). Failure to reduce the exposure of confluent cells to high levels of 
growth factors, causes cell overgrowth, depletion of nutrients, accumulation of waste 
products, loss of adherence and, ultimately, cell death (Temm-Grove et al., 1999). 
4.2.1 Fusion 
Fusion and differentiation can be assessed in terms of morphology and/ or 
the expression of characteristic proteins. The gross morphological change which 
characterises fusion is the formation of myotubes. These may be observed over a 
series of discrete time intervals and are most often quantified as "percent fusion". 
This value reflects the number of nuclei contained within myotubes divided by the 
total number of nuclei in the population. It is determined microscopically within a 
field of cells, by counting nuclei and subjectively classifying them into either 
"myoblast" (lor 2 nuclei) or "myotube" P-3 nuclei). Alternatively, a Flow Cytometer 
(or Fluorescent Automated Cell Sorter; FACS) may be used. This device is a laser 
based detection system and provides a multiparameter snapshot of individual cell 
characteristics. Specifically, the forward and side scatter of a laser beam, deflected by 
a single cell falling through space, reflects the cell size and complexity (granularity) 
respectively. For analysis by flow cytometry, cells are freed into a solution of PBS 
before being individually analysed by laser. This rapidly generates a description of the 
population. It is anticipated that large complex cells, representing myotubes, will 
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appear as a distinct sllb-popu lation over the fusion period and will be distinguishable 
from smaller myoblas ts. 
As described in section 2.2.15, C2C12 myoblasts were propagated in 
complete growth media (10 % Foetal Ca lf Serum (FeS) in D ulbecco's Modified 
Eagles Media (DMEM), 37°C, 5 % CO,) where they were seen to double every 18 -
24 hours. Upon reaching: conOucnce, the media was changed to differentiatio n media 
containing low levels of growth factors (2 % Horse Serum (lIS) in DMEM). Within 
24 hours o f changing the media, multinuclc:::att: m yu lLIues could be distinguished (sec 
Figure 4.1 ). 
Figure 4.1. Photographs of myoblasts exposed to differentiation media. Times are expressed 
as hours after initial exposure. Cells grown on coverslips were fixed with methanol before being air 
dried and stained with Gicmsa solution, bar represents 100 ~lm (400 x). 
The conditions employed in these experiments appear suitable fo r the 
induction o f fusion. Parallel alignment is evident by 24 hours and clear 
distinguishable ml~tinucleate myotubes are visible by 48 hours. Tt is notable that the 
myotube nuclei aggregate within the cell structure and, generally, do no t appear 
randomly rustribured throughoUl lhe cYloplasm. 
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Fusion \V~s C)tlantified in two ways. Conventional microscopic cell counting 
demands that cells be grown on coversl.ips for ease of staining. FACS analysis 
requires ce lls to be freed from their growth surface into a solution of PBS which is 
drawn into the analyser tube. Cells are then rapidly (200 - 500 I second) quantified 
fo r size and granularity. The distribution o f ce ll s at 0 hours is defined as the typical 
distribution of myoblasts and called "tegion 1" (RI ). At subsequent times, as fusion 
progresses, cell s or events falJjng outside this defined region are observed. These 
events, which exhibit greater granularity and size, probably represent the myotubcs 
and are contained in "region 2" (R2), as shown in Figure 4.2. 
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Figure 4.2 FACS results from cells harvested at 0, 24, 48, 72, 96 and 240 hours after 
induction of fusion. Each point on the scatter graph describes the side scatter (granularny) and 
forward scatter (size) of a single cell (event). Approximately 50 000 events are depicted in each 
graph. Events may be included in region 1 (Rl) or region 2 (R2) groupings. 
The majority of cells (> 99 %) at 0 hours are mononucleate myoblasts and 
are captured by the Rl "gatc". The R2 gate was set to include the larger more 
complex cells. At the early time points (0 and 24 hours) there was little fu sion and 
consequently the R2 group probably represen ts mitotically dividing myoblasts. The 
collection of events outside the R 1 and R2 gates (especially those in the top left of 
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the plo ts) were no t included in the analysis since their relative1y small size and high 
complexi ty sugges t they arc dead o r d ying cells. 
The fu sio n percentage determined b}' FACS was calcula ted by dividing the 
number o f events in regio n 2 (R2) by the slim o f all events (ie. R 1 + R2 + non-gated 
events). Figure 4.3 displays the rusio n trends dete rmined by FACS and conven tional 
microsco pic ccU counting approaches. It is apparent that co nventional ceU co unting 
using covcrslips produced a sign ificantly di fferent growth pro file than the FACS 
mt:tho J o f determining fu sio n. Cell counting es tabLshed that approximately SO % of 
the nuclei wen;: contained within fused myotubes by 96 hours. FACS analysis 
determined the fu sed pcn::clllage was o nly ·1 %. Clearly, based o n the microscopic 
o bservatio ns, the FACS procedure grossly underes timated the ex tent o f fusio n. 
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Figure 4.3 Graph comparing % fusion values determined by microscopic examination 
(manual counting) and FACS analysis. C2C12 myoblasls were grown 10 confluence in complele 
media. rinsed with PBS and media replaced with differentiation media to promole fusion. 
C2C12 myoblasts growth and fusio n rate has been compared by o ther 
researchers under a varie ty o f culture conditions. 1t was o bserved that the most 
effective serum additive at pro mo ting pro li feration was 10 0/0 Fe S and 2 % H S was 
the most effective at pro mo ting fu sio n (remm-G rove et ai, 1999). The study also 
rcpo rted that with 2 % HS, fu sio n was initiated at 30 ho urs and after 05 homs 
betwcen 50 and 60 % o f the nuclei were contained wi thin the myotll bes. 11, is was a 
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faster rate of fusion than was seen in this work. Namely, at 96 hours the fusion rate 
had declined and only 45 - 50 % of the nuclei were contained within the myotubes, 
as determined by microscopic examination. The difference between the studies could 
be due to several important variables. The most likely explanation is the variation in 
growth factors in the 10 % calf serum additive. Another explanation is the 
characteristics of the cell line under investigation. For example, rat L8 myoblast are a 
commonly used cell line. After growing L8s to 50 % confluence in DMEM 
supplemented with 15 % FCS, they are usually induced to fuse by changing the 
media to DMEM + 2 % HS and 4 units of insulin per 100 ml. After 24 - 48 hours of 
residual proliferation the cells reached confluence and by 72 - 96 hours the cells align 
and fusion starts. Between 120 - 168 hours 60 - 80 % of myoblasts have fused and 
form'ed myotubes (Barnoy et aI., 1996: Barnoy et aI., 1997). This process in the L8's is 
significantly slower than the C2C12 cells used in this work and illustrates the 
possibility of intrinsic but dissimilar biochemical qualities impacting upon fusion 
dynamics. Such idiosyncrasies are not be peculiar to cell lines. Primary cultures have 
also displayed variability in regards to the initiation and completion of fusion and to 
the extent that nuclei are distributed in myotubes (Cottin et ai, 1994; Elamrani et ai, 
1995; Balcerzak et ai, 1998). A common theme is (i) the sigmoidal shape of the % 
fusion curve and (ii) the ultimate percentage of nuclei contained within myotubes is 
between 50 and 80 %. This latter observation indicates that over the time period 
examined a significant proportion of cells remain mononucleate. 
FACS analysis does not seem to be a suitable technique for assessing the 
fusion percentage. Only 2 % fusion had occurred even after 10 days of culture in the 
differentiation media. This is a considerable underestimation relative to the manual 
cell count and is probably due to the change from adherent growth conditions to 
suspension in a liquid milieu. After extensive fusion, C2C12 myotubes appear as large 
as 1 mm in length (see Figure 4.1) and often multi-branched in structure. However, 
following trypsin digestion, the released myotubes altered from their elongated 
morphology into a more compact spherical form. It seems likely that the inability of 
the F ACS to differentiate myoblasts from myotubes is largely due to the loss of their 
distinctive morphology under these circumstances and a failure to distinguish the 
subtle volume changes which accompany and are indicative of fusion. According to 
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microscopic examination, fusion approached a plateau at 96 hours. FACS analysis 
demonstrated the increase occurred between 96 and 240 hours. These differences 
may be attributed to the fact that the two approaches measure different parameters. 
The microscope quantifies the number of nuclei as a feature of cell type whilst FACS 
measures size and granularity of the cells. It is likely, therefore, that the increase in % 
fusion from 96 to 240 hours measured by FACS is due to a net increase in protein 
synthesis associated with the development oflarger cells. These larger cells are then 
classified as myotubes on the basis of size and granularity and not because of 
significant additional fusion. This underscores the unsuitability of F ACS analysis for 
the determination of % fusion compared to other techniques such as direct manual 
cell counting. 
4.2.2 Protein indicators 
Concomitant with fusion are fluctuations in protein content and specific 
changes in protein proftle. For example, the release of eH] - tyrosine during protein 
degradation appears to decline by about 20 % in myotubes which are exposed to 10 
% horse serum (Hong & Forsberg 1994) and stay repressed for 96 hours. Under the 
same conditions, protein synthesis can be stimulated and a net gain in total protein 
content can occur (Gulve & Dice 1989). A recent paper by Ertbjerg et a~ (2000) the 
total protein content of C2C12 cells could be reduced by 16 % with the addition of 
epinephrine after fusion induction. Concomitant with the decline in pmtein content 
was a three-fold increase in assayable 11- and m-calpain, and a third increase in 
calpastatin activity. This indicates that calpains may be directly involved in 
hormonally regulated protein catabolism in myotubes. 
It seems that once the drive for cell proliferation has been released, cells 
redirect their metabolic activity from the mitotic cycle into protein synthesis. Perhaps 
more significant, however, is the release of inhibition from myogenic regulatory 
factors such as MyoDl and myogenin. These factors drive the expression of muscle 
specific proteins which biochemically distinguish the developing myotubes. Western 
blotting, which permits the identification and visualisation of specific proteins, allows 
the detection of muscle proteins which characterise the fusion period. 
Chapter 4:Characterisation of C2C12 fusion and transfection optimisation 87 
In this work, to enable Western analysis, cells were cultured to 100 % 
confluence in DMEM + 10 % FCS. Upon reaching confluence, the plates were 
washed twice with PBS and the media replaced with DMEM + 2 % HS to induce 
fusion. After addition of fusion media, the cells were collected at 0,24,48, 72 and 96 
hours to provide a representative cross-section of fusion at different stages. Proteins 
were extracted, SDS-PAGE fractionated and used in Western analysis as described in 
sections 2.2.16, 2.2.4.2, and 2.2.14 respectively. 
In a study by Dourdin et al (1999), adherent myoblasts were grown for 36 
hours under differentiation conditions, incubated for 30 minutes in PBS containing 1 
% Triton X-100 and rinsed twice with PBS to leave the cytoskeletal remains. 
Electrophoresis of the harvested cytoskeletal remains revealed 7 major bands. The 
largest of the four bands were identified as myosin, vimentin, desmin and actin. In 
this work the representative myofibrillar proteins myosin, desmin and troponin T 
were selected as indicators of myotube differentiation. Myosin has been previously 
noted as a good indicator of biochemical differentiation (Okazaki & Holtzer 1966, 
Ludolph & Konieczny 1995) and desmin and troponin T as myogenic indicators. 
The latter, in addition, are substrates for calpain (Di Lisa et all 1995, Dourdin et all 
1999, Geesink & Koohmaraie 1999). Desmin and troponin T may be useful to 
monitor since the objective of Chapter 5 is to perturb calpain activity which may alter 
the proteolysis of substrates such as desmin and troponin T. To investigate the 
calpain system thoroughly, Il-calpain, m-calpain, and calpastatin were also included in 
the Western analysis protocol. 
4.2.2.1 Troponin T 
Troponin T (TnT) is one subunit of the troponin complex which associates 
with actin and myosin and acts as a calcium sensitive switch during muscle 
contraction. TnT has been previously detected in C2C12 myoblasts 3 days after 
fusion induction (Crescenzi et all 1994). In this work, full sized TnT (35 kDa) was 
very faintly detected in the 0 hour samples and increased over the 96 hour fusion 
period (see Figure 4.4). 
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Figure 4.4 Troponin T levels over 96 hour lusion period. Approximately 100 u9 01 total protein 
extracted Irom C2C12's was electrophoresed through a 10 % SDS·PAGE gel and transferred to 
nitrocellulose before being probed with anti·troponin T antibody (en) at 1 : 100 dilution. An 
immunoreactive fragment appears below the full size troponin T at late stages of fusion. 
In addjtion to full sized tropOllll1 T (35 kDa), immunoreacti vity between the 
TnT monoclonal antibody «(..3) and a smaller fragment (approximately 30 kDa) 
became apparent after 48 hours. The intensity of the small fragment rapidly increased 
from 72 to 96 hours, while the fu ll-sized TnT band remained re latively static, TnT is 
particularly susceptible to proteolys is by I.l-calpain and, to a lesser extent, by m-
cal pain both in vilro and in silll (Di Lisa ,I aI., 1995). Cal pain proteolys is of TnT 
produces several fragments with molecular weights from 27 to 30 kDa (Ho ,I aI., 
1994). Tt is possible that the small fragment witnessed in this study were products of 
calpain proteolys is. The degradatio n of recognition epito pes may preclude, however, 
the detection of any additional fragments. Furthermore, the failure to detect the 30 
kDa TnT isoform may be due to the absence of the putative proteolytic machinery 
responsible for its generatio n. TnT has been fou nd to be expressed in C2C12 which 
have been prevented fro m fu sing (Crescenzi el aI, 1994) demonstrating that TnT is 
no t an indicator of fusio n but an indicato r of differentiation. 
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4.2.2.2 Desmin 
Desmin (53 kDa) is a major protein subunit of muscle-type intermediate 
fihments. 1n mature muscle, desmin is found at the myofibril periphery and 
surrounding the 7.-cl isc. 
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Figure 4.5 Desmin levels over 96 hour lusion period. Approximately 100 ug of total protein 
extracted from C2C12's was electrophoresed through a 10 % 50S-PAGE gel and transfened to 
nitrocellulose before being probed with anti-desmin antibody (D3) at 1 : 100 dilution. 
III vif1v stuclies on desmin extracted from primary muscle cultures have 
demonstrated that the proteolys is of desmin by m-calpain produces fragmen ts 
ranging in size from 30 to 40 kDa (Oourd in ,/ ai, 1999). In this thesis, the desmi n 
antibody (03) has successfully detected desmin in C2C12 extracts (Allen ,/ ai, 199M) 
and, in other work, demonstrated the protective effect of the Callipyge phenotype 
(over-expression of calpastacin) o n desrn_in degradation (Geesink & Koohmarrue 
1999). Additionally, desmin has been used as a marker in primary cell preparations to 
differentiate between cul tured muscle ceLI s and contaminating cell types (Allen et al.) 
199R; T emm-Grove ,/ ai, 1999). In primary cultures of myoblasts, desmin levels at 
36 - 44 hours (time of maximum fusion) decrease by 40 % compared to the levels at 
20 ho urs and increase again when the rate of fu sio n declines (Ehmrani el al.) 1995). 
In contrast, evidence in Figure 4.5 shows desrrun levels increase by 300 % over the 
96 hour culture period as myoblasts differentiate into myotubes. These differences 
may result from differing experimental procedures. Dourrlin , / ai (1999) and 
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E lamrani , / "I. (1995) used media containing 10 % HS to stimulate fusion in a 
primary culture and were able to demonstrate declines in desmin. The experiments 
described in this thesis used 2 % HS and an es tablished cell line. The effect of the 
serum concentratio n is iJJustratcd by the fact that 5 % HS is significancl y less potent 
than 2 % HS at stimulating myoblast fusion (femm-Grove , / aI., 1999). By inference, 
10 % H S may be even less e ffective. Moreover, primary ceU cul tures arc at a 
disadvantage compared to cell lines, in that it is almost impossible to eliminate 
contaminating no n-muscle cell s whkh contribute lheir protein 10 tota l po pulatio n 
extracts. 
4.2.2.3 Myosin 
Myosin (200 kDa) is une ur the main protein components o f muscle ti ssue 
where it function s as parr of the contractile tt pparatus. Because myosin is o nly 
expressed in myotubes and myoblasts commincd to rnyugcnes is (Okazaki & 11 0 ltzcr 
1966) it has been used as a marker of myoblas[ differentiatio n (L.udulph & 
Konieczny 1995). 
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Figure 4.6 Myosin levels over 96 hour fusion period. Approximalely 100 ug of lotal prolein 
extraCied from C2C12 's was electrophoresed through a 10 % SOS-PAGE gel and transferred 10 
nitrocellulose belore being probed with anli·myosin antibody (MF20) all : 2000 dilution. 
In normal fusing C2C12 cells, myosin heavy chain protein was detected by 
immuno-fl uorescence at 3 days (Fuentealba , / ai, 1999). This agrees with the blo t 
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shown in Figure 4.6, which initially detects myosin at 48 hours and shows myosin 
steadily increases over the 72 and 96 hours culture period. In a study by Hartley et al. 
(1991) the appearance of two myosin isoforms (embryonic and ventricular) in foetal 
chicken myoblasts and adult myotubes were compared. They found that in 
myoblasts, both myosin isoforms were expressed and that the expression was not 
prevented by eliminating fusion with EGTA. This suggests that the appearance of 
myosin indicates biochemical differentiation and not fusion. This assertion is 
supported by two other studies. Fuentealba et al. (1999) used antisense technology to 
indirectly hasten myogenin expression which resulted in accelerated myosin 
appearance, while Crescenzi et al. (1994) abolished C2C12 fusion by infecting cells 
with the myc oncogene without affecting the appearance of myosin. The anti-myosin· 
antibody used in this thesis has been used successfully to detect myosin in extracts 
from primary muscle cell cultures (Hartley et aI., 1991) and in C2C12 cells (Crescenzi 
etal.,1994). 
4.2.2.4 J..l-Calpain 
J..l-Calpain (110 kDa) is one of the two ubiquitous calpain proteases that is 
potentially involved in the fusion process. The appearance and expression of J..l-
calpain in the soluble cytosolic fraction is constitutive. 
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figure 4.71l-calpain levels over 96 hour fusion period. Approximately 100 ug of total protein 
extracted from CZC1Z's was electrophoresed through a 7.5 % SDS·PAGE gel and transferred to 
nitrocellulose before being probed with an\i·Il·calpain antibedy (BZF9) at 1 : Z5 dilution. 
Several anti -J.!-calpain antibodies were tested for their efficacy in detecling Jl-
calpain from C2C12. Antibody "2H2" is a monoclonal raised agai nst domain II o f 
human Il-calpain. The "Forsberg anti-Il-calpai n" is a polyclonal antibody raised 
against the N-terminal sequence of human Il-calpain (SEEllTPVYCTGVSAQVQ 
KQRC; Forsberg personal communication). Neither of these antibodies 
demon str~ted reactivity against C2C12 protein ex tract (data not shown). A third 
antibody, B2F9. was generated as a monoclo nal against the 80 kDa subunit of native 
bovine ske letal muscle protein (Geesink & Koohmaraie 1999). As shown in Figure 
4.7, this antibody sliccessfully reacted against two protein bands of simiJar size and 
was, therefore, chosen for this investigatio n. The mo lecular weight marker indicates 
that these bands are approximately 78 kDa and 75 kDa in size. The double band 
pattern most likely represents full sized Il-calpain and an N -terminally truncated 
autolytic product. As noted previously. calpains undergo a two stage autoproteolysis 
with truncation of the 80 kDa isoform into 78 kDa and 76 kDa isoforms. The B2F9 
antibody has been previously used to detect aU three isoform s in ovine skeletal 
muscle extract (Geesink & Koohmaraie 1999). Close examination of the Western 
blot reveals a thirn hand (which has not reproduced in Figure 4.7) about equal 
distance below the 78 kDa and 75 kDa bands, which probably represents the second 
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autolytic product. The slight size difference between the traditional 80 / 78 / 76 kDa 
isoforms and the 78 / 75 / 72 kDa shown in these data is probably due to inaccuracy 
in calibration against the molecular weight markers. There is no evidence in the 
literature of murine /l-calpain migrating at these small sizes. The intensity of the two 
bands apparent in Figure 4.7 increased over the 96 hour culture period which is a 
trend reported previously by Barnoy et al (1996:1997). These authors observed that 
/l-calpain increases to 120 - 170 % of its initial level by 48 hours with no subsequent 
changes over the next 120 hour period. In contrast, some studies have detected /l-
calpain in primary myoblast cultures only after 6 days of fusion (Cottin et aI., 1994) 
while others failed to detect /l-calpain in 50 % fused C2C12 extracts despite using 
large scale cultures (femm-Grove et aI., 1999). In this latter study the authors 
concluded that the levels of /l-calpain were non-existent or fall below the sensitivity 
of the antibody. 
The fact that this research was able to detect /l-calpain where other authors 
have failed suggests that attention should be directed at confirming the identity of the 
protein despite the validated specificity of the B2F9 monoclonal antibody (Geesink 
& Koohmaraie 1999). For this reason, samples of non-denatured protein were 
analysed for proteolytic activity using zymographic gels (see section 2.2.17) and 
transferred from non-denaturing gels for Western blotting as shown in Figure 4.8. 
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Figure 4.8 Casein zymographic gels and Western demonstrating activity and identifying 11-
and m-calpain. Zymographic gels were loaded with 400 ~g/lane C2C12 myoblast extract. gels 
were incubated with 400 mM CaCI2 (A). 100 flM CaCI2 (8), 10 ~M CaCI2 (C) and 100 flM EDTA 
(0). Similarly loaded non,denaluring gels were elewophoresed and transferred, before being 
probed with anti-fl-calpain (B2F9) or anti-m-calpain (ForSberg anti-m-calpain) antibodies. 
As has been previously shown, Jl-caJpain and m-calpain migrated differently 
through ,I nun-denaturing gel miJjcu despite having similar sizes (Raser el ai, 1995). 
As a consequence of the.::: grea ler negative charge carried by m calpain (which is 
reflected in its late elution frum weakly basic DEAE io n-exchange columns) ffi -
calpain migrates further through the gel than J..l-calpain. Its identity is illllicated by the 
observation lhat proteolytic activity in this size range is essentially undcceccable at 
calcium concentratio ns of 100 and 10 mM. Extra evidence is provided by the 
\Vestern blot showing reactivity of anti-m-calpain antibody with the more negatively 
charged, high calcium demanding proteolytic activity, and reactivity between anti-/.!-
calpain with the proteolytic activity demanding low caJcium concentrations. Note 
that the anti J.l-calpajn antibody reacted weakJy against non-denatured Il-calpain 
relative to lhe uenatu red J.1-caJpain shown in Figure 4.7. This is possibly due to the 
fact that the original antigen was denatured J.l-calpajn large subunjt which had been 
gel extracted from SDS-PAGE (Geesink - personal communication) and the epilope 
is less accessible to the monoclonal antibody, hence, the poor reactivity. The anti m-
calpain antibody is, apparencly, less affected by the non-denatured structure of its 
Chapter 4:Characterisation of C2C12 fusion and transfection optimisation 95 
target. This is not surprising because it is a po lyclonal mixture of antibodies 
recognising many differen t epitopes some of which are likely to remain accessible. In 
conclusion, there is li ttle doubt that both m- and Il·calpain are present in an active 
state in C2C12 myoblasts. Failure to detect these proteins with Western blotting may 
be.:: a feature of sample preparation or antibody specificity. 
4.2.2.5 m-Calpain 
As no ted by casein zymography the secund ubiquitous component o f the 
calpain system, m-calpain (11 0 kDa), is detectable in C2C12 extract. 
o 24 48 72 96 
- 2!1OkUa 
- 150kOa 
- lOOkOa 
"'"-- - .- - -
- 7SkOa 
- SOkOa 
- J7kOa 
- 2SkOa 
Figure 4.9 m-calpain levels over 96 hour fusion period. Approximately 100 u9 of total protein 
extracted from C2C1l's was electrophoresed through a 10 % SOS·PAGE gel and transferred to 
nitrocellulose before being probed with anti-m-calpain antibody (Forsberg anti-m-calpain) at 1 : 500 
dilution. 
Two anti-m-calpain antibodies were compared to determine which was the 
most suitable for detection of m-calpain in C2C12 extracts. Firstly, the monoclonal 
antibody 107-82 (Geesink & Goll 1995) which recognises domains JlI and IV of the 
large subunit was tested. In these studies this antibody displayed no immunoreactivity 
with C2C12 extract (data not shown), which contrasts to the experimental resuJts of 
Temm-Grove elol. (1999) who found this antibody successfull y reacted with C2C12 
extrac ts. Differences in antibody dilution factor and protein load fai l to explain these 
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differences suggesting that sample preparation may be a factor. An anti-m-calpain 
polyclonal antibody raised against mammalian large subunit N-terminaI18-mer 
polypeptide (Huang & Forsberg 1998) was also tested. This presented a clear banding 
pattern with no major cross-reactivity and was chosen for all subsequent experiments 
in this work. Western blots revealed, that from 0 - 24 hours m-calpain levels 
increased by 220 % and remained elevated from 24 - 72 hours but fell to 150 % of 
the initial levels at 96 hours (Figure 4.9). This result has been mirrored in previous 
experiments on C2C12's by Temm-Grove et al. (1999) where m-calpain levels 
paralleled the fusion rate. Levels, as measured by Temm-Grove ct al. (1999), 
increased from 79 arbitrary units (au) to 111 au, and then decreased to 47 au. This 
has also' been reported by Cottin et al. (1994) who observed a large increase in m-
calpain from days 2 - 6 (18 -100 au) and a decrease at day 8 to 70 au. Again these 
changes closely paralleled the fusion dynamics which showed a rapid but tapering 
fusion from 2 to 6 days, and a decline in fusion by day 8. In contrast, Barnoy ct al. 
(1996: 1997) found that the levels of m-calpain increased between 0 and 48 hours to 
130 - 160 % of their initial levels. There were no subsequent significant changes. 
Kwak et al. (1993a) also observed a significant increase in m-calpain levels over 72 
hours without a subsequent decline. 
The fact that some of the researchers failed to observe a reduction in m-
calpain, as observed in this thesis, could be due to differences in cell type and/or 
growth conditions. Furthermore, it is impossible to determine whether the decline in 
m-calpain is actually occurring in the studies or if the decline is masked by significant 
asynchronous fusion events. In addition, there are two factors which should be 
considered when attempting to accurately measure m-calpain. 
First, Temm-Grove ct al. (1999) found that a large proportion of m-calpain 
extracted from C2C12's existed as a large aggregate and failed to enter the separating 
gel, unless the percentage of ~-MCE in the loading buffer was increased from 5 % to 
8 %. The authors, however, did not speculate whether this phenomenon is a feature 
of the extraction process or a characteristic of in situ events. The ~-MCE 
concentration of protein samples used in this thesis was < 1 %. There was no 
evidence of large immunoreactive protein failing to migrate into the gel. 
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Second, Brusus el al (1994) detected m-calpain by immuno-fluorescence and 
fo und it was unevenly scattered around no n-permeabili sed myoblasts at 60 hours 
after fu sio n induction. The fact that the ce lls had not been made permeable to 
antibodies lead the authors to conclude that the detected m-calpain was externalisecl . 
This conclusion was reinforced by clectronmicrographs which clearly depicted anti-
m-caJpajn antibody associated with the extracellular matrix of myoblasts induced to 
fuse (Dourdin pi aI, 1997). In summary, obtaining an accurate sample of m-calpain in 
a PAGE gel reguircs attention to sample preparatio n nnd may account fo r some of 
the djrre;:rcnces re ported in the li terature. 
4.2.2.6 Calpasta tin 
'Ill is thesis is built upon the premise that by manipuladng levels of caJpascaun 
it may be possible to alter myoblast fusio n. Fo r thjs reason severa] anti -calpastatin 
antibodies were tested to assess their abi li ties to detect endogenous calpastatin in 
non-heated and heated soluble pro tein ex tracts from murine muscle. Ovine samples 
were included as controls. TIle fo ur po lyclo nal an tibodies generated in Chapter 3 
were tested alo ng with mo noclonal antibodies 1 F7 and 3B9 (see Figure 4.10). 
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Figure 4.10 Westem blots performed to determine effectiveness of anti-calpastatin 
antibodies. SDS-PAGE gels (10 %) were loaded with 50 fig total soluble protein lrom ovine 
sketetal muscle (A), 7.5 fig heated total soluble protein from ovine skeletal muscle (B) , 50 fig total 
soluble protein from murine skeletal muscle (e) and 7.5 fig heated total soluble protein Irom murine 
skeletal muscle (0). Following elecuophOfesis, proteins were transferred lOf Western analysis using 
polyclonal antibodies produced from recombinant ovine domain L (551. 566; 1:100) and domain 1 
(552, 567; 1 :100), and using monoclonal antibodies raised against human domain 4 (1 F7; 1:5000) 
and bovine domains 2 - 4 (389; 1:100). 
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Monoclonal antibody 1F7 was raised against domain N of human calpastatin 
(Thompson & Goll, unpublished data). In these blots the antibody recognised a 120 
kDa heat stable protein, which is likely to be calpastatin, from ovine tissue but was 
not able to detect this protein in total murine extract or in heated murine extract. In 
the latter sample, two pairs of similarly sized bands at approximately 50 kDa and 20 
kDa were detected. An almost identical blot was obtained using monoclonal antibody 
3B9 (Doumit & Koohmaraie 1999) which was raised against an undefined region of 
recombinant bovine calpastatin domains 2 - 4 (Doumit ct a/., 1996). Again, 
immunoreactivity was seen with a 120 kDa protein in non-heated and heated ovine 
skeletal muscle extract, no reactivity was seen in non-heated murine extract. Two 
pairs of bands (50 kDa and 20 kDa) reacted in the heated murine extract. 
Monoclonal antibody 1F7 has been successfully used by Temm-Grove ct al. (1999) to 
detect a 137 kDa isoform of calpastatin in C2C12 extract. Therefore, it is surprising 
that this antibody failed to detect anything in non-boiled murine extract or in C2C12 
extract which was also tested (data not shown). 
As noted, the only murine proteins recognised by the IF7 and 3B9 antibodies 
were two pairs of closely related proteins at 50 kDa and 20kDa. Both were only 
detectable only in the heated extract. The main effect of heating is to purify the 
soluble extract. By loading the maximum allowable volume of calpastatin enriched 
extract onto a gel the detection of calpastatin is enhanced. It is possible, therefore, 
that these smaller bands represent calpastatin fragments which are present below the 
levels of detection in the non-boiled extract. These fragments may result from 
proteolysis of calpastatin. Notably, calpain has been demonstrated to have the ability 
to degrade calpastatin into fragments ranging from 29 kDa to 100 kDa (Doumit & 
Koohmaraie 1999). However, the nature of these bands remains uncertain and 
neither 1F7 or 3B9 appear suitable antibodies to detect full length calpastatin from 
murine tissue. 
The four polyclonal antibodies described in Chapter 3 were also investigated 
for their efficacy in detecting murine calpastatin. As demonstrated in Figure 3.13 
each of these antibodies was effective in detecting a 120 kDa heat stable protein in 
ovine samples. With respect to murine extracts their immunoreactivity varied. 
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Antibody 567 was able to detect a protein at approximately 110 kDa in both heated 
and non-heated samples. A recent paper by Takano e/ al. (2000) repons that an anti-
calpastatin polycional .ntibody recognised two major bands (70 kDa and 110 kD.) in 
mo use testi s, altho ugh they suggest that the smaller band is specjfic to this ti ssue. 
The relatively sljght size difference beLween the immuno reactive ovine protein (120 
kDa) and this immunoreactive protein is similar to o ther repo rted species specific 
differences ([.k.no e/ ai, 1986a). Antibody 552 which, like 567, was raised against 
recombinant domain 1 detected a 11 0 kDa protein, although only in the heated 
extract. As already mentio ned, heating enriches lhe sample in favour o f calpastatin. 
The lack of reactivity in the non-heated sample may be simply due to poor 
sensitivity. Antibodies 551 and 566 were also no t successful in detecting 11 0 kDa 
proteins in either the heated or non-heated samples. AU these results shuw that 
antibody 567 is sui table for the detection of full length murine calp.starin . The 
Western analysjs of C2C12 extract using this anLibody is shown in Figure 4. t I. 
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Figure 4.11 Calpaslalin levels over 96 hour fusion period. Controls were included which 
contain: 50 119 total soluble protein from ovine skelelal muscle (A), 7.5 119 healed lolal soluble 
prolein from ovine skeletal muscle (8). 50 ~g total soluble protein from murine skeletal muscle (C) 
and 7.5 ~g heated total soluble protein from murine skeletal muscle (0). Approximately 100 ug of 
total protein was extracled from C2C12·s at from O. 24. 48. 72 and 96 hours post-induction and. 
together with conlrols. was electrophoresed Ihrough a 10 % SDS-PAGE gel. transferred 10 
nitrocellulose. and probed with anti-calpaslatin antibody (567) al l : 100 dilution. Immunoreactive 
bands in C2C1 2 extract are arrowed. 
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Figure 4.11 shows that the Western with antibody 567 failed to detect 
calpastatin in C2C12 extract. This demonstrates that full length murine calpastatin is 
either: (i) absent or (ii) present at very low levels or (iii) structurally different from 
native in vivo ovine and murine calpastatin. Two proteins were detected by antibody 
567 (arrowed). These proteins correspond to the non-heat stable proteins detected in 
non-boiled murine extract and are unlikely to be calpastatin isoforms. Previously, and 
under different experimental conditions, Barnoy ct al. (1996:1997) found that 
calpastatin levels declined to 20 - 30 % of their initial levels at the start of fusion (72 -
96 hours) and then increased to 70 - 80 % of the initial levels by 120 hours. This was 
also observed by Balcerzak ct al. (1998) who, using a different cell preparation, 
observed a 60 % reduction in calpastatin protein at the time of maximum fusion and 
an increase back to normallevels after fusion was completed. In contrast, Temm-
Grove ct al. (1999) observed that calpastatin levels increased as cells passed from the 
proliferative to the fusion stage and continued to increase to the point at which 
fusion was represented by 50 % nuclei in the myotubes. It is not possible to 
speculate as to the cause of these experimental differences. Cell type, antibody 
specificity and growth conditions can all be contributing factors. 
4.2.3 Conclusions 
Several useful indicators of differentiation have been confirmed. Myosin, 
Troponin T and desmin all accrue in response to biochemical determination of 
C2C12 myoblasts. These modifications to the proteome are mediated by reducing 
the growth factor concentration in their immediate surroundings. An important point 
to note is that these proteins are markers of biochemical differentiation and are not 
representative of fusion. 
Troponin T and desmin are both substrates for calpain. Proteolytic fragments 
of these proteins may provide a measure of calpain activity in vivo. With respect to 
desmin there is no evidence of proteolytic fragments in C2C12 extract. Previous 
work has used a monoclonal antibody (D3) in desmin blots and detected fragments 
from calpain proteolysis (Geesink & Koohmaraie 1999). Failure of D3 to detect 
proteolytic fragments in this work indicates a lack of proteolysis rather than an 
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inability of the antibody to recognise its epitope. The troponin T blots revealed the 
existence of a fragment resulting from its degradation. While the size of this fragment 
is similar to some of those generated by calpain in vivo (Geesink & Koohmaraie 
1999), it cannot be concluded that calpain is responsible for the proteolytic products. 
While the appearance of a 30 kDa TnT fragment does not specifically coincide with 
the presence of either Jl- or m-calpain, it is of interest to examine the dynamics of 
this fragment in cells transfected with calpastatin variants. 
With respect to the calpain and calpastatin system, several differences are 
evident between published results and the data obtained in these experiments. 
Essentially, both Jl-calpain and m-calpain were detected in C2C12 extracts at all time 
periods during the fusion process. Jl-Calpain clearly displayed the products of 
autolysis which is evidence of its activity in vivo. Autolytic products of m-calpain were 
not discernible in the Western blots although Brown & Crawford (1993) noted that 
the autolytic products of m-calpains large subunit wer~ difficult to resolve on SDS-
PAGE. Both proteases are present in an active native form as demonstrated by 
casein zymography. 
Endogenous calpastatin was not detected in the C2C12 extract. Several 
antibodies were examined for their ability to detect calpastatin but all were 
unsuccessful despite some having immunoreactive responsiveness to C2C12 or 
murine skeletal muscle extracts. It was concluded, that endogenous calpastatin is 
either absent or present below the levels of detection. 
4.3 Construction of calpastatin - EGFP expression plasmids 
The second issue this chapter addresses is the functionality of calpastatin 
domain L and its inhibitory regions 1-4. Reports suggest that domain L may facilitate 
the localisation of calpastatin to the plasma membrane. This could be an important 
consideration with respect to myoblast fusion, particularly if calpain is active in this 
region. To this end, plasmids were designed which would express domains of 
calpastatin with attached EGFP protein. A vector permitting C-terminal attachment 
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was chosen to ensure that the interactions between domain L and any potential 
membrane components would not be disrupted. 
As described in Chapter 3, an appreciation of the ovine calpastatin cDNA 
sequence (Appendix B) facilitated construction of PCR primers which specifically 
amplify domains Land lor, when used in combination, domains L+1. Again, primer 
sequences were designed to include restriction enzyme sites which match those 
contained in the multiple cloning site of the GFP vector. After amplification and 
restriction digestion, sticky-ended ligation allowed insertion of the amplimer into the 
vector, in both the correct orientation and reading frame with respect to the C-
terminally attached GFP. Figure 4.12 provides a schematic overview of the process. 
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Figure 4.12 Construction of GFP-calpastatin plasmids. Ovine calpastatin eDNA contained 
within pBluescript II KS. plasmid (pBSCnlstn) wns cx~acted from ~anslormed bacteria, and 
purified. Digestion with Xba1 and Sac1 released a fragment containing domains L·1 ; Ihis was used 
as template DNA in PCR reactions. Three reactions were pertormed using pomer combinations of 
DlGFP" & DlGFP", D1GFP" & 01 GFP" and Dl GFP" & 01 GFP", generating amplimers 01 
domains l , 1 and l . 1 respectively. The PCR products were gel purified and digested with 
restrd ion enzymes to generate sticky-ended products. These could then be ligated into a similarty 
digested pEGFP-N3 vector. The resuitant construct is then suitable lor introduction into E. coli lor 
propagation. Following extraction, plasmid is purified and transleeted into myoblasts to achieve 
expression of retombinant fusion proteins. 
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4.3.1 Template preparation 
Generation of calpastatin-GFP encoding constructs starts with the 
preparation of a template DNA embracing the domain Land 1 regions. This was 
performed as described in section 3.2.1. Briefly, a double digestion of pBSCals1? 
using the restriction enzymes Xba1 and Sad produced three fragments. The largest 
of the fragments represents the pBSKS vector. The smaller fragments represent the 
totality of the calpastatin insert. Agarose gel electrophoresis and DEAE membrane 
extraction permitted isolation of the smaller 862 bp fragment containing domains L 
and 1 and a short sequence of domain 2. After purification, band homogeneity and 
. size was confirmed by gel electrophoresis and the fragment was used in PCR. 
Quantity and purity of DNA template was determined according to section 2.2.6. 
4.3.2 Amplification of calpastatin domains 
Three PCR reactions were performed as described in section 2.2.9 using the 
862 bp fragment as template DNA and the primers shown in Figure 4.13. 
A 
B 
5'crGCCGGAATTCGCC4C~TCCCACAGAAGCCAAGGCT3' 
• EcoRl 
5C:AGCCGGTCGACTGCAGAAGGTTTACTTGGCTTGG 3' 
• SaIl 
C 
5'CAGCCGGAATTCGCC4C~CAAAGTCAGACATGGATACTGCT3' 
• EcoRl 
D 
5'CTGCCGGTCGACCTCTTCCACTTTTCTTCTTTTC 3' 
• SaIl 
Figure 4.13 peR primer sequences used for the amplification of domains Land 1 prior to 
insertion into pEGFP-N3. Bold nucleotide sequence is homologous to ovine cDNA, boxed ·ATGo 
represents upstream start codons, restriction enzyme locations are noted together with cut points 
(arrowed), italicised nucleotides represent a Kozak consensus translation initiation site. Remaining 
nucleotides are non-homologous to ovine cDNA but are included to provide an ·overhang" region. 
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In producing primers for the construction of GST-calpastatin constructs 
there was no need to include start codons because the upstream GST cDNA 
contained its own ATG sequence. In this instance polymerase activity would 
continue downstream through the calpastatin cDNA until reaching a stop codon; 
accordingly such codon sequences were included in both 3' primers (see section 
3.2.2). In the instance of pEGFP constructs, the translation product will be N-
terminal calpastatin with C-terminally attached EGFP. Thus, it is necessary to 
guarantee the presence of appropriate start codons (ATG) at the commencement of 
the calpastatin coding sequence and the absence of intervening stop codons. In the 
case of domain L, a start codon is recognisable which demarcates the beginning of 
the domains translated sequence (see Appendix B). After scrutinising domain 1, an 
in-frame ATG was found at nucleotide position 10. However, for completeness it 
was resolved to include a start codon immediately upstream of the domains first 
codon. This ensures the inclusion of the three amino acids which would otht;rwise 
have been lost. Furthermore, the context of the ATG at nucleotide position 10 was 
not characteristic of the archetypical Kozak consensus translation initiation sequence. 
The Kozak sequence (5' .. . CCAj GCCATGG ... 3') is known to be present in the 
majority of eukaryotic sequences and be the peptide chain initiation site (Kozak 
1987). To accentuate the desired peptide initiation site in the EGFP constructs, 
Kozak sequences were included before the start codons in both 5' primers. No stop 
co dons were found within either domains coding sequence. Thus, termination of 
translation would be effected by the GFP cDNA stop codon. 
After peR, amplimer fragments were gel electrophoresed and extracted using 
DEAE membrane, ethanol precipitated, and digested with EcoRl and Sall to 
produce sticky-ends. The pEGFP-N3 expression vector (see Appendix A.4) was 
similarly digested before gel fractionation and ethanol precipitation. After 
precipitation, all products (pCR amplimers and digested pEGFP-N3) were subjected 
to phenol j chloroform extraction (see section 2.2.2.3) and quantified prior to 
ligation. 
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4.3.3 Ligation and transformation 
PCR products were ligated separately into a digested pEGFP-N3 vector and 
the resultant products used to transform competent DHSa. E. coli (see section 2.2.1). 
Bacteria were selected through their resistance to kanamycin antibiotic encoded by 
their plasmid. After 24 hours the plates were examined. Based on "blue-white" 
selection the procedure appeared to have been 100 % successful in producing 
plasmids containing inserts. The plasmid DNA from 5 colonies peculiar to each 
transformation treatment were harvested according to the miniprep protocol (section 
2.2.2.1). After a double restriction enzyme digestion designed to remove the insert, 
the nature of the insert was assesseo by gel electrophoresis. Bacterial colonies grown 
from individual bacterium successfully transformed with each of the three plasmids, 
were used to inoculate volumes of "Terrific Broth". A very high purity plasmid DNA 
was extracted from these bacteria according to the midiprep protocol (see section 
2.2.2.2) and used in subsequent transfection experiments. DHSa. strain E. coli were 
used since they have a defective endA 1 gene (Grant et aI., 1990). The absence of this 
gene product (endonuclease 1) is thought to improve the quality of plasmids, and is a 
vital concern for successful transfection. 
The positioning of the inserted DNA within the multiple cloning site means 
that there are 36 bp (12 amino acid residues) between the C-terrninus of calpastatin 
and the N-terminus of GFP. These so-called "linker" regions can have significant 
effects upon the stability of the green fluorescent protein fusion proteins. Recently, 
Prescott et al. (1999) examined the effect of different lengths of linker regions (23 -
28 bp = long linker, and 5 - 7 bp = short linker) on GFP fusion proteins. While a 
long linker limited degradation of one fusion partner, a short linker seemed to favour 
another. Thus, while there are no rules on the ideal linker length between different 
fusion partners, an optimum length should be investigated when designing plasmids. 
4.3.4 Sequencing data 
As a final confirmation, the plasmids generated by this work (pEGFP- DL, 
pEGFP-Dl and pEGFP-DLt) were sequenced using the primers originally used for 
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the amplification of respective insen s. Once again, lhe structural organisation of 
these sequences was similar to the reported ovine calpasmtin eDNA sC(luence and to 
other caJpastatin sequences when submitted to GenBank for comparison. The 
detailed sequence data depicted in Figure 4.14 is provided in Appendix D. 
Ovine Calpastatin Domain l 
S" pEGFP·Ol s~qut:nce 
3' pEGFP·Ol sequence 
5' pEGFP-Dl1 sequence 
Ovine Calpastatln Domain I 
Dt r.F~') ) 
Dl1GF~· 
.1 00% 
,
' 00% 
------'11-"-'· ''-----
___________ --"Ir·~'~%--, 
5· pEGFP·01 sequence ----l.!!~ _____ J~,,91-'%"---
3· pEGFP-01 tlcqucnce 199 % . 
3' pEGFP·Dl1 sequence ------'. 
A 
B 
Figure 4.14 Homology trees comparing insert sequence data with domains of ovine 
calpastatin. Ovine calpastatin domain l compared to 5' sequence 01 inserts encoding domain l 
and domains l + 1. and the ,everse complementary sequence of 3' sequenced domain l. Ovine 
calpastatin domain 1 compa,ed to inserts encoding ,eve,se complementary sequences of 3' 
sequenced domain 1 and domain L + 1, and 5' sequenced domain 1. Percentage homology 
between closest pairings is displayed. 
4.3.5 Summary 
Regions of the ovine calpastatin cDNA sequence, corresponding to domains 
Land 1, have been peR amplified separately and, in combination, to produce cDNA 
for domain L, 1 and L+ 1. Separately, the three sequences have been incorporated 
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into a mammalian expression vector for protein expression. The recombinant 
product will consist of domains of calpastatin and C-terminally attached GFP. 
4.4 Optimisation of C2C12 myoblast transfection with FuGENE 6 reagent 
Transfer of DNA into eukaryotic cells is a standard technique in molecular 
biology. Mechanical, electrical or retroviral methods have been used to accomplish 
this transfer. Protocols which employ "uptake - enhancing" chemicals have been 
substantially refined and are now commonly used. The basic principle is to form a 
complex from negatively charged DNA and positively charged chemicals (usually 
polymers). Subsequently, the complexes are taken up by the cell through endocytosis' 
and subjected to lysosomal processing. Entrapped DNA is released from the 
complex, either before or after entering the nucleus, and gene transcription takes 
place. 
The most common examples of this approach are protocols using calcium -
phosphate or cationic lipid. In the former, after mixing CaP04 and DNA in a 
HEPES buffer, a precipitate is formed and taken into the cells by an endocytic 
mechanism. With cationic lipids, an association is formed between the lipids and the 
negatively charged DNA which produces a net neutral or positive charged complex. 
The complex then associates with the negatively charged cell membrane and is 
assimilated into the cell through endocytosis. 
Transfection efficiency describes the percentage or proportion of cells which 
receive and express the exogenous DNA. It is dependent upon the efficiency of 
DNA delivery (ie. the number of DNA molecules that penetrate the nucleus) and the 
efficiency of expression (ie. fraction of DNA molecules that undergo transcription). 
The efficiency of transcription can be improved with the use of strong promoters 
and enhancers. However, significant improvements in the efficiency of delivery 
remains elusive. The reason for this is that successful DNA delivery must overcome 
three barriers. First, a low uptake over the plasma membrane. Second, an inadequate 
release and limited stability of the DNA once within the cell. Third, a lack of nuclear 
targeting (Luo & Saltzman 2000). 
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A transfection experiment may be classified as either "transient" or "stable" 
in nature. As already noted, transfections are rarely 100 % successful. Transient 
transfections produce a mixed population of transfected and non-transfected cells. In 
stable transfections, attempts are made to isolate and propagate clones containing the 
transfected DNA. Typically, this isolation is accomplished through transfectants 
expressing resistance to antibiotics, displaying altered morphological characteristics 
or being furnished with an essential gene missing from the host cell line. These 
protocols are time consuming and may have detrimental effects on cells. 
Furthermore, because myoblasts have a finite number of mitotic cycles before 
senescence (Webster & Blau 1990), the potential survival time of successful 
transform ants is low. Therefore, unless a population needs to be enriched, transient 
transfections are preferable. 
4.4.1 FuGENE 6 transfection of C2C12 myoblasts 
The literature contains numerous examples where DNA has been introduced 
into muscle cells (Dickson 1996). Transfection techniques that have been used 
include: microinjection of DNA (Hansen ct a/.J 1991); the use of calcium - phosphate 
(Donoghue ct aLJ 1988; Cribbs ct a/.J 1989; Rosenthal ct a/.J 1989; Ernst ct a/.J 1991; 
Bishopric ct a/.J 1992; Edmondson ct a/.J 1992; Huang & Forsberg 1998); viral vectors 
(Crescenzi ct a/.J 1994; Kessler ct aLJ 1996) and liposomes (Blanton ct aLJ 2000). The 
calcium - phosphate method is the preferred technique but it has been demonstrated 
that there is considerable replicate variability which is inherent with the technology 
(Song & Lahiri 1995). Thus, different transfection techniques yield variable results. 
The main sources of variation is cell type and methodology. 
FuGENE 6 from Roche Molecular Biochemicals is a relatively recent 
addition to the suite of available transfection reagents. The manufacturers do not 
provide composition details but state that FuGENE 6 is a "proprietary blend of 
lipids and other components". Several articles refer to it as a lipid based delivery 
system (Ritter 1998). It is, in essence, a chemical delivery system. 
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Such lipid based delivery systems have been successful in delivering GFP 
reporter plasmids into primary myoblast cultures and established cell lines. The 
system has produced both stable and transient transfections (Moss et aI., 1996; 
Turnacioglu et aI., 1997). FuGENE 6 has also been successful in transfecting a wide 
variety of established and primary mammalian cells lines including L8 rat skeletal 
myoblasts (Zelzer et aI., 1998) and cardiac myocytes (Noah et aI., 1998). FuGENE 6 
was selected for these experiments on the grounds of its relative ease of use and 
recorded efficiency. 
4.4.2 FuGENE 6 transfection optimisation 
In accordance with the manufacturer's recommendations, a variety of DNA 
and FuGENE 6 concentrations were compared to determine the best combination 
of the components. Very pure EGFP-N3 plasmid DNA was quantified by 
spectrophotometry and agarose gel electrophoresis according to section 2.2.6 and 
diluted to a concentration of 1 /1g/I.ll FuGENE 6, supplied in an ethanol solution, 
was used directly. However care must be taken to minimise the possibility of 
evaporation from this volatile solution. Titrations of FuGENE 6 solution were 
added to serum free DMEM to a final volume of 100 J1l and incubated at RT for 5 
minutes. During this time, titrations of DNA were pipetted into microfuge tubes and 
maintained on ice until the FuGENE 6 solution could be added drop - wise. The 
mixture was incubated at RT for a further 15 minutes before being pipetted into the 
growth media of cells grown in 24 well plates with 1.0 ml media. After 24 hours, the 
cells were trypsinised from the plate according to section 2.2.15.1, washed once with 
DMEM + 10 % FeS, washed again with PBS and finally resuspended in a volume of 
200 /11 PBS. The total volume of cell suspension was pipetted into individual wells of 
a 96 well black plastic microtitre plate. These plates are designed to minimise the 
background by being non - reflective which prevents "spill - over" of illumination 
from adjacent wells. Fluorescence was measured with a BMG Fluorostar plate reader, 
arranged with overhead excitation (480 nm) and emission (520 nm) fibre-optic 
cables. Ten measurements of each well were taken at 20 seconds intervals with lateral 
shaking of the plate between measurements. Values were averaged and plotted in 
Figure 4.15. 
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Figure 4.15 Optimisation of conditions for FuGENE Gtransfection. Plasmid EGFp·N3 DNA 
was transfected into C2C12 myoblasts (50 - 80 % conlluen!) at concentrations from 0.16 - 2.01'9 
with FuGENE 6 at volumes from 0 - 4 1'1. 
The relative fluo rescence values were determined by the BMG plate reader 
and are presented in Figure 4.1 5 without moctifica tion. On average, an empt}' we ll 
presented a relative fluorescence of 380. Non-transformed heaJthy ceUs showed an 
average fluo rescence of ·1400. These values represent the back!,:rrolllld well and cell 
fluo rescence or auto - fluorescence. Only values greater than the~e va lues wou ld 
indjcate transformation . Values less lhan the background ind.ic:ne a reduction in auto 
- fluo rescence and may be result from cell death. Across a particular volume o f 
PuG ENE 6, fluorescence generally increases with increasing DNA concentration. 
The exceptio n to tlus is when tl1e concentration of DNA equaJs or exceeds the 
vulume of FuGENE 6. This agrees with the manufacturer notes, which state that 
excess DNA, with n:specl to PuGENE 6, can be detrimental to cell transformation. 
The greatest relative nuorescence was achieved by combining 4111 FuGENE 
6 with 1.33 Ilg DNA to be diluted in 1.0 ml of growth media. However, for the 
purpose of thjs experiment, transfection optimisation was defined as those 
conditions in which the minimum amount of reagent achieves the greatest acceptable 
fluorescence. As a result, relatively large increases in reagent consumption which 
results in onJy slight improvement in fluorescence, are inefficient. An example o f this 
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is illustrated by comparing the fluorescence from [3 J.1I FuGENE 6 + 2 119 DNA] versus 
[4 J.1I FuGENE 6 + 1.33 DNA] versus [4 III FuGENE 6 + 2.0 119 DNA]. The 25 % increase 
in FuGENE 6 usage resulted in a relatively small improvement in fluorescence; 17 % 
± 8.4 for [1.33 119 DNA] and 12 % ± 6.7 for [2.0 119 DNA] when compared to [3 III 
FuGENE 6 + 2 119 DNA] fluorescence. It is notable that [2 J.1I FuGENE 6 + 1.33 u9 DNA] 
resulted in only slightly less fluorescence than [3 J.1I FuGENE 6 + 2 119 DNA], and 
represents an even more significant saving in both DNA and FuGENE 6. However, 
[2 J.1I FuGENE 6 + 1.33 u9 DNA] achieves only 73 % fluorescence attained using [4 III 
FuGENE 6 + 1.33 DNA] and represents a substantial decrease from potential 
efficiency. Therefore, while this loss was considered too great, the compromise in 
transfection efficiency resulting from using [3 III FuGENE 6 + 2 119 DNA] is acceptable 
given the saving in FuGENE 6 which is the most expensive reagent (DNA is 
inexpensive to produce). It was decided that these volumes represent the optimised 
combination when transfecting C2C12 growing in 24 well plate with 1.0 ml growth 
media. Reagent volumes are increased or decreased proportionately when 
transfecting cells in larger or smaller volumes of media. 
4.5 Discussion 
Myogenesis describes the process by which precursor muscle cells 
(myoblasts) differentiate biochemically and morphologically into determined muscle 
tissue (myotubes). By controlling the environment in which myoblasts grow, it is 
possible to alter the conditions and promote this progression. 
Morphological differentiation is manifested as myoblast fusion which is an 
easily inducible process monitored by quantifying the chronological appearance of 
myotubes. Direct observation and manual counting is the preferable method for 
determining percent fusion over time. This procedure revealed that under the 
experimental conditions in this study, approximately 50 - 60 % of myoblasts fuse to 
form myotubes over the first 96 hours of fusion induction, and that the most rapid 
fusion occurred between 24 and 72 hours. F ACS analysis is not sensitive enough to 
discern myoblasts and myotubes once they are suspended in solution. It is not a 
suitable technique for quantifying fusion. 
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Several muscle specific proteins are only apparent in biochemically 
differentiated muscle cells. Myosin, troponin T and desmin all exhibit clear 
associations with differentiation. Both 1.1.- and m-calpain are detectable in C2Cl2 
extracts throughout the fusion period. Although components of the calpain system 
have been implicated in regulating the fusion process, the trends in calpain levels do 
not relate to any fusion event. Endogenous calpastatin is an important parameter in 
this work, since the initial objective of this thesis was the manipulation of levels of 
this protein. Several attempts using Western blotting were made to detect calpastatin 
in C2C12 extracts, however, all were unsuccessful. While this does not mean that 
calpastatin is completely absent from C2Cl2's, it does mean that the effects from 
expressing calpastatin variants (described in Chapter 5) should not be influenced by 
endogenous calpastatin. 
As described previously three calpastatin variants were used in this work. 
They represented domain L, domain 1 or domains Land 1 together. In Chapter 3, 
these eDNA sequences were combined with GST eDNA to provide an affinity tag 
with which to purify the expressed product. In this chapter, the intention was to 
generate calpastatin constructs with a factor which will enable visualisation of the 
hybrid protein. GFP is marketed as a fluorescent tag for tracing proteins within living 
systems. Furthermore, the robust and non-reactive nature of GFP make it an ideal 
fusion partner. Controlled mutations have since produced enhanced GFP (EGFP) 
which emit higher levels of light than their wild-type progenitors. This chapter 
described the successful creation of eukaryotic expression plasmids whose products 
combine the calpastatin variants and N-terminally associated EGFP. 
Several techniques are available to facilitate the introduction of plasmid DNA 
into living cells. Efficacy, expense, ease of use and effects upon cell viability are all 
criteria on which a particular technique may be selected. For these experiments 
FuGENE 6 reagent was selected. This is a liposomal reagent which combines with 
DNA to produce a cell penetrating complex. The optimal ratio of reagent to DNA 
was determined for transfection of C2C12 cells with pEGFP-N3 plasmid. 
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Chapter 5 
Expression of calpastatin variants in fusing myoblasts 
5.1 Introduction 
Several papers have described the impact of calpastatin on myoblast fusion 
(Brustis ct aI., 1994; Temm-Grove ct aI., 1999). The examination of fusing cells 
revealed that calpastatin mRNA and protein levels are down-regulated during fusion 
(Bamoy ct aI., 1996; Balcerzak ct aI., 1998). This thesis sought to express calpastatin in 
a manner which would inhibit calpain activity and fusion. The approach used was 
influenced by two reported experimental findings. First, Mellgren showed that certain 
regions of the protein (specifically domain L) facilitated the binding of calpastatin to 
plasma membranes (Mellgren ct aI., 1987a; Mellgren 1988; Mellgren ct aI., 1989). 
Second, phosphorylation of calpastatin's domain L changes the inhibitory potential 
(Salamino ct aI., 1994a; Salamino et aI., 1994b; Avema ct aI., 1999). While this data 
underscores the importance of domain L in regulating the function of calpastatin, it 
is inconclusive about whether these attributes have an in vivo function. Thus, when 
investigating the impact of calpastatin on fusion, it seems prudent to investigate both 
the structure and function of calpastatin. Expressing domains L, 1 and L1 in 
combination with EGFP allows several questions to be addressed. The first question 
is "what is the effect of expressing calpastatin on myoblasts during fusion?". The 
second question is "are there any differences in effect between the calpastatin 
variants?" and the third question is, "do the calpastatin variants show differential 
subcellular localisation at any stage during fusion?". 
This Chapter reports the successful expression of calpastatin variant / EGFP 
hybrids in myoblasts during fusion. The first segment of the chapter reports on using 
F ACS analysis to calculate transfection efficiency. The effect of calpastatin 
expression upon the rate and extent of cell fusion is then determined by counting 
cells directly with a microscope. Fluctuation in the levels of certain proteins may 
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indicate whether there are subtle changes associated with biochemical differentiation 
and changes to in vivo proteolysis. Analysis of these proteins will be performed using 
Western blotting. Finally, fluorescent microscopy will be used to detect evidence of 
differential subcellular localisation of the EGFP - calpastatin variants. 
To perform these experiments, five batches of cells were growth on 100 mm 
tissue culture plates until they reached 50 - 80 % confluence. Four of these batches 
were then transfected with plasmid pEGFP-N3 (control EGFP), and plasmids 
pEGFP-DL, pEGFP-Dl or pEGFP-DLl (encoding calpastatin variants and EGFP). 
The fifth batch was left untreated to serve as a negative control. The pEGFP-N3 
transfection is intended to control any effect due to the transfection process and for 
the expression of EGFP itself. Each batch of cells was grown for a further 24 hours 
before being washed, passaged and re-plated at equivalent densities over five 175 cm2 
flasks and five 35 mm plates containing sterile coverslips. Cells were cultured with 
complete growth media and reached confluence simultaneously. At this time the 
coverslip from one 35 mm plate, from each batch, was recovered and washed. Cells 
were then fixed, stained, and counted for the determination of percentage fusion (see 
section 2.2.15.6). Similarly, one 175 cm2 flask from each of the five batches was 
washed and the cells collected for protein extraction and Western blotting as 
described in section 2.2.15.5. Note that prior to homogenisation of the cells, a sub-
sample was removed for immediate FACS analysis (to determine transfection 
efficiency) as described in section 2.2.17. The remaining four flasks and plates from 
each batch were washed with PBS and the complete growth media replaced with 
differentiation media. At 24 hour intervals, a flask and plate were selected from each 
batch and the cells were either extracted or stained as described above. Thus, after 
four days, samples of protein had been collected from cells transfected with each of 
the four plasmids and from control cells at 0, 24, 48, 72 and 96 hours after fusion 
induction. 
\ 
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5.2 Transfection efficiency of C2C12 
As noted in section 4.4, transfection efficiency describes the proportion of 
cells which receive and express exogenous DNA. It is rare for transfections to be 
100% efficient and significant variation is not uncommon. In any experiment using 
transfection it is desirable to measure the extent of transfection efficiency. To obtain 
this information F ACS analysis was particularly suitable since the technique is 
reproducible and accurately measures the fluorescence emitted by individual cells 
within a population of cells. The data can also be directed to reflect specific· 
subpopulations and can be compared to control cells. 
As described in the introduction, sub-samples of cells for F ACS analysis were 
collected from treatments at each time interval. Because these cells cannot be stored 
for extended periods of time, the samples were analysed daily, shortly after being 
harvested. Any "between-day" variation, which may arise from fluctuations in the 
F ACS equipment, was controlled for by applying a sample of sub-confluent 
"calibration" myoblasts cultured in complete media each day. The fluorescence of 
both the control and treated cells was investigated using the parameters described in 
section 2.2.17. As noted in Chapter 4, each analysis performed by the FACS 
generates a scatter plot showing size and granularity of all the cells (raw F ACS data is 
provided in Appendix C). Within the scatter of individual cells or "events" two 
regions were defined; Rl and R2. The intensity of fluorescence emitted by cells 
falling within either R region can be plotted as shown in Figure 5.1. 
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Figure 5.1 Fluorescence of the R1 region at 0 hours as determined by FACS analysis. The 
results contrast control (A) and transfected C2C12 cells at 0 hours of fusion. Transfected cells are 
represented by B (pEGFP-DL), C (pEGFP-D1), D (pEGFP-DL 1) and E (pEGFP-N3). The X axis 
describes the level or intensity of emitted light in arbitrary units from 0 - 1000. The V axis is a direct 
count of cells, the average total number of cells counted in each trace is 50 000. Note that while 
this figure depicts 0 hour R1 plots only, both R1 and R2 plots can be drawn at any time point. 
Two arbitrarily positioned markers have been included within each "R" plot. 
The M2 marker encompasses the total range of fluorescence intensities emitted by 
control cells. Cells falling within this region are defined as non-fluorescing and any 
detected emissions are considered to represent background noise. The Ml marker 
embraces all cells displaying greater levels of fluorescence and defines transfected 
cells. Control cells were analysed at each time interval. Since there were no significant 
changes in their background proflle, the Ml - M2 boundaries were not altered during 
the experiment. Because the Ml range determined at 0 hours for Rl encompassed all 
non-fluorescing events in both Rl and R2 regions, these M ranges were applied to 
the Rl and R2 plots for all cell treatments at each sampling time. 
Transfection efficiency is expressed as a percentage and is calculated from the 
whole cell population by summing all Ml events and dividing by the total (Ml + M2) 
events. It is apparent that transfection resulted in a significant proportion of the cell 
population expressing EGFP. As shown in Table 5.1, the percent transfection at 0 
hours of fusion ranged from 56 % (pEGFP-DL) to 33 % (pEGFP-DLl). 
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Table 5.1 Characteristics 01 translected and control CZC1Z myoblasts populations at the 
initiation of fusion (0 hours). Shown are the total cell counts. the cell count of the M1 fraction, the 
percentage transfeetion derived Irom these two values and the mean fluorescence 01 the Ml 
fraction in arbilrary units (AU). 
The data indicates that the transfecti o n was successful in producing a mixed 
popu lation of transfectants and non-transfectants and that the mean fluorescence at 
o ho urs is 50 - 100 times higher than background IcveJs. These results indicate that 
the cal pasta tin containing constructs have the capacity to drive expression of EGFP. 
The percentn.ge o f cell s tran sfected within each t-reMment over the experimental 
period is graphically represented in rigtlfc 5.2. 
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Figure 5.2. Graph showing fluorescence over the experimental period. The percentage 01 the 
total cell population nuorescing was calculated by summing the Ml counts from Rl and R2 groups 
and dividing by ule total cell counts. 
FACS represents a simple and accurate method for determining transfection 
efficiency. An alternative approach is to count flu orescent cells directly using 
microscopy. This approach, however, was not used for three reasons. Firs t, 
Chapter 5: Expression of calpastatin variants in fusing myoblasts. 119 
differentiation of fluorescing and non-fluorescing cells is subjective and only possible 
when the difference is relatively large. Since there is a broad range of fluorescence 
intensities, weakly fluorescing cells may not be scored and the resulting transfection 
efficiency will be skewed. Second, to calculate the transfection efficiency both the 
number of fluorescent cells and the total number of cells must be determined. In 
these experiments, examination of fluorescence and the counting of cells required 
two different slide preparations. This is because Geimsa, which is commonly used to 
identify and count muscle cell populations (Kosower & Barnoy 2000), involves 
methanol fixation which destroys GFP fluorescence. The distribution of transfected 
cells is uneven, and the two slide preparations required to calculate transfection 
efficiency are not guaranteed to harbour representative cell populations. Third, the 
counting of fluorescent cells can be difficult when they are clustered together. 
Identifying whether a particular fluorescent body is comprised of one large cell or 
several smaller cells requires good subject definition. Combining fluorescence with 
another mode of microscopy (eg. phase contrast or differential interference contrast) 
may solve the definition problem. Indeed, the use of alternative stains and the use of 
modern microscopic equipment may have made direct observation a viable approach 
for calculating transfection efficiency. For example, staining a transfected cell 
preparation with Hoechst 33342 will not perturb EGFP fluorescence but would 
allow nuclei to be distinguished. Multimode microscopes with digital cameras and 
image analysis software will now permit fluorescent images to be overlayed with high 
contrast light images. 
5.3 The effect of transfection upon the rate and extent of fusion 
A successful transfection makes it possible to address whether an active 
recombinant GFP-calpastatin has impacted upon the rate or extent of fusion. As 
asserted in section 4.2, the direct counting of stained cells is the most simple and 
accurate method to estimate the percentage of nuclei contained in fused cells. 
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5.3.1 Microscopic examination and quantification of fusion 
Cells from each transfection were grown on coversHps. At appropriate times 
the coverslips were removed and the cells fixed, stained, and brightfeild microscope 
photographs taken. These are presented in Figure 5.3. 
a Hours 24 Hours 48 Hours 72 Hours 96 Hours 
pEGFP-N3 
pEGFP-DL 
pEGFP-Dl 
pEGFP-DL+l 
Figure 5.3 Photographs of experimental cells induced to fuse. Transfccled and non· 
lransfcctcd C2C12 cells were, plated onto coverslips and induced to fuse as described. At 24 hour 
intervals, cell we,. fixed and slained (Bar = 100 ~m) . 
Subjectively, all the cell popu.lations appear to exhibit similar "normal" 
morphologies, alignment and fusion. Moreover, there were no obvious differences in 
cell density, plate coverage or cell mortality. The percentage fusion was ca1culated 
from these images as described in seccion 4.2."1. These data arc presented in Table 5.2 
and graphically represented in Figure 5.4. 
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Table 5.2 Estimation of the extent of fusion over 96 hours determined by direct cell 
counting. Cells falling within the microscopes field of view were counted and scored as myoblasts 
or myotubes. The stained nuclei within these cells were counted. The percent of fused cells is 
estimated by dividing Ihe number of myotube nuclei by the lotal number of nuclei. 
Figure 5.4 Graph showing percent fusion of treatment cells over the culture period. After 
fixation and staining. random fields were viewed with a light microscope and nuclei were counted 
and allocated into myoblast or myotube categories. 
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The percentage fusion of the control cells (those transfected with pEGFP-
N3) is almost identical to the growth proftle of untreated cells shown in the previous 
Chapter (see Figure 4.2). This indicates that the experimental protocol is robust and 
reproducible. Unfortunately, there were no conspicuous differences between the rate 
or extent of fusion in myoblasts expressing the calpastatin variants. 
5.3.2 F ACS analysis of R2 region fluorescence 
Despite transfection being successful, the expression of calpastatin - EGFP 
failed to significantly influence the overall rate or extent of myoblast fusion. This 
may indicate that calpastatin is totally ineffective or that the impact of calpastatin is 
mil10r and cannot be discerned through direct microscopic examination. Sections 
4.2.2.4 and 4.2.2.5 established that 11- and m-calpain are present in C2C12 cells 
during the fusion process. It seems reasonable to assume, therefore, that for 
calpastatin to prevent fusion, it must be present in C2C12 cells in sufficient amounts 
to repress calpain activity below that required for myoblast fusion. However, if only a 
few cells are expressing sufficient active calpastatin - EGFP to eliminate calpain 
activity then their presence may escape detection on examination of the entire cell 
population. Moreover, since the level of calpastatin expression is likely to be 
correlated to the intensity of EGFP fluorescence the mean fluorescence of myotubes 
should be compared between the treatments. 
At this stage of experimentation, the most simple approach was to compare 
the mean fluorescence of the R2 groups between treatments. The FACS designated 
R2 region was an identifiable cell population presenting a large and granular 
morphology. In section 4.2.1, R2 was explored as a measure to quantify percent cell 
fusion. It was revealed that the R2 values were not numerically representative of 
fusion, and that the F ACS device was unable to isolate all the myotubes from mixed 
cell populations. Nevertheless, the cell bodies that were separated are likely to be 
myotubes since they are, by definition, large and complex. Within this framework, 
the mean fluorescence of the transformed myotubes were compared in Figure 5.5. 
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Figure 5.5 Mean fluorescence of Ml cells falling within the R2 region. The Ml subdivision 
within R2 describes cells whose fluorescence exceeds background levels determined in non-
transformed cells. The X axis describes Ihe level I intensity of emilled light in arbitrary units from 0 
- 3000. The Y axis shows time after fusion induction. 
The data presented in Figure 5.5 seeks to reveal any effect of treatment on 
the intensity of fluo rescence emitted by transfected myotubes. At each time interval, 
and for each treatment. the mean fl uorescence was calculated by summing the total 
fluorescence o f the Ml cells and clividing this figure by the nllmber o f M J cells. As 
already noted, the Ml division embraces ceUs whose flu orescence exceeds the 
background levels defin ed by non-transformed ceUs. AU ceUs within M I must, 
therefore, be transfected. By selectively examining the M 1 mean fluorescence, as 
opposed to tvn +M2 mean fluorescence, the impact of different transfection 
efficiencies on mean fluorescence is avoided. 
There are no dear treatment effects on the mean fluo rescence of myotubes. 
The large variations observed 0 and 24 hours are diffi cult to explain or associate with 
a treatment effect since little or no fu sion takes place at this time. Indeed, over the 
period o f greatest fu sion (48 and 72 hours) the mean fluorescence of the transformed 
myotubes converge. These trends may be due to the relatively small number o f cells 
used to calculate 0 and 24 hour means (from 19 to 50 cells) compared to the greater 
numher used at later times (up to 300 cells at 96 hours). The larger sample size at 
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later times gives an accurate mean value compared to the more variable early mean 
values. 
A common trend in treatmems is that the mean levels of fluorescence 
converge from 72 hours. \'V11en expressed as a percemage, tlus decline is almost 
uniform across the R 1 regions as shown in Figure 5.6. This is not unexpected since 
the experiment seeks onl y to transiently transfect cells. It would appear that whatever 
system is responsible for the reduction in fl uorescence in these cel1s, it is not affected 
by the treatment. 
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Figure 5.6 Percent decline in mean nuorescence of R1 across treatments. Values were 
calculaled relative 10 0 hour mean nuorescence. 
5.3.3 Summary 
FACS is a suitable method for determining transfection efficiency, and 
reveals that a significant proportion of C2C12 cells growing in culture were 
successfully transfected with pEGFP plasmids. The percentage of cells expressing 
EGPF was similar between the treatments and did no t fluctuate significantly over the 
96 hours of fusion culture. lmportantly, however, direct microscopic examination of 
fi xed ceUs djd not reveal any differences between treatments with respect to the rate 
or extent of fusion. Thi s indicates that the calpastatin va riants are eilher completely 
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ineffective or have only a minor impact on the fusion process. To investigate 
whether strong expression levels reduced fusion, the mean fluorescence of 
transformed myotubes was compared. The differences which were seen are probably 
due to differences in the number of observations and the inaccuracies associated with 
this rather than a treatment effect upon fusion. Another direct approach is to 
microscopically examine transfected cells with fluorescence. While the potential to 
observe and track cells by microscopy during the fusion process would have been 
advantageous, at the time that these experiments were undertaken there was no 
readily available inverted fluorescent microscope. This restricted experiments to 
using an upright microscope whose objectives were above the stage, and permitted 
examination of slide mounted samples only. 
5.4 Western analysis to compare protein dynamics 
In the previous chapter, the level of several proteins were seen to change in 
association with myogenesis. Although there is disagreement in the literature 
concerning fluctuations of specific proteins, differences may be explained by 
variations in the sample or the method of analysis. The use of a consistent 
methodology in these experiments has permitted the effect of a treatment to be 
determined. 
The following series of Western blots were performed under consistent 
conditions. Each Western blot examines the dynamics of a particular protein over 
the 96 hours of fusion from cultured cells transfected with one of the four 
experimental plasmids. While every attempt was made to equalise sample recovery, 
the sources of variability were the protein load, success of transfer and, most 
importantly, the antibody titre. Several of these variables are not relevant to a "within 
blot" comparison but are important when analysing "between blots". Westerns, 
therefore, focussed upon identifying qualitative and not quantitative differences 
between the treatments. 
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5.4.1 Traponin T 
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Figure 5.7 Comparison between experimental treatments of Troponi" T levels over 96 hours. 
Samples of protein (100 ug) were electrophoresed on an 10 % 50S-PAGE gel before being probed 
with anti·troponin T antibody (eTJ) at 1 : 100 dilution. 
The \'(Iestern blots in Figure 5.7 show little variation from the control blo t in 
Figure -1.3. A single band migrating at around 35 kDa became apparent afrer 24 
hours of fusion induction and became more intense during the incubation period. 1\ 
smaller (30 kDa) immunoreactive band was apparent after 48 ho urs and increased 
fram 48 to 96 hours. As described in section 4.2.2.1, this 30 kDa protein may be a 
proteolytic product resulting from calpain action. However, there is no indication 
from Figure 5.7 that the expression of active regions of calpastatin has impeded or 
reduced the rate o f appearance of th is fragme nt. 
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5.4.2 D esmin 
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Figure 5.8 Comparison between experimental treatmenls of Oesmin levels over 96 hours. 
Samples of prolein (100 ug) were electrophoresed on a 10 % SOS·PAGE gel before being probed 
with anli·desmin anlibody (03) at 1 : 100 dilution. 
As shown in Figure 4.4 and reflected in the blots in Figure 5.8, the desmin 
levels in the C2C 12'5 increased over the culture period. \X1hilc this protein is a 
substrate fo r cal pain (Do urdin et aI., 1999) there is no indicatio n that pro teolys is 
occurred and, consequently, there is no evidence of a protective effect from the 
expression o f calpastatin. 
5.4.3 M yosin 
pEGFP-N3 
o 14 48 71 96 
pEGFP-DL 
0 144871 96 
pEGFP-D1 
0 2448 72 96 
pEGFP-DL+1 
0 244872 96 
- I ==n8~ -loollDol 
-75lf)_ 
-"' .. " 
- 311.0. 
- 25..0. 
Figure 5.9 Comparison between experimenlallrealmenls of Myosin levels over 96 hours. 
Samples of prolein (100 ug) were electrophoresed on a 10 % SDS·PAGE gel before being probed 
with anli·myosin antibody (MF20) at 1 : 2000 dilution. 
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Myosin is a good indica lOr of myoblast diff<.::renualion. The blo ts shown in 
Figure 5.9 reflect the trend shown in non-transfected fu sing myoblasts. There is no 
evidence of qualitative differences wh ich can be attributed to the expression of the 
transfected plasmid. The reduced appearance of immunoreacuve protein in the 
pEGFP-N3 myosin blot is an example of between blot variauon. The lightness o f 
this blot is probably clue to incomplete colour development rather tha n significantly 
reduced levels of myosin. 
5.4.4 ~-calpain 
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Figure 5.10 Comparison between experimental treatments of l1-calpain levels over 96 hours. 
Samples 01 protein (100 ug) were ele<:~ophoresed on a 10 % SOS-PAGE gel belore being probed 
with anti-fl-calpain antibody (B2F9) at 1 : 25 dilution. 
Figure 5.10 demo nstrates tha t ~-calpain from transformed ceUs consistentJy 
displayed a double banding pattern throughout the culture period. This pattern was 
previously seen in non-transformed cells (see Figure 4.7). The larger band represents 
the 80 kDa isoform of ~-calpain. The smaller 78 kDa band results from autolysis. A 
faint band, below the 78 kDa iso form, is not clear in Figure 5. 10 and probably 
represents the second truncation product at 76 kDa . During the 96 hour fusion 
period, the intensity of the two prominent bands increased. There are no 
conspicuous djfferences between the treatments. 
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5.4.5 m-caJpain 
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Figure 5.11 Comparison between experimental treatments of m-calpain levels over 96 hours. 
Samples of protein (100 ug) were electrophoresed on a 10 % SDS·PAGE gel before being probed 
with anti-m-calpain antibody (Forsberg anli.m-calpain) at 1 : 500 dilution. 
] n accordance with the results from non-transformed contro l ce ll s, m-cllipain 
is detectable throughout the culture period (Fig ure 5. 11 ). Between 0 and 24 hours, 
the detectable levels increased between 50 and 200 % (relative to 0 hours) and then 
graduaUy decJjned over the culture period untiJ they reached the original levels. 
5.4.6 Calpastatin 
As nUlcu in Chapter 4, po lyclo nal antibodies 567 and 552 have the capacity 
to detect murine skeletal muscle calpm:itarin. Huwt:.vcr, lh c;sc; antibodies and a 
selection of other anti-calpastatin antibodies were unable to detect a calpastatin-like 
protein in non-transformed C2C12 extract. This probably indicates that the levels o f 
endogenous calpastatin fall below the sensitivity of the antibodies. E ndogeno us 
calpastatin is, there fo re, unlikely to have any significant impact o n the results 
o btained from trans fectio ns. \Vesterns to detect cal pasta tin variants are presented in 
the following subsections 5.4.8 and 5.4.9. 
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5.4.7 GFP 
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Figure 5.12 Comparison 01 EGFP levels between experimental treatments over 96 hours. 
Samples of protein (100 u9) were electrophoresed on a 10 % SDS·PAGE gel before being prohed 
with anti·GFP antibody at 1 : 1000 dillilion. 
In each transfection the GFP antibody reacted with a pro tein species which 
was absent in non-transformed control ceUs. As expected, EGFP expressed alone 
migrates at the smaUest size whjle a com binauon of larger bands arc apparent in 
domain L, 1 and L1 transfectants (Figure 5.12). 
pEGFP.N3 - GFP antibody reacts with a single band migrating at 
approximately 25 kDa in the pEGPF-N3 extract. This size corresponds to the 25-
26 kDa size range previously reported for recombinant G FP iso form s (\'(Iard 1998). 
The JcveJs of this protein remain unchanged over the experimental period despite 
large fluctuatio ns being observed in detectable nuorescence. This implies that some 
factor(s) contributes to the relationship between protein and fluorescence. 
pEGFP.D/ . - The pEGFP-DL transfectant protein extract contai ns two 
immunoreactive bands migrating at apprOximately 38 kDa and 26 kDa. The 
predicted molecular weight of a DL-EGFP hybrid is 38.4. Based upon densiromeuic 
examinations, the larger fragment increased by 200 % from 0 to 24 hours and then 
declined to 25 % of the initial levels by 96 hours. In contrast, the smailer fragment, 
which is almost 4 fold stro nger than the larger at U hours, increased to 150 % of the 
initiallevcls over the fu sion period. 
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pEGFP-Dl - Two immunoreactive bands were visible in the total protein 
extracts from pEGFP-D1 transfectants with molecular weights of 49 kDa and 46 
kDa. The predicted molecular weight of a D1-EGFP hybrid is 41.6 kDa. The 
similarity of the sizes of the bands indicates they have not reproduced well in Figure 
5.13. Both bands declined between 48 and 96 hours to 50 % of their initial levels. 
pEGFP-DLl - Probing the protein extract from pEGFP-DLt transfectants 
with anti-GFP antibody revealed three bands. While the predicted size ofDLt-
EGFP is 53.1 kDa, these bands migrate at 63 kDa, 52 kDa and 49 kDa. Once again 
the small size differences between the two smaller bands has not reproduced very 
well in Figure 5.13. The 63 kDa band increases in intensity steadily to 200 % of its 
initial levels over the experimental period. Concurrently, the smaller 52 kDa and 49 
kDa bands increase by 250 % and 180 % respectively. 
The relative complexity of the blotting results indicate that some factor(s) 
was shaping the products expressed by the EGFP vectors. The observed size 
differences between the predicted and observed proteins were not unexpected. 
Aberrant migrations have been observed in other published experiments as discussed 
in Chapter 3. In each transformation, the largest band was considered to be the intact 
protein product corresponding to the transfected plasmid. Truncated 
immunoreactive proteins in these blots must retain the EGFP epitope. They could 
arise from proteolysis, structural instability or inappropriate transcription I 
translation. These blots suggest that proteolysis is a potential mechanism because the 
ratio of 38 kDa to 26 kDa protein in the pEGFP-DL transfectants varies over the 96 
hour culture period. If the truncation was caused by instability or improper protein 
synthesis it would be constant, irrespective of the level of expression. However, in 
the pEGFP-DL transformants, a peak ofEGFP expression (reflected by 
fluorescence) corresponded with the maximum amount of 38 kDa protein. This 
indicates that a mechanism with limited capacity (such as proteolysis) is responsible 
for truncation of the protein products. A hypothesis which can be developed from 
the key observations is: 
Chapter 5: Expression of calpastatin variants in fusing myoblasts. 132 
(1) The control pEGFP-N3 plasmid produces a single band of 25 kDa which 
is an appropriate size for recombinant GPF (Wood 1998). This 
establishes that EGFP is not a substrate for the suspected proteolytic 
mechanism. 
(2) The pEGFP-DL product migrates as two fragments. Both contain the 
GFP epitope. The larger 38 kDa band represents a full sized DL-EGFP 
while the smaller 26 kDa band retains GFP immunoreactivity but 
migrates 1 kDa larger than the control EGFP. This suggests there is a 
truncation site 1 kDa upstream from the N-Terminus ofEGFP which 
leads to the separation of domain L from EGFP. As noted in 4.3.3, 
ligation of the calpastatin cDNA into the pEGFP multiple cloning site 
results in the inclusion of a 12 amino acid linker region between the end 
of each calpastatin variant and the C-terminally attached EGFP. This 
linker encodes a polypeptide with a predicted molecular weight of 1026 
Da. It is possible, therefore, that the 26 kDa band represents a protein 
composed of all or part of the linker peptide attached to EGFP. 
(3) The pEGFP-Dl protein also migrates as two bands at 49 kDa and 46 
kDa. Since both bands retain GFP immunoreactivity and EGFP does not 
appear to be affected by the truncation mechanism, it is feasible that the 
size difference is due to the liberation of a short peptide region from the 
N-terminus of domain 1. The nature of some of these products may be 
confirmed by probing Western Blots with anti-domain L and domain 1 
antibodies. 
(4) The GFP reactive protein product from pEGFP-DLl transfections 
migrates as three bands at 63 kDa, 52 kDa and 49 kDa. There is no 
obvious explanation for the appearance of these bands. Two possible 
interpretations exist. First, the 63 kDa band probably represents full size 
domain Ll + EGFP protein. Second, the 3 kDa difference between the 
smaller bands is analogous to the 3 kDa difference seen in domain 1 + 
EGFP which possibly results from N-terminal truncation of domain 1. 
Therefore, the 49 kDa protein may represent domain 1 + EGFP after 
the 3 kDa truncation. The 52 kDa protein may represent domain 1 + 
EGFP before the 3 kDa truncation. The 63 kDa protein represents full 
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size domain LI + EGFP. A sign ifi cant issue raised by this propusal is 
that the 52 kDa and 49 kDa proteins are larger than the 49 kDa and 46 
kDa proteins seen in pEGFP-Dl transfectants. There is no apparent 
reason for this difference. 
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Figure 5.13 Comparison between experimental treatments of Calpastatin Domain L levels 
over 96 hours. Samples of protein (100 ug) were electrophoresed on a 10 % SOS·PAGE gel 
before being probed with anti·calpastatin domain L antibody (552) at 1 : 100 dilution. 
Antibody 552 was raised against domajn L antigen and. as shown in Figme 
5.13, cross- reacted with protein species from pEGFP-DL and pEGFP-DLl 
transfectants onJy. 
pEGFP·N3 alld pEGFP·Dl - Protein extracts from both pEGFP-N3 and 
pF.GPP-Dl transfectants did not demonstrate any cross-reactivity with anti-do main 
L antibody. 
pEG1-1'-DL - Protein extracted from pEGFP-DL transfectants contained one 
38 kDa immunoreactive band whkh migrated and Aucmated in a manner identical to 
the 38 kDa protein detected by anti-GFP. Specifically, protein levels increased by 250 
% berween 0 and 24 hours and subsequently declined to 50 % of the initial levels. 
The immunoreactivity of this band, with both the GFP and domain L antibodies, 
suggests that this is the expressed product from the pEGFP-DL plasmid. As shown 
in Figure 5.13, the rise and faU of the 38 kDa band, which has now been identified as 
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domain L + EGFP may be caused by proteolysis. Proteolysis ncar the C-terminus of 
domain L would liberate a rela tively large peptide migrating at 12 kDa. 
Unfortunately, bands of 10 kDa and 15 kDa in the molecular weight marker migrated 
from the 10 % gel. O n this basis, the dom:dn L remna nt would also have migrated 
from the gel. 
pEGFP-DLI - Figure 5.13 shows that the level of a 63 kD. GFP 
immuno reactive pro tein increases over the experimen tal period. In contrast, thjs blot 
identifies the same protein using anti-domain L antibody but demo nstrates a dedine 
in its levels to 50 % o f the initial levels over the experimental period. This 
contradjcrjo n may result from inaccuracy of the image analysis especially of the 
lighLly cOlllmstcd GFP blot. 
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Figure 5.14 Comparison between experimental treatments of Calpaslatin Domain 1 levels 
over 96 hours. Samples of protein (100 ug) were elec~ophoresed on a 10 % SDS·PAGE gel 
before being probed with anti·calpastatin domain 1 antibody (566) at 1 : 100 dilution. 
Antibody 566 was raised against domain 1 antigen and, as shown in Figure 
5.14, cross-reacted with protein species from pEGFP-Dl and pEGFP-DU 
transfectants only. 
pEGFP-N3 alld pEGFP-DL - Protein extracts from the pEGFP-N3 and 
pEGFP-DL transformants should no t contain immunologically reactive domain 1. 
The light banding patterns in these Westerns are due to non-specific cross-reactivity. 
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pEGFP-Dl - The anti-domain 1 polyclonal antibodies raised in Chapter 3 
have demonstrated a poor reactivity against the domain lantigen. Nevertheless, two 
unique bands are apparent in pEGFP-Dl extract. These bands correspond to a 49 
kDa and 46 kDa doublet using anti-GFP. The bands are too faint to be measured 
accurately using densitometry. 
pEGFP-DLl - The poor reactivity is repeated when probing the extract from 
pEGFP-DLl transfectants. The Western blots revealed three bands at 63 kDa, 52 
kDa and 49 kDa. While the bands not reproduce well they are very similar in 
migratory pattern to those seen with the anti-GFP antibody. They probably represent 
the full sized Ll-EGFP and two truncated products. 
5.4.10 Summary 
A selection of proteins were examined in order to monitor biochemical 
differentiation and in vivo proteolysis. The Western blots presented in this chapter do 
not provide any evidence of significant effects of transfection on biochemical 
differentiation. The way in which myosin, des min and troponin T appear, is similar 
to non-treated cells and the negative control pEGFP-N3 treated cells. Desmin and 
troponin T were included in the analysis because they are efficient indicators of 
differentiation and, in addition, are substrates for calpain in vivo. The transfection of 
C2C12 myoblasts with calpastatin variants and the expression of recombinant 
protein has the potential to reduce calpain activity in vivo. This may be reflected in 
altered substrate proteolysis. It was established in Chapter 4 that desmin was not 
subject to proteolysis in fusing C2C12's. Troponin T, however, showed a banding 
pattern which may result from proteolysis. The pattern was also detected in the 
transfected cell extract. Unfortunately, there were no apparent differences between 
control and treated cells. A simple conclusion is that calpain is not responsible for 
the proteolysis of troponin T. However, several other interpretations are possible: (i) 
calpastatin may be separated from any calpain - troponin T associations (ii) the 
troponin T fragments may not be produced by proteolysis (iii) the calpastatin protein 
produced from the vector may be inactive. 
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There were no significant differences between the treatments with respect to 
J.l- and m-calpain protein levels. It is not known whether expression of calpastatin 
variants will impact on the expression of endogenous calpain. However, calpain 
autolysis is an indicator of in vivo activity and elevated levels of calpastatin can delay 
the appearance of autolytic products (Geesink & Koohmaraie 1999). Therefore, J.l-
and m-calpain were investigated, not only because they represent integral 
components of the fusion process, but also because their autolysis provides another 
measure of calpastatin activity. Unfortunately, the autolytic products of m-calpain 
were not resolved by SDS-PAGE in these experiments. Moreover, J.l-calpain 
autolysis was similar in all the cell extracts and was independent of the treatments. 
There are two possible interpretations of this data: (i) inhibitory calpastatin is 
physically isolated from active calpain and (ii) recombinantly expressed calpastatin is 
inactive. 
The Western blots exploring the products of the EGFP vectors revealed 
some unexpected result. It appears that recombinant calpastatin is either structurally 
unstable or susceptible to proteolysis in C2C12's. The principal observations have 
been gathered and an explanatory model is proposed. 
As discussed in each section (5.4.7 - 5.4.9) EGFP itself appears to be stable 
throughout the fusion process. A point located in or around the EGFP linker is 
subject however to truncation in domain L + EGFP hybrids. A small portion of 
domain l's N-terminus is also susceptible to truncation. Finally, the region 
demarcating domain L from domain 1 appears unstable in pEGFP-DLl 
transfectants. The putative sites of instability or proteolysis are shown schematically 
in Figure 5.15. 
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Potential Fragment Sizes 
• Domain L ::.GFPa 38 kDa - 26 kDa - 12 kDa 
63kDa·52kDa·~·15kDa·12kDa·3kDa 
Figure 5.15 Schematic diagram showing the hypothetical cut points in recombinant 
calpastatin expression products. Four separate protein products are encoded by me EGFP 
plasmids used in this thesis. Protein products from plasmids combining regions of calpastatin with 
EGFP include an additional 10 amino acids between the C·terminus of calpastatin and Ihe N· 
terminus of EGFP (=). Points of structural instability or proleolytic susceptibility in Ihese products 
are denoled with red arrows. The potential fragments resulting from truncation at these points Dre 
reported, those that have been detected in Western blots are underlined. 
Recombinant calpastatin variants are also prone to truncation. The djagram 
(Figure 5.15) depicts the hypothesised points within the protein where the 
truncations occur, To confirm the accuracy o f this model. representative samples of 
each protein were on the same gel and probed with antj·GFP (sec Figure 5.16). The 
anti-GFP antibody will detect full-sized products from aU four transfectams as well 
as the truncated products which have been diffi cult to resolve. Samples of the 
transfectams were compared to provide representative banding patterns proposed by 
Figure 5.16. 
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Figure 5.16 Anti-GFP Western blot of representative samples from each pEGFP transfection. 
Prolein samples (lOO~g) from control cells al day 1 (A) and day 4 (B) were compared wilh samples 
of prolein from day 1 pEGFP-OL (C). day 4 pEGFP-Dl (0). dAy 4 pEGFP-OL 1 (E) and day 1 
pEGFP (F). The panicular days were chosen for each IransfecHon 10 provide Ihe besl 
representation of prutein flagments. Proteins were electrophoresed through a 10 % SOS-PAGE 
gel, transferred and probed with anli-GFP antibody (1:100). 
Figure 5. 16 provides information that contributes to the model presented in 
Figure 5. 15. As well as resolving the close band pairings within pEGFP-Dl and 
pEGFP-DL1 transfectants, the presence of a 26 kDa band was revealed. Due to its 
relatively faint presence, thjs 26 kDa brllld was no t detected in Figure 5.12. On a size 
basis, this fragment corresponds to the pEGFP-DL transfectant band resulting fro m 
truncation at the linker. Previo usly, it was not d ear whether this truncation took 
place within the Linker region or was at the N -terminus of domain L. An inability to 
detect the 26 kDa protein in either pEGFP-Dl or pEGFP-DLl extract inferred thal 
the cleavage was occurring at domajn L's N -terminus. However, Figure 5. 16 refutt:s 
tlus by exposing the 26 kDa protein in pEGFP-DI and pEGFP-DLl extracts, and 
thus estabHshing that the truncation point lies within the linker regio n. 
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The model proposed in Figure 5.15 relies on several untested assumptions. 
Several issues need addressing in order to reconcile the observations made in this 
chapter. They are: 
(i) why is a large portion of domain U + EGFP's N-terminus removed 
(63 kDa -+ 52 kDa), 
(ii) why is the 3 kDa of domain l's N-terminus removed (49 kDa -+ 46 
kDa for pEGFP-Dl transfectants, and 52 kDa -+ 49 kDa for 
pEGFP-DLl transfectants), 
(iii) why, does domain 1 + EGFP from pEGFP-DU (52 kDa) 
transfectants migrate differently to domain 1 + EGFP from pEGFP-
Dl (49 kDa) transfectants. 
Clearly, the model proposed in Figure 5.15 is inadequate and does not fully 
explain the complex expression patterns apparent in transfected cells. Furthermore, it 
is not possible to speculate whether the appearance of the unexpected fragmentation 
patterns is associated with the apparent failure of the calpastatin variants to impact 
on fusion. Potentially, jf calpastatin is subject to proteolysis or suffers from structural 
instability then these effects may explain the poor inhibitory potential. 
5.5 Microscopic examination to detect EGFP 
To date, the results have shown that the expression of calpastatin - EGFP 
hybrids have failed to have any effect on the fusion of C2C12 myoblasts. Despite the 
FACS analysis and Western blots demonstrating that there is expression ofEGFP, 
efforts to detect calpastatin activity in the C2C12 extracts were inconclusive. An 
important aspect in the conception of this work was to design calpastatin variants 
containing the three possible arrangements of domains Land 1 ie. DL, Dl and DU. 
The design was based on the evidence that in vivo calpastatin localises to the plasma 
membrane via domain L. In addition, domain L is apparently the region preferentially 
phosphorylated (Averna et aI., 1999) and leads to accumulation of the protein at the 
plasma membrane (Adachi etal., 1991). As a consequence, fluorescent microscope 
photographs were taken to establish the intracellular location ofEGFP. The 
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expectation is that cells transfected with DL or DU would preferentially localise to 
the plasma membrane and that 01 would be dispersed thro ugho ut the cytosol. As 
shown in Figure 5. 17 this was no t the case. 
Day 0 Day4 
pEGFP-N3 
pEGFP-DL 
pEGFP-D1 
pEGFP-DL 1 
Figure 5.17. Photographs of fusing e2e12 cells Iranslected with calpastatin • EGFP hybrids. 
Photographs were taken at 0 and 96 hours after fusion induction. Cells were Ifansfected with 
pEGFP·N3 (A), pEGFP·DL (8), pEGFP·D1 (e) and pEGFP·DL 1 (0). Photographs used 
Fujichrome Sensia II 400 film, an automatic light meter and were photographed at x400 
magnirlCation. 
Despite the resul ts in Figure 5.2 which indicated that transfection efficiency 
was high, microsco pic examjnatio n revealed there were relatively few representative 
muscle cells which fluo resced brightly. \Xlhile C2C1 2 ceUs were evenly dispersed over 
the slide surface, sub-popu.latio ns of fluo rescent cell s were no t evenly dispersed and 
appeared in localised regions. Thjs may re fl ect an uneven distributio n o f the 
transfectio n mix and / o r pockets o f s ibling celis derjved fro m the tmnsfected 
parcl1ls. 
Chapter 5: Expression of calpaslalin variants in fusing myoblasts. 141 
The photographs shown in Figure 5.17 indicate differential subcellular 
localisation. It would appear that at all stages of fusion, EGFP is evenly dispersed 
throughout the cells transfected with pEGFP-N3 and pEGFP-DL. It is not possible 
from these images to be certain if the diffuse cytoplasmic fluorescence is throughout 
the cytoplasm or associated with the plasma membrane. These distributions appear 
similar when observing the whole cells from above although a plasma membrane 
distribution may produce a ring effect where the cross sectional area of the cell is the 
greatest. In contrast, pEGFP-Dl and pEGFP-DLl transfectants demonstrate 
localised EGFP fluorescence. By comparing the size of the localised fluorescence, 
relative to the cell size, with a Giemsa stained cell and images of nuclear stained 
C2C12 myotubes (Crescenzi et aL, 1994), it is possible to speculate that the 
fluorescence is in or around the nucleus. Examination of pEGFP-Dl and pEGFP-
DLl transfectants reveals a small amount of evenly dispersed fluorescence. This is 
not unexpected since protein expression takes place within the cytoplasm. 
In both distribution proftles, diffuse and localised, the fluorescent agent may 
predominantly bind to membranes. As noted, direct observation of the whole cell 
from above does not provide enough detail to resolve this question. Confocal 
microscopy is a technique whereby the whole cell or tissue sample is exposed to 
lasers. This permits the investigator to virtually section the sample in three 
dimensions. Focussing the lasers up and down provides images of the cell on a single 
plane and establishes whether the fluorescence shows any membrane association. 
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pEGFP-DL 1 
Figure 5.18. Confocal images of Iransfected C2C12 at 0 and 96 hours after fusion induction. 
In each instance. images were captured from the transect plane providing Ihe greatest information. 
The pictures in Figure 5.18 verify that the distribu tion seen with pEG FP-N3 
and pEGFP-DL transfectants is diffuse and throughout the cytoplasm. There is no 
preference for the plasma membrane. [n the case of pEG FP-D I and pEG FP-D Ll 
transfectants, fluo rescence \Vas th roughout the subcellular compan mcnt and was not 
res tricted to the internal phospholipid membranes. 
Contrary to expectations, in these experiments, domain L did not 
demonstrate potential to direct cal pasta tin's localisatio n to the plasma membrane. 
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Remarkably, it appears that domain 1 may playa significant role in directing 
calpastatin to the nucleus. This was demonstrated by EGFP hybrids including 
domain 1 which exhibited preferential localisation to the nucleus. The model 
proposed to explain the complex recombinant calpastatin patterns (Figure 5.15) 
suggests that domain L is removed from the EGFP component, while domain 1 
remains attached. If this model is accurate, then domain L may exhibit membrane 
associations which would not be reflected in the localisation ofEGFP. In contrast, 
the bulk of domain 1 remains attached to the EGFP component. It seems likely that 
the failure of expressed calpastatin to perturb fusion may be due to this distribution. 
That is, domain 1 is the only region of the introduced cDNA with the ability to 
influence calpain activity, and sequestering domain 1 within the nucleus prohibits it 
from influencing calpain mediated proteolysis at the plasma membrane or within the 
cytoplasm in general. 
Previously, the calpain and calpastatin system has been associated with the 
nucleus and nuclear events. Gilchrist et a/. (1994) wrote an excellent review which 
discussed the importance of calcium and calcium binding proteins, including calpain, 
in the nucleus. It has been observed in vitro that 11- and m-calpain are able to 
solubilise the nuclear protein Hl kinase and that the calcium concentration required 
for m-calpain activity was reduced to 3 11M (Mellgren & Rozanov 1990; Mellgren 
1991). This is close to physiological concentrations of calcium and is dependent upon 
the presence of DNA (Mellgren et a/., 1993). These results indicate that DNA has the 
capacity to regulate the action of the calpain system and proteolysis. 
Moreover, nuclear protease activity has been detected in a variety of rat 
tissues (Gopalakrishna & Barsky 1986) and in differentiating cells where it is thought 
to playa role in nuclear function by regulating transcription factor turnover (Scholtz 
et a/., 1996). For example, the c-mos proto-oncogene product pp39mos, accumulates in 
mature oocytes and arrests meiosis. Upon fertilisation there is a large transient 
increase in calcium and pp39"IOS levels decline. The inclusion of calpain inhibitors 
(leupeptin, E-64, antipain or calpastatin) prevents degradation of pp39mos (Watanabe 
et a/., 1989; Watanabe et a/., 1991) which strongly indicates that the pp39mos cytostatic 
factor is a target for selective calpain proteolysis. Other transcription factors have 
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also been shown to be sensitive to calpain (Watt & Molloy 1993). In particular, cfas 
and cjun proto-oncogene products are short lived proteins with a high susceptibility 
to calpain proteolysis (Hirai ct al, 1991, Carillo ct al, 1994; Carillo ct al, 1996). As a 
heterodimer they form a large part of the AP-1 translational activator protein. The 
latter is a critical transcriptional activator protein (Gutman & Wasylyk 1991) with 
myogenic regulatory potential. Specifically, the AP-1 protein suppresses the 
transcriptional activation of certain muscle specific proteins by myogenin and 
MyoD1 (Li et al, 1992). Moreover, co-expression of cjun with calpastatin sense or 
anti-sense cDNA resulted in a decrease and increase, respectively, in the transcription 
of c-J un induced CAT expression (Hirai ct al, 1991). Note that in vivo calpain 
mediated proteolysis of c-FOS and c-JUN is probably a cytoplasmic event regulating 
levels of full length protein that is available for nuclear transport (Carillo ct al, 1994). 
More recently, nuclear factor KB, which regulates a wide variety of viral and cellular 
genes, has demonstrated a specific sensitivity to both /1- and m-calpain (Liu ct al, 
1996). As well as nuclear functions, calpain has displayed a potential involvement in 
structural changes taking place in the nucleus. Leupeptin inhibited proteolytic activity 
has been associated with lamin proteins which contribute to the nuclear scaffold 
(fokes & Clawson 1989). Also, the microinjection of m-calpain into PtK] cells 
accelerates mitotic spindle disassembly and the start of anaphase (Schollmeyer 1988). 
Both events demand the disruption of the karyoskeleton. In these experiments, 
specific localisation of m-calpain to the chromosomes, nuclear membrane and mid-
body regions were witnessed at different phases of the mitotic cycle. 
Several other studies have reported distinct nuclear subcellular localisation. 
Mellgren and Lu (1994) demonstrated, using digitonin permeabilised A431 cells, that 
FITC labelled /1-calpain was localised to the nucleus in an energy (ATP) dependent 
manner. Interestingly, the translocation could be repressed by co-incubation with a 
Nuclear Localisation Signal (NLS) peptide suggesting that the mechanism 
responsible for translocation of /1-calpain recognises this sequence in this protein. In 
another study, examination of a human primary myoblast cell culture demonstrated a 
specific nuclear distribution of /1-calpain, during maturation into myotubes. 
However, m-calpain was diffusely distributed throughout the cytoplasm 
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(Moraczewski et a/. I 1996). The lack of m-calpain nuclear translocation was also 
witnessed by Mellgren & Lu (1994) who saw FITC labelled m-calpain dispersed 
through the cytoplasm and Dourdin et a/. (1997) who reported extracellular 
distribution of m-calpain. 
With respect to calpastatin, localisation experiments have generated a variety 
of results. Calpastatin has been found associated with myocardial sarcolemma and 
sarcoplasmic reticulum vesicles (Lane et a/.I 1985; Mellgren et a/. I 1987a; Mellgren et 
a/.I 1987b). Recently, FITC labelled calpastatin introduced into permeabilised A431 
cells demonstrated no selective transport to the nucleus or any other compartment 
(Mellgren & Lu 1994). Calpastatin has been localised to two granular, non-membrane 
bound structures, roughly 1 Jlm in diameter close to nuclear invaginations (De Tullio 
et a/.I 1999). This pattern was also found in several murine and human cell lines. The 
authors noted that following differentiation induction ofLAN-5 neuroblastoma cells, 
calpastatin is displaced from its granular form into the soluble fraction where its 
absolute levels decline. It is unclear why different studies produce such widely 
differing results. Sample type and preparation, antibody characteristics and other 
variables could possibly explain some of the differences. 
Examination of the downstream domain 1 primer depicted in Figure 4.13 
revealed a similarity with reported nuclear localisation consensus signals. This primer 
encodes domain 1's C terminal amino acid residues, as defined in Appendix B, which 
are PPKEKRRKV. The basic nature of this sequence exhibits the characteristics of 
other NLS. Specifically, NLS are: (1) short sequences of 8-10 residues, and (2) 
contain a high proportion of charged residues such as K and R (Garcia-Bustos et a/., 
1991; Silver 1991). An archetypal example of NLS is PKKKRKV, this is apparent in 
SV 40 T antigen (Matheny et a/., 1994) and shares similarities with a multitude of 
putative NLS (Boulikas 1994). 
As noted earlier, studies examining the subcellular localisation of calpastatin 
have generated variable results. Certainly there is no clear evidence of calpastatin's 
nuclear localisation as seen in this chapter. This is despite the PPKEKRRKV 
sequence being an integral part of this protein, and being present in a number of 
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other calpastatin sequences (Takano et aI., 1986b; Mainelli et aJ., 1996; Takano et aJ., 
2000). The reason for this may be the absolute requirement for the NLS to be 
presented on the surface of a targeted protein. Strong NLS sequences have no ability 
to direct proteins when buried within the quaternary structure of the protein (Garcia-
Bustos etal., 1991). The amplification of domains L1 and 1 resulted in the relative 
relocation of this NLS to the C-terminus of the protein. After folding, this sequence 
may be exposed in a manner which enables it to interact with the nuclear pore 
complex proteins, and culminates in its active importation. 
5.6 Discussion 
The experimental work in Chapter 4 was preparatory for the experiments 
reported in this Chapter. Plasmids combining regions of calpastatin cDNA were 
combined with EGFP cDNA in mammalian expression vectors. These were 
successfully introduced into proliferating myoblasts using FuGENE 6 reagent. FACS 
analysis allowed the transfection efficiency to be determined along with a variety of 
oth"er physical parameters. 
Despite a relatively high proportion of cells expressing EGFP, there were no 
clear indications of reduced fusion at the gross level. Western analysis also failed to 
detect any significant effects from calpastatin expression either as altered proteolytic 
patterns of calpain substrates or as reduced calpain autolysis. What it did reveal, 
however, was evidence that recombinant calpastatin is susceptible to truncation 
following expression in C2C12's. 
This is a crucial result since it fails to support the hypothesis that expression 
of calpastatin perturbs fusion events. It is not possible to determine if the structural 
decomposition of the calpastatin isoform is related to its lack of physiological impact. 
Microscopic examination revealed that recombinant calpastatin variants combining 
domains 1 or L1 with EGFP were preferentially located within the cell nucleus. This 
is probably a critical observation which explains why the inhibitory calpastatin 
isoforms did not affect fusion. Some mechanism must be responsible for targeting 
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and transporting domain 1 containing isoforms to the cell nucleus after their 
manufacture. Once retained within this intracellular body calpastatin is effectively 
isolated from proteolytic events which occur in the cell, including those taking place 
at the plasma membrane. Unfortunately, the presence of a potential NLS in domain 1 
may have predestined this localisation outcome. Changing the position of the domain 
1 downstream primer could have been used to eliminate this short region and would 
have contributed to confirming its importance in nuclear targeting. Equally, however, 
there is potential to investigate the role of this sequence in regulating the targeting of 
proteins to the nucleus. 
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Chapter 6 
Conclusions and Future Work 
Despite the ubiquitous nature of the calpains and their endogenous inhibitor 
calpastatin, the physiological function(s) of this protease system remains uncertain. 
The developmental process of myogenesis is dramatic and tightly regulated. Available 
evidence strongly supports a role for calpains in proteolytic events accompanying 
plasma membrane reconstruction. Moreover, fluctuations in the level of calpastatin 
expression seem to be a permissive requirement for the fusion process. This thesis 
sought to investigate the potential physiological role that calpastatin plays in 
myoblast fusion. In addition, investigation into proteolysis regulation at the plasma 
membrane was inspired by reports that calpastatin's domain L may be responsible 
for targeting calpastatin to this region and / or be involved in regulating its inhibitory 
activity. 
A major objective of this thesis was to produce fusion competent myoblasts 
expressing regions of ovine calpastatin hybridised to EGFP. This outcome has been 
achieved through a linear experimental approach. Initially, the particular regions of 
ovine calpastatin (domain L, domain 1 and domains Ll) were expressed in 
prokaryotes, purified, assayed in vitro, and used as antigens in the production of 
polyclonal antibodies. The approach used to generate prokaryotic expression vectors 
was also employed to produce eukaryotic expression vectors combining calpastatin 
with EGFP. After optimising the transfection conditions, these vectors were 
introduced into cultured myoblasts (C2C12's). Cells were grown under conditions 
that stimulated both morphological and biochemical differentiation. Microscopic 
examination, FACS analysis and Western blotting were used to monitor aspects of 
myogenesis in control cells and treated cells. 
While regions of calpastatin have been expressed in myoblasts together with 
EGFP, they produced no detectable effects upon the fusion process aspects or 
biochemical differentiation. Based upon the results there are two potential 
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explanations for this: (i) the truncation of recombinant calpastatin may indicate a loss 
of functionality or (n) the nuclear localisation of the expressed calpastatins embracing 
domain 1 may prevent the inhibitor from acting upon free cytosolic or plasma 
membrane bound calpain. 
The failure of recombinant calpastatin to interfere with fusion does not 
negate the likely role of this protein in regulating the processes via calpain inhibition. 
Significant data exists in the literature which provides convincing evidence for 
calpastatins to have a potential impact in fusion events. However, further research 
should be directed at establishing the validity of the two explanations mentioned 
above. 
Extraction and purification of recombinant calpastatin from large scale 
cultures of transfected myoblasts followed by in vitro assays should establish the 
functional capacity of the truncated protein. Care should be taken to limit any 
proteolysis immediately following extraction. Purification of recombinant calpastatin 
may employ traditional chromatographic techniques together with heat denaturation. 
The EGFP polypeptide may provide the opportunity to employ an additional affinity 
chromatographic step. Alternatively, zymography may be a suitable technique to 
detect the calpastatin truncation products using an approach that has not been 
attempted previously. Non-denatured protein samples extracted from myoblasts 
could be electrophoresed through a zymographic gel prepared from a fluorescent 
substrate, such as BODIPY-FL (Thompson et a/., 2000b). This gel could then be 
incubated in the presence of excess calpain and calcium over a period of time which 
allows diffusion of the protease into the gel matrix. Calpain that is not inhibited by 
electrophoresed calpastatin will proteolyse the casein substrate resulting in 
fluorescence. This approach, while not establishing the quantity of calpastatin, may 
qualitatively assess the truncated isoforms. 
The second issue addresses whether calpastatin's localisation in the nucleus 
reduces its potential to modify calpain activity in the cytoplasmic compartment. The 
most effective way of answering this question is to prevent recombinant calpastatin 
from entering the nucleus. Although nuclear pores allow the diffusion of relatively 
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large proteins into and out of the nucleus, the differential inclusion of only 
recombinants containing domain 1 implies that the mechanism of relocation is 
selective and active. Previously, A TP depleting reagents and expression with nuclear 
localisation sequence peptide have demonstrated an ability to retard nuclear 
importation (Mellgren & Lu 1994). Either of these approaches could be used to 
restrict the activity of recombinant calpastatin in the cytoplasm. 
While this thesis was not successful in detecting an effect of recombinant 
calpastatin upon myoblast fusion, it has reported some valuable observations and 
developed some useful techniques. These have the potential to be applied in other 
experiments. 
A significant product from the initial work was the expression and 
purification of relatively large quantities of recombinant calpastatin from bacteria. 
The ability to manipulate the cDNA sequence with, for example, site-directed 
mutagenesis permits the production of defined proteins. This enables very precise 
exploration of structure and function. Moreover, the generation of pure proteins 
creates an opportunity to produce specific antibodies, which in tern can be used in 
diagnostic tests (eg. Western) in vivo manipulation (eg. applying "anti-x" antibodies to 
systems in tissue culture) and purification approaches (eg. calpastatin affinity 
chromatography). Significantly, Chapter 3 revealed that domain 1 activity in vitro was 
enhanced when associated with domain L. The mechanism behind this observation is 
unclear, although the domain L specific phosphorylation has been associated with 
augmentation of activity (Salamino et a/., 1994a; Salami no et a/., 1994b; Averna et a/., 
1999). 
While Chapter 4 was primarily directed towards establishing methods that 
quantify aspects of "normal" myoblast differentiation, it was able to assess the 
validity of several published observations. Significantly, in these experiments Jl-
calpain was detected in fusing myoblasts. This contrast with previous reports which 
found Jl-calpain at late stages of fusion (Cottin et a/., 1994) or not at all (femm-
Grove et a/., 1999). Additionally, after testing a selection of antibodies, only one 
(created during the course of this work) demonstrated immunoreactivity against 
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murine calpastatin. Moreover, this reactivity was witnessed only in mature skeletal 
muscle while myoblasts in culture did not appear to contain detectable levels of this 
protein. This observation is contrary to a number of other studies which report 
detecting calpastatin in muscle cultures. 
The final segment of work in this thesis developed techniques for analysing 
the fusion of myoblasts and for detecting EGFP. The opportunity to directly 
visualise proteins in vivo is attractive to cell biologists interested in investigating the 
function of cellular machinery. To my knowledge, this is the first example of this 
labelling technique being employed to explore the calpain system. The potential to 
apply this technology to answer other questions is considerable. The availability of 
GFP mutants emitting fluorescence at differing wavelengths means that differentially 
labelling calpain isoforms and calpastatin and observing their interactions is 
potentially possible. Together with labelled substrates, this type of data could 
establish a complete description of the action in vivo of the calpain system under a 
variety of conditions. Artificial vector systems would also permit controlled protein 
expression through the inclusion of inducible promoters or temporally regulated 
promoters (eg. myosin light chain promoter). 
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Appendix A.l - pBluescript Plasmid Map 
Naol131 
Alflll1153 
Plasmid map of the pBS KS II phagemid commerciaU), ava ilable from Stratagene. 
GeneBank accession number #X52327. 
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Appendix A.2 - pBSCalstn Plasmid Map 
ColEI ori 
Pvull 4809 
BssHfI 4629 
EcoR14544 
p.l3SCabtn 
6798 hp 
Plasmid map of pBSCalstn . Plasmid is composed of the complete ovine cDNA 
inserted into the pBSKS vector (CoUingwood 1994). 
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Appendix A.3 - pGEX-4T -1 Plasmid Map 
918 977 
I Th_ I I U.U VfJJ, Pill AIlJJ Gly sod Pro Gill Pile Pro Gly Atg l.u Glu Atg PIQ Hit lug Asp 
~~~~~~~~~~~~~~~~~~~~ 
Nar1(4a071 
Hpa I (417a) 
L--l I -.---
BamH I E",R I Sma I SaIl Xho I Noll Step codon. 
pGEX-4T-' 
4969bp 
Mlul (3668) 
TIII111 1(\136) 
Altlll (120) 
P$tl (1918) 
Plasmid map of the commercially available pGEX-4T-l vector (APB). Included is 
an expanded view of the plasmids multiple cloning site. GeneBank accession number 
U13853. 
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Appendix A.4 - pEGFP-N3 Plasmid Map 
Eco01091 
fJiSl) 
'" 
ApBlI 
143~1 
Stu I 
I]S7~ 1 
pEGFP-N3 
4.7 kb 
" 
MCS 
1191'&S) 
8st{; 1113651 
Norl ll29S) 
Xba 1' " . tE 
0,.111 IT S' C) 
'" 
.. 
" H .I, ,,~~ .!iCt GGAC1C I.Gi tel CGA G(l c~cc AAT l eT GOG 'Cec GHT f.cCCC9 G(j)fCG{GJ. r" A'f Gee },te mr:i"G 
NII ,I Ec04HII B,It' .nol \ HII~!!1 CcoAl 'nl SIll ... ", \ ApI' s,;rtll ,rem I 
,S!;! 1 Acel AJpJIII 8,,1201 X(II,II -' (,,~I sun Stnli 
Plasmid map of the pEGFP-N3 plasmid commercially available from Clontech . 
Included is a description o f the plasmids multiple cloning site. GeneBank accession 
number U57609. 
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Appendix B - Ovine Calpastatin cDNA Sequence 
SEQ New: 2199 bPi 
Composition 744 A; 557 C; 526 G; 372 T; 0 OTHER 
Percentage: 34% A; 25% C; 24% G; 17% T; O%OTHER 
Molecular Weight (kDa): ssDNA: 679.99 
ORIGIN 
~Xba1 cut site 
dsDNA: 1355.7 
ACTGTCTAGA CCGGTCACCA AGGTAACTAC TTCCTCCGCT TCAGCCAGCA AGTCTTCCAG 
~Start of Domain L 
TIATGAATCCC ACAGAAGCCA AGGCTGTAAA AACAGAACCT GAGAAGAAGC CGCAATCATC 
~ DL 5' primers Qinding site 
TAAGCCAAAA AGCCAACCCA AGCACCCCTC AGATACAAGA AGCAAGCATG CTCCTAAGGA 
AAAAGCTGTT TCCAAGTCAA GCGAGCAGCC ACCATCAGAG AAATCAACAA AACCAAAGAC 
CAAGTCACAG GACGAGATTT CCGGTGGTGG AAAGAGCGCT GTTCCTGCTG TTGCAGCTGC 
AGCATCTGCC GAACCAGCTG ACAAGAATAA AGAAAGTAAA TTGTTAACAT CGGCCGTGCC 
Domain L ~ Domain 1 boundary 
AGTTGAATCC AAGCCAAGTA AACCTTCTGC AIAAGTCAGAC ATGGATACTG CTCAGGATGA 
DL 3' primer binding site~ ~ D1 5'primer binding site 
CTTAATAGAC ACTTTAGGAG AACCTGAAGA GACAAAAGAA GATACCACAA CATATACTGG 
ACCTGAAGTT TCGGATCCAA TGAGTTCTAC CTACCTCGAG GAACTGGGTA AAAGAGAAGT 
CACACTTCCT CCAAAATATA GGGAACTTTT GAATAAAGAA GAAGGGATCG CAGGGCCTCC 
TCCAGACTCC TCGAAACCCC TGGGGCCCAA TGACGCCATC GATGCCTTGT CATCAGACTT 
CACCTGCAGT TCCCCTACAG CTGATGCAAA GAAAACTGAG AAAGAGAAAT CTACAGAAGA 
GGCTTTAAAA GCTCAGTCAG CTGGGGTGAT CAGAAGTGCT GCTCCACCCA AAGAGAAAAG 
Domain 1 ~ Domain 2 boundary 
AAGAAAAGTG GAAGAGIGATA CCATGACTGA GCAAGCCCTG GAGGCCCTGT CTGCCTCCCT 
~ DL 3' primer binding site 
~Sac1 cut site 
GGGCACCCGG AAGCCAGAGC CAGAGCTOGA CCCCAGCTCC ATTAAGGAGG TCGATGAGGC 
AAAAGCCAAA GAAGAGAAAG TAAAGAAATG TGGTGAAGAT GAGGAAACAG TCCCATCGGA 
GTATAGATTA AAGCCGGCCA CAGATAAAGA TGGAAAACCA CTCTTGCCAG AGGCTGAAGA 
AAAACCCAAG CCCCTGAGTG AATCAGAACT CATCGATGAA CTCTCAGAAG ATTTTGACCG 
GTCTAAGTGT AAAGAAAAAC AATCTAAGCC AACTGAAAAA ACAGAGGCAT CCCCGGCCGC 
TGCCCCTGTG CCTGTGGCAG AGGATGTGCC TCGGACCTCC ATGTGTTCTG TGCAGTCAGC 
Domain 2 ~ Domain 3 boundary 
TCCACCCACA GCAGCTICCAG CGAAGGGCAT GGTGCCAGAC GATGCTGTGG AAGCCTTGGC 
182 
TGGAAGCCTG GGCAAAAAGG AAGCAGATCC AGAAGACGGA AAGCCTGTGG AGGATAAAGT 
CAAGGAGAAA GCCAAAGAAG AGGATCGTGA GAAACTTGGT GAAAGAGAAG AAACGATTCC 
TCCTGATTAC AGATTAGAAG AGGCCAAGGA TAAAGACGGA AAACCACTGC CGCCAAAAGA 
GGTCAAGGAA CCGCTCCCAC CCTTGAGTGA AGACTTCCTC CTCGATGCTC TGTCCAAGGA 
CTTCACTGTC CCCTCAGACA CGTCATCGCC TCAATTTGAA GATGCTAAAC TTTCAGCTGT 
CGTCTCTGAA GTGGTTTCCC AAACCCCAGC TCCAACCACC CAGGCAGCCG GTCCACCCCG 
Domain 3 ~ Domain 4 boundary 
CGACTCTGCG CAGCGTGACiA ACAAAGAACT TGACGATGCC CTGGATCAAC TTTCTGACAG 
TCTCGGGCAA AGACAGCCTG ATCCAGATGA GCATAAACCT GTAGAGGATA AAGTCAAGGA 
AAAAGCCAAA GCTGAACACA GAGACAAGCT GGGAGAAAGA GATGACACCA TCCCACCTAA 
ATACCAGCAT CTTCTGGATG ATAACAAGGA GGGCACACCC GGGAAGCCAA AGGCATCAGA 
GAAGCCCGAG GCATCAGAGA AACCTGCAGG TGCCCAGGAC CCCATTGACG CCCTCTCAGG 
GGACTTGGAC AGCTGTCCCT CAACTACAGA AGCCTCAACA AACACAGCAA AGGACAAAGA 
CAAGAAGCCT GCTTCCAGTG ACAAAGCACC CAGGAATGGC GGGAAAGCAA AGGATTCCAC 
End of Domain 4 ~ 
AAAGGCAAAG GAGGAAACTiT CCAAGCCAAA AGCTGATGGA AAAAGTACAA GTTAAAATTC 
ACAGTATTTG GTTCTGCATA TACAATCTGC AGCAGGTAGA AGAACGTCTG AAGAACAAAA 
~Xbal cut site 
GCCTTTGACA ACAGAAACAA TTCCTGGGTG GCTTCTAGA 
Complete ovine calpastatin sequence encoding domains L, 1,2,3 and 4. Domain 
boundaries are noted in Blue, restriction enzyme sites are labelled in red and regions to 
which the primers shown in Figures 3.3 and 4.13 are underlined. 
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Appendix C - Raw FACS Results 
The following pages present raw FACS results obtained from C2C12 cells at 0,24, 
48, 72, 96 and 240 hours (Days 0, 1,2,3,4 and 10). At each time interval five sets of data 
are presented. These represent control cells (C), and cells trans fee ted with pEGFP-DL 
(DL), pEGFP-D1 (Dl), pEGFP-DLl (DLl) and pEGFP-N3 (N3). Within each data set 
three graphical plots are presented. The scatter plot reflects all measured events (cells) in 
terms of size ry axis) and granularity (X axis), and depicts the R1 and R2 regions 
described in section 4.2.1. Events captured by R1 and R2 regions were further analysed 
for their fluorescence intensity. The two line plots within each data set depict the.number 
of events ry axis) versus fluorescence intensity (X axis). In all instances, the left-hand line 
plot describes R1, while the right-hand plot describes R2. Line plots also present the Ml 
and M2 divisions described in section 5.2. 
Below each graph are tabulated results which describe that particular graph. 
Parameters described in the scatter plot tables are: 
• "Events" = the number of cells falling within R1 and R2 groups, 
• "% Gated" = percentage of total events falling within R1 and R2 groups, 
• "% Total" = percentage of total events falling within R1 and R2 groups, 
• "X Mean" = the mean granularity of R1 and R2, 
• "Y Mean" = the mean size of R1 and R2. 
The two line plots reflect R1 and R2 groups separately. Parameters described in 
each line plot table are: 
• "Events" = the number of cells falling within M1 and M2 groupings within 
the particular R grouping, 
• "% Gated" = events falling within M1 and M2 expressed as a percentage of 
the number of events within the particular R grouping, 
• "% Total" = events falling within the M1 and M2 regions of each R grouping 
expressed as a percentage of the total number of events irrespective of the R 
grouping, 
• "Mean" = mean fluorescence of M1 and M2 groups within the particular R 
grouping. 
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Appendix D - Sequence Data 
The following pages present raw sequence data of calpastatin cDNA's included in 
pGEX-4T-l and pEGFP-N3 expression vectors. 
Sequences DLGST' and DLGSTs'describe the nucleotide sequence determined by 
sequencing pGEX-DL plasmid. Similarly, sequences DUGST' / DUGSTs' and 
D1GST' / D1GSTs' describe pGEX-DLl and pGEX-Dl plasmids respectively. 
Sequences DLGFp3' and DLGFps'describe the nucleotide sequence determined by 
sequencing pEGFP-DL plasmid. Similarly, sequences DUGFp3' / DUGFps' and 
D1GFp3' / D1GFps' describe pEGFP-DLl and pEGFP-Dl plasmids respectively. 
peR primers used in generating these sequences are shown in Table 2.3 
190 
ABIJ!.. 
PRISM" 
IVIUUI:::I 
Version 2.1.1 
,------
pGEX-DL Sequenced with pGEX3' primer 
-.----.-.----------.---.-. .----------------------r 
C CCTGT CAT C ACCG A A ACGCGCN AGG CA A A CG! C AG r C AGT C /J. C A A r G CG GC C GC! eN A' C A ACT r- A I G C A A A AG G 1 i T AC'j ., G G CT 1 G GAT 1 CA A C"' GG CA CG Gee N A" I\J T r A AC A AT T T AC 1 T T C T T TAT. 
10 20 30 40 50 70 p,r, 90 100 1 0 120 130 
c; 1 -:3 T CA Gel G G T 1 CG G CA A A T Gel G CAN C I G CA ,. C AG C AG Go A A C A G C(l C 1 C . 1 1 C C A. C C A CGG G A A Ale j co ! C C ! GiG A C ; 
140 150 160 170 180 190 ,00 210 
1 G A It 1 Nee GGGGA T Nee c eee CG A A NC A A A 1 r C CG A A ' roo A G A AN G"; CC CC CC C C NC A A A C IGN:,GCCI-ICC CCCGCCAAGGCCNGCCAIATA CT1GCCGGA 1 iiCCAIT1TNNT"lfNCAATTTGNTGGAAAA 
410 420 430 ,\.110 ,\',1 460 480 490 ~r)(.1 ~J 1 (i 52(' 530 
.cecerCA A A (C ' •• ,1AAAAAAAAAC'AA 
570 
GGAA A A C CC eeG CC GGGCCCN: GGG' 'CCCCC' 'AAAAA''JAACCCCCCAAAAAACCi! r T TT"! AANAAAAAAAAAAITCCCC OOAAf 
630 640 "',P 660 670 I 540 550 580 590 610 
I 
I 
.-----------.- ~ .... - /"... - . - ~ ~~ ~
ABI~ 
PRISM" 
Model 
Version 2,1.1 
GNNNNNNNNGTNNNTNTGGACQAJ eeT CCAAAA1CGG 
10 20 30 
Cf GGi 
pGEX-DL Sequenced with pGEX5' primer 
CCGCGl GG ArCCCCGG AAI CA A' C C CNCA G A AG C CA NG G N I G 1 NG A A ACA G A ACC I G AGGA A N A AG C CGC A AT CA T C T A AG C CA A A A AG CCA A 
':'0 60 70 60 90 100 110 120 130 
GCAAGCACCCCT CANAr ACA AG A AACAAGCA:GC! CCNAACiG ANAAAGCiGl 11 CCNAG I C' f>.GCGAGCANCCNCCA: CAG AGAAA1CNNCAAAACCAAAGACi ANN,C"TCAGGANAAGATTTCCGGTGGTGGAA 
140 150 160 170 180 1S0 200 210 220 230 240 25() • 00 270 
30n 
C' 1 ceQ GGGGCCNTNiCC CCNGGG" . , .. : f: 1GGGGGG 'N' INGGGGGGGCCCGCCG NAACGCCCC"t ccccc"r 1[, I CNAAAAAAGGGAG11Nf r 111 lNNNCCGCCCCNAAAAAAAAAAAANGGGGGGCC 
560 570 590 610 520 630 640 650 "';c· 670 680 690 
N 
(j) 
ABI'£" Version 2.1.1 pGEX-D1 Sequenced with pGEX3' primer PRISM" 
r--'-~;";:;,,,:c..:.._---------------.-----.---. 
rCCTG' CA CACCGA A ACGCGCN AGQCAA A CQ'CAQ'CAG CACAAlQCQQCCGC'CAA' CAACl AcrCI'CCAC' "C'NC111IC1C' rGGG1GGAGCANCAC11C1NAICACCCCAGCTGACTGAG 
10 20 30 !n 50 r'll 70 So 90 100 110 120 130 
Ii j\ i\ II 
I ! , 
I ! i\ '-. I! . 
, " 
~GCNJ\:CCC~ Ie Ie' 1 rAr;CAAAANl ieee A:A 
280 290 
1 G G A GG A A N IN' 1 G A C' 1 C . C ,ACCCAGJ ;CCNCC A1NllAGG1IAGAAC'(CCAI iGGAflCCCGAAAC"l :CCAGGTTCCCAGT ATATGTT, 
340 350 360 :l.lO 380 390 t10D 
500 
(V) 
en 
ABt~ 
PRISM" 
Model 
Version 2.1.1 pGEX-D1 Sequenced with pGEX5' primer 
TNNN T NrNG ACG TeeT C CAA A T CG G T CT Gar r CCGCG 1 GG A"I CCCCG G A A1 1 CA AN 1 CA J ACA"\ GG Al ACI GC ( CT G G A Ta ACl f A A 1 AN ACA CT T TAG GAGA Ace T G A AG AG ACA A A AG A AG AT ACCCC Nee A T AT ACT G 
10 20 30 40 50 .. ,(' 70 !;n 90 100 110 120 130 140 
A A CC C C .. G G G G Nee N A 1 G A eNG C N 1 eGA "r Gee 1 'G r C! I C A f'J A C' 'C AC C "r G C AG: iCC C C ,. C AG C : G A ~ G C G NAG A AA AC i GAG A A A GA NA A ! C ICC ANA A A A 00 N ! T AAAA C T eee T eN NC TGOOGTTG A 1 CT 
280 290 300 320 ~30 340 350 360 370 380 390 400 410 
G C 'G C"I C C C C C C C eGA NAN A AA A N A A A A A ANi G GA A. A AT i 
420 430 440 450 
Model 
Version 2,1,1 pGEX-DL 1 Sequenced with pGEX3' primer ABtA:.. PRISM'· 
r-c;:..;:.:=...::..;;.--------,---------------------------------
1eCTQr CA CAcn:;AAACGCGCNAGGCAAA CG:CAG1CAG!CACAAlf)CGGCCGCiCAA:,CAAC! !ACiC!NCCACI f r-.lC1NCl ICTC', ITGGGIGGANCANCACl rcrGATCACCCCAGCTGACTGAGC' 
10 20 30 50 70 80 'It) 100 110 120 130 
1" T T A A A Nee NC T NeT G l A A A -1 j 1 C ; C T 1 r ere A G: : N C 
140 150 160 I", 
fl [t II 
) 
! 
1 G CA ' C AGe i G ' AG G G G A AC : G C AG G 1 G A Ai; C . G A iNA C A AGG C A. rCA A 1 G G eN feN I 
190 200 210 220 230,\ 
II 
1\ Ii I! 
'\ 
IGGGCCCCAGGGGT i TCNANGANTCTGGAGGAGG 
240 lSI) 260 
rGGG'I ATe TN C C T r T T G r TeN CC TN CCAG G T T T CCN eee C i AAA AN r 1 N 1 -I CC r A A : AAA i . ! CC AC C C C A A A A C A A I 1 Nrc CC N i NT T T T T'" G A A crT T T 1 GGCA A A A A G G G TN r T A A eN T T T G G GC T 'I T 
410 420 430 440 450 460 470 480 490 500 510 520 530 
GA',"·CCCN N CNNGG CACCGG CCCAAA', 
540 550 560 
'AAACA' 
570 
lAC'lNGC 
580 
c CC C i ; NN C N C C NNG G iT' N C C G G N A A A A A 1 N C NT N G C NAN N T T G C A A A A A A A A A NN A A A A A C 
,'I n 620 630 640 650 
ABI~ 
PRISM'· 
Model 
Version 2,1,1 pGEX-DL 1 Sequenced with pGEX5' primer 
GNNN NN NNNG 1 fNNNT N r T G ACGA'I eer C CAA A A 1 CG G Ie' G Gl CCQCG I G G A! eee CG G A At CA A: C C CNCA G A AG C eN NG G N r G r NN 1A A ACA G A ACe! G AG A AN A AG C CG C A ATe ATe T A AG C CA A A A AGe CA A C 
10 20 30 40 SO 60 10 BO 90 100 110 120 130 140 
NAGCGC~GllCCTGC1G' !GCAGC1GCAf\JCAjC~GCCGAACCAGC GACAANAAl AAANAAAG" I Ai Gl iNACAICGQCCG·IGCCNNT rGAA~CCCANCCAAG! AAAccrTC 1 GCAAAGr CNCACATGGATAC1G 
280 290 300 l~" 320 330 350 3f.~; 370 380 390 400 410 
<0 
0) 
ABIi.f!.. Version 2.1.1 pGFP-DL Sequenced with pGFP3' primer 
PRISM' 
GG C T C A C CCG G T G AN AG , CCI CGCCCl 1 G Cl CACC A I G G T G G CN A [ G GAl C CCG GG CC C GCG G [ ACC G I C A ACT G CA N A AG G T 11 ACT T G G Clr G G AI rCA A C r G G CA CG G C CG A 1 NT T A A CA AT T TACT T T 
1Q 20 30 M:· 60 70 80 90 100 110 120 130 
r G r CA G C i G G T 1 CG G C A A A 1 G C ! G CAN C 1 G CA A C AGe A G G A AC A G CG C : 
150 1 0 ,;" 180 
i 
T eCA 1 G G r G G CG A A j TeN A A C J TG A GCT CC A N Arc: GA N • CCCG G ' ANCGC I A CGGA 1'\ C f GA A GG 1 . CAe; AAAC CA era::;; GC '1 1 A'l AT A A CCTC CGCNC Cf\Ol ACA C C eel ACCG CCCCA T 'r T NC NT CC A TGGGGGG AAA T TTt 
-1 H) 420 <130 440 450 .1'.,':0 480 490 500 510 520 530 540 
/ \ 
Moael 
Version 2.1,1 pGFP·OL Sequenced with pGFP5' primer ABI~ PRISM'· 
,.--'"-"''-''-'-'------------------------_._-------------_. 
------------------------,-
TT NNG NG NGGTG T NCG T AGCG N T CCN G A I CA NAT CI CG AGC I CA AGCI 1 CG A A r 1 CG CCACC A I G A A I C CCACA A A AG CC A NG G CT G! A A A A AC AG A ACC T G A N A A N A AGCCG CA AT CAT C T A A G CCA A A A AG CCA A cr 
10 20 30 40 50 60 70 80 90 100 110 120 130 
G A NeG C ~ G 1 ~ C C T Gel G r TG CAGe i G C AGe Ale 1 Gee G A Ace AG C ' G A CA AG A A ; A A AGA A A '; A AN 1 I G I r A A CA leG Gee G I GC C AGT I G A A 1 ceCA AGe C A AG r 1 A A AC C T 1 eel GC AG r C GA CG G T Ace GCGGG CC 
280 ?9[' 300 310 330" 340 350 360 370 380 390 400 410 
ABIA. 
PRISM" 
Model 
Version 2.1.1 pGFP-D1 Sequenced with pGFP3' primer 
GGG A C A C CCG G NG A A AGCT CC' CGCC C' T GC' CACCAT GG' GGCN A'GGATCCCGGGCCCGCGG' ACCGrCAACCTCl TCCAC11 1 TcrTel"! T rCTCl TTGGGIGGAGCAGCACTTCTGATCACCCCAGCTGA 
10 20 30 
.. "\ " 70 80 no ~G('I 110 120 130 
I G AG C T f r 1 A A AGe ere r 1 C i G T A A AT T"I CTc"r I ! C' GA G ! I T N CiT -: G CA I C AGe j G ; AG G Q G 1\ A C ! G GAG G \ G A It. lie i G A I G A CA AGG Cit. 1 C N A r G G CG rCA T I G G Gee CC AG GO G 1 1 TeN A GG A NT C T G G 
140 150 160 ,." 180 190 2 0 210 220 230 240 250 260 
GrTGG1Arc TCCTT1TGT1C1CC!Ta;AGG";lTCC!CCC1AAAG;rGfrCC1A iAAAl CCNrCCGAAAACCAN:fATCCCA1GI1TC1GAAAC"lr"lTGCCCA1GGGTNG eNAAATT CCCAAAC 
410 420 4JO 1 ~r 450 460 
c: 'GAAAGCCGC AAAAA 
540 550 
C " G A A 
560 
. C C C C N G GG' A A CC C CC , AA N C G G A A " 
570 
470 480 490 500 510 520 530 
N' 'GNAAAGGGG' 'CCCCCNrNAAA A CNCC I CCCCCGGCC'T1ATAATAAAAAACCCCCCCCCACCCGG 
600 610 620 630 6<0 650 660 
(j) 
(j) 
Model 
Version 2. 1.1 pGFP-D1 Sequenced with pGFP5' primer ABIA. PRISM" r-..-=-==:=...:=-=-----------------------.------.--------------
TNtlNGNG GG G' G T N CG 1 AGCGCI Acce; GAl !CAG A I Cl CG AGC' C A AGC' 1 CG A A' r CGCCAC CA 1 G G CA A AG 1 C AG A CA T GG A I A C I G C I C I G GAr G ACT ., A A 1 AG A CA CT I , AG G AG A ACCT G A AG AG AGA A A AG A AG A 
10 20 .r) 40 GO 70 80 90 100 110 120 130 140 
ACCACNACA 1 Al 
150 
C ! C C AA A ere c ! ax; A A AGee c ! G GGG C C C A A I G A CGe C A ! eGA 1 GC C: 1 G 1 GAl C AGA C' ! C AC C I G C AG! ! C cc ceT A C AG C T G A 1 G C A A AGA AA AG i GA N A A AGA N A AAT C T AGAGA AGA NG C T T T AAAA C T eCA 
;'j\() '9~) 300 310 320 \ ~q '.',(, 360 370 380 390 400 410 
• : eGG A G N 1\ G NAT C C C 1 GGA . A c: A I T 1 ; 1 C eGA' cc rei Gee C eTA C C ; N: GG' \ N' CC 
560 570 '~~!" 590 '"';l' 
o 
o 
N 
ABIA 
PRISM" 
Model 
Version 2.1.1 pGFP-DL 1 Sequenced with pGFP3' primer 
NGQCNa::A C CCGGTGGAACAQCl CCT CGCCC~I T GCI CACC A r G GIG G eN A IGG AT CC CGGG CCCGCGG' ACCGT CA ACCl Cl T CCACT 1 r T C T T crT 1 T CTC 1 T~; GG G ~I GG AG CAN CA CT T C TG AT CACCCCAG CT G A 
10 20 30 40 5 60 70 eo I·C' 100 fO 120 130 
A 1 G : f T G P"G G""I ATe -: 1 CC 1 r 1 1 G' C N C ~ \ C A GG - 'C Nee CiA A A T 1 G r " C '; A l , A A l . CAN C CC A A A N C A G i A ~ C C A ! C 'GA Ci rrG CANAA GGTl T A C I TGGCT TOGA r CCN CTGGCAC GGCGAAT 
410 420 1 g) 440 450 460 470 j" , II,t) 500 "H' 520 530 
o 
N 
ABI~ 
PRISM'· 
Model 
Version 2. 1. 1 pGFP-DL 1 Sequenced with pGFP5' primer 
r T CCGNG NGGf G rGACG r NAGCGC' ANC N GAl C AG Ar C I CG A GCI C A AG Cf \ CG A A 1 , CG CC AC C A' G A A 1 C CC A C A G A AG CCAGG G NT G r A A A A AC A G A AC CT G AG A AG A AGCCG CA A 1 CA '\ C I A A G CCA A A A AGC CA 
, 20 30 40 50 60 70 80 90 100 110 1?0 130 1 
AAGAGCGC'G'·CC 1 GC1GT lGCAGC:GCAGCA1C i GCCGAACCAGC:GACAAGAA,'AAAGAAAGI,NAA:1G: iAACA1CGGCCG!GCCAG1 !GAA.1CCAAGCGAAG11AAACGilC lGGAAAGTTCAGACATGGA 
280 290 300 ::1 1' 320 330 340 360 './1.1 380 390 400 410 
AC1GCTC lGGA1GACf TAATAGACACI lAGGAGAACCC'GAAGAAACCAAAGAAGAA1Aa::;CACAACAINIACIGGACC'IGAANrT: CNGATl CCATGNNi rCC'iACCC1 ACA1ANAAGAACrGGGTTNAAAAAAA 
.t:m .1'0 440 450 460 470 480 490 ':00 510 520 s:~o 540 550 
N 
o 
N 
Appendix E Abbreviations 
1° primary 
dNTP deoxynucleoside 2° secondary 
triphosphate 3° tertiary 
DSHB developmental studies ABR Affinity Bioreagents 
hybridoma bank AEBSF 4-(2-aminoethyD 
DTT dithiothreitol benzenesulfonyl 
E64 trans-epoxysuccinyl-L-fluoride 
leucylamido-Amp ampicillin 
4-guanidino) butane APB Amersham Pharmacia 
E. coli Escherichia coli Biotech 
APS ammonium EDTA ethylenediamine-
tetraacetic acid persulphate 
EGFP enhanced green ATP adenosine triphosphate 
fluorescent protein ATCC American Type 
EGTA ethylene glycol-bis(~-Culture Collection 
aminoethyl ether) N,N, au arbitrary units 
N' ,N' -tetraacetic acid ~-MCE ~-mercaptoethanol 
FACS fluorescent automated BMP bitmap 
cell sorter BCA bicinchoninic acid 
FCS foetal calf serum BSA bovine serum albumin 
FITC fluoroscein 
°C degrees Celsius Isothiocyanate CaMLD calmodulin like 
g gravity domain GFP green fluorescent CAPS 3-[cyclohexylamino]-1- protein propanesulphonic acid GSH reduced glutathione CBND 1-chloro-2,4- GST glutathione-S-Dinitrobenzene 
transferase CCS central consensus HEPES N-[2-hydroxyethyl] 
sequence piperazine-N' -[2-
cDNA complementary DNA 
ethanesulphonic acid] 
cm centimetre HS horse serum DL ovine calpastatin IGF-1 insulin-like growth domain L factor 1 D1 ovine calpastatin 
IPTG isopropyl-~-D-thio-domain 1 
galactopyranoside DLl ovine calpastatin 
Kana kanamycin domains Land 1 
kDa kiloDalton ddH20 dis tilled deionised 
kg kilogram water 
LB luria bertani DEAE diethylaminoethyl 
LGMD2A limb girdle muscular DMEM dulbecco's modified 
dystrophy type 2A eagle media 
LP82 lens protein 82 DMSO dimethyl sulphoxide 
M molar DNA deoxyribonucleic acid 
ml millilitre 
203 
mg milligram TBE Tris-borate-EDTA 
mM milliMolar TCA trichloroacetic acid 
mRNA messenger RNA TnT troponin T 
NEB New England Biolab TY tryptone yeast 
ng nanograms RNA ribonucleic acid 
NLS nuclear localisation Rpm revolutions per minute 
Signal RT room temperature (20 
nm nanometre - 25°C) 
OSU Oregon state university TBS tris buffered saline 
PAGE polyacrylamide gel TTBS TBS + Tween 20 
electrophoresis TCA trichloroacetic acid 
PBS phosphate buffered TEMED N,N,N',N'-
saline tetramethylenediamine 
PCR polymerase chain Tris-HCI tris [hydroxymethyl] 
reaction aminomethane 
PDB protein denaturing hydrochloride 
buffer UV ultraviolet 
PIPES piperazine-N,N'-bis[2- UVP Ultraviolet Products 
ethanesulphonic acid] Ilg microgram 
PKA protein kinase A III microlitre 
PKC protein kinase C 
Ilm micrometre PKM protein kinase M 
IlM microMolar PMSF phenylmethylsuphonyl 
Fluoride V volts 
PVDF polyvinylidine v/v volume to volume 
difluoride w/v weight to volume 
SDS sodium dodecyl X-gal 5-bromo-4-chromo-3-
Sulphate indolyl-~-D-
t time galactosidase 
TB terrific broth 
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Appendix F - Major suppliers of reagents, consumables 
and equipment 
Mfinity Bioreagents Incorporated., Golden, co. USA. 
Antibodies 
Anchor NZ Milk Corporation Limited., Auckland, New Zealand. 
Amersham Pharmacia Biotech., Uppsala, Sweden. 
Non-fat Dry Milk 
Antibodies 
Bacteria 
Plasmid DNA 
American Type Culture Collection., Manassas, VA. USA. 
BDH Laboratories., Poole, Dorset. UK. 
Ammonium Acetate 
Boric Acid 
Bromophenol Blue 
CaCl2 
Chloroform 
Dimethylformamide 
DMSO 
DPX Mountant 
EDTA 
Ethanol 
Ethidium Bromide 
Glacial Acetic Acid 
Glass Wool 
Glycerol 
Glycine 
HCI 
Mammalian Cell Line 
Isoamylalcohol 
Isopropanol 
KCl 
KH2P04 
K 2HP04 
Methanol 
MgCl2 
MgS04 
NaCl 
NaOH 
Phenol 
Sodium Acetate 
Sucrose 
TeA 
Triton X-100 
Beckman Instruments Incorporated., Palo Alto, CA. USA. 
Beckton Dickinson., San Jose, CA.USA. 
Bio-Rad Laboratories., Hercules, CA. USA. 
Acrylamide 
Beckman JAlO rotor 
Beckman JA20 rotor 
Beckman J2MI centrifuge 
FACS Vantage flow Cytometer 
Alkaline Phosphatase 
Conjugate Substrate Kit 
205 
APS 
BioRad Protein Assay 
GelAir Drying System 
Microradiance Confocal 
System 
Mini-Protean II 
BMG LabTechnologies., Offenburg, Germany. 
Mini-Sub Cell GT 
Nitrocellulose Membrane 
TEMED 
Transblot Apparatus 
UV Transparent Cuvettes 
Fluostar Type 0403 
Clontech Laboratories Inc., Palo Alto, CA. USA. 
Plasmid DNA 
Corning Costar Corporation., Cambridge, MA. USA. 
100 mm Sterile Culture Plates 
Developmental Studies Hybridoma Bank., Iowa City, IA. USA. 
Antibodies 
Esco Products Incorporated., Oak Ridge, NJ. USA. 
Falcon., Lincoln, NJ. USA. 
FMC Bioproducts., Rockland, ME. USA. 
Genset., Paris, France. 
Microscope slides and coverslips 
Centrifuge tubes (15 ml and 50 ml) 
Polypropylene tubes (14 ml) 
T175 em Culture Flasks 
35 mm Culture Plates 
SeaKem Agarose 
Oligonucleotides 
Germantown (New Zealand) Company., Manukau City, New Zealand. 
Gibco BRL Life Technologies., Gaithersburg, MD. USA. 
Bacto-tryptone 
DMEM 
DNA Molecular Weight 
Marker (AHindIII) 
FCS 
Fungizone 
Geneticin 
Agar 
HS 
Kanamycin 
Penicillin-Streptomycin 
Trypsin / EDTA 
Yeast extract 
Heat Systems Ultrasonics Incorporated.,· Farmingdale, NY. USA. 
Sonicator W-225 
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Heraeus Sepatech GmbH., Osterode, Germany. 
Hybaid Limited., Ashford, Middlesex. UK. 
Kinematica., Uttau, Switzerland. 
Lynnon Biosoft., Vaudreuil, Quebec. Canada. 
MicroTek International Incorporated., Taiwan. 
Millipore Corporation., Bedford, MA. USA. 
Heraeus Biofuge 13 (microfuge) 
Heraeus Christ (varifuge) 
Hybaid MiniOven MKII 
Polytron PT31 00 
DNAMAN Version 4.0a 
MicroTek Scan Maker X6el 
MicroTek Scan Wizard ver 2.48 
Immobilon-P PVDF 
Nalgene Nunc International., Rochester NY. USA. 
New England Biolabs., Beverly, MA. USA, 
Olympus., Tokyo,Japan. 
Perkin-Elmer Cetus., Norwark, CT. USA. 
Cryovials (1.5 ml) 
Bacteria 
Olympus CH2 Light Microscope 
Olympus IX-70 Inverted Microscope 
Perkin Elmer GeneAmp PCR System 2400 
Pierce Laboratories., Rockford, IL. USA. 
Riverlea Dairies., Auckland, New Zealand. 
Roche Molecular Biochemicals., Mannheim, Germany. 
Antibodies 
CAPS 
Dnase-free Rnase 
NaN3 
BCA Protein Assay 
BSA 
Casein Alacid 730 
PIPES 
Restriction Enzymes 
T4 DNA Ligase 
TRIS-HCl 
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Sarstedt., Numbrecht, Germany. 
Microfuge tubes (1.5 ml) 
Savant., New York, NY. USA. 
SpeedVac Concentrator 
Schleicher & Schuell., Dassel, Germany. 
Sigma., St. Louis, MO. USA. 
AEBSF 
Ampicillin 
Antibodies 
Aprotonin 
P-MCE 
d-limonene 
Freund's Complete Adjuvant 
Giemsa Solution 
Glutathione Agarose Beads 
Stratagene., La J oila, CA. USA. 
Unicam Limited., Cambridge, UK. 
DEAE Membrane NA-45 
IPTG 
Ketamine H Cl 
Lysozyme 
Paraformaldehyde 
PMSF 
SDS 
X-Gal 
Xylazine HCl 
Plasmid DNA 
Unicam UV4 Spectrophotometer 
Ultra Violet Products., Cambridge, UK. 
Qiagen GmbH., Hilden, Germany. 
Zeiss., Oberkochen, West Germany. 
ImageStore 5000 gel Documentation System 
GelBlot Pro Image Analysis System 
UV Transilluminator 
Plasmid Midi Kit 
Taq Polymerase and buffers 
Zeiss Standard Microscope with Hg Lamp 
Zeiss MC63 Photomicrographic regulator 
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Recombinant calpastatin generated in Chapter 3 was used for analytical 
purposes in the following paper. Conditional upon several recommended changes 
this paper (partial Purification and Characterisation of Chinkook Salmon 
(Oncorf?ynchlls tshml!Jtscha) Calpains and an Evaluation of their Role in Postmortem 
Proteolysis) was accepted for publication on the July 26,2000, by the Journal of 
Food Science, Chicago, IL. USA. 
Partial Purification and Characterization of Chinook Salmon (Oncorl!Jnchus Ishauytscha) Calpains and an 
Evaluation of their Role in Postmortem Proteolysis 
Geert H. Geesinkl , James D. Morton, Matthew P. Kent and Roy Bickerstaffe 
Molecular Biotechnology Group, Animal and Food Science Division, Lincoln University, 
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ITo whom correspondence should be addressed: P.O.Box 84. 
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ABSTRACT 
The involvement of calpains in the proteolysis of salmon muscle proteins during refrigerated storage 
was investigated. m-Calpain and J.1-calpain were purified and partially purified, respectively. Salmon m-
calpain had similar calcium requirements and specific activity against casein as ovine m-calpain. 
Salmon J.1-calpain had similar calcium requirements as ovine J.1-calpain, but a lower specific activity 
against casein than ovine J.1-calpain. Autolysis patterns of both calpains differed from those of ovine 
calpains, and their activities were less than those reported for mammalian muscles. Calpastatin activity 
was relatively high and comparable to that reported for bovine muscles. Little proteolysis and fiber 
fragmentation was observed during refrigerated storage. However, proteolysis could be reproduced by 
incubation of myofibrils with m-calpain. 
Key words: calpain, proteolysis, muscle, salmon, Oncorl!Jnchus tshauytscha 
Introduction 
Firmness is an important aspect of fish quality. It deterioriates during postmortem storage. Most of 
the studies on the deterioration of fish muscle structure during storage have focused on degradation 
of the connective tissue component of the muscle. Changes in connective tissue have been observed 
at an ultrastructural level (Hallett and Bremner, 1988; Ando and others 1991) together with an 
increase in collagen solubility during storage (Sato and others 1997; Aidos and others 1999). In 
contrast to fish, weakening of the mammalian and avian muscle structure post mortem is considered 
desirable since it improves tenderness. In the latter case the connective tissue component is little 
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affected by postmortem storage, but a large number of myofibrillar and cytoskeletal proteins are 
degraded (Geesink and Koohmaraie 1999a). It is generally accepted that the calcium-dependent 
proteinases (calpains) are responsible for this degradation (for a review see Koohmaraie 1996). The 
results of a number of recent studies indicate that some of the changes associated with the action of 
calpains also occur in fish muscle. These changes include degradation of tirin and dystrophin, release 
of ""-actinin from the myofibrillar structure and loss of Z-line integrity (Watson and others 1992; 
Papa and others 1996, 1997). In contrast, little degradation of the calpain substrate desmin was 
observed during storage of sea bass, brown trout and turbot (Verrez-Bagnis and others 1999). 
Relatively little is known about the calpain system in fish muscle. m-Calpain has been 
purified from carp and tilapia muscle (Sakamoto and others 1985; Wang and others 1993). J.l-Calpain 
has not been purified from fish muscle, but the presence of a Ca2+ -dependent caseinolytic peak eluting 
before m-calpain on an anion-exchange column may indicate its presence in carp muscle (Sakamoto 
and others 1985). Wang and others (1993), however, did not detect J.l-calpain activity in tilapia muscle. 
The objective of our study was to characterize the calpain system in salmon muscle and to evaluate its 
role in postmortem proteolysis during refrigerated storage of the muscle. 
Materials and Methods 
Materials 
The experiments were carried out using Chinook salmon (Oncorl?Jnchus tshall!Jfscha) from a commercial 
farm in Canterbury, New Zealand. Sexually immature salmon ranging in weight from 0.3 to 1.5 kg 
were used. Sexually mature salmon were not used since these are of little commercial value due to a 
decrease in muscle fat content and an increase in water content. The fish were sacrificed by a blow on 
the head followed by bleeding. The white dorsal muscle was dissected and used in the various 
experiments. Ovine J.l- and m-calpain were purified from skeletal muscle according to Edmunds and 
others (1991). 
DEAE-Sepharose Fast Flow, Butyl-Sepharose 4 Fast Flow, Mono Q HR 10/10, Phenyl-Sepharose 
CL-4B, Blue Sepharose CL-6B and the pGEX-4T-l vector were purchased from Amersham 
Pharmacia Biotech (Buckinghamshire, UK). Reactive Red 120, glutathione agarose beads and alkaline 
phosphatase labeled anti mouse IgG were purchased from Sigma Chemical Co. (St. Louis, Mo., 
U.S.A.). Monoclonal anti-J.l-calpain (clone 9A4H8D3) was purchased from Affmity Bioreagents, Inc. 
(Golden, Col., U.S.A.). Distilled water and only analytical grade chemicals were used. 
Calpain purification 
m-Calpain. Muscle (750 g) was homogenized in 3 volumes extraction buffer (100 roM Tris/HCl, pH 
8.0,10 roM EDTA, 0.05% 2-mercaptoethanol [MCE], 2 mM phenylmethylsulfonyl fluoride [pMSFJ) 
using a Waring blender (2 x 20 sec, high speed). After centrifugation (17,700 x gmax, 1 h, 4°C), the 
supernatant was filtered through glass wool and loaded onto a DEAE-Sepharose Fast Flow column (5 
x 50 em, 4 mL/min, 10 mL/fraction). The column was washed with 1 L elution buffer (20 mM 
Tris/HCl, pH 7.35, 0.5 mM EDTA, 0.05% MCE), and eluted with a gradient of 0 to 125 mM NaCl in 
950 mL elution buffer followed by 125 to 500 mM NaC! in 1800 mL elution buffer and 500 mL 
elution buffer containing 500 roM NaC!. Fractions containing calpain activity were collected (540 mL), 
and a third of the pooled fractions was loaded on a Reactive Red 120 column (1.5 x 25 em, 1 mL/ min, 
10 mL/fraction) equilibrated with elution buffer containing 0.5 M NaC!. The column was washed with 
90 mL elution buffer containing 0.5 M NaC!, and eluted with 90 mL elution buffer, pH 8.3. 
Chromatography on the Reactive Red 120 column was repeated twice for the remaining pooled 
fractions from the DEAE-Sepharose column. Fractions containing calpain activity were collected and 
loaded onto a Mono Q HR 10/10 column (2 mL/min, 4 mL/fraction) equilibrated with elution 
buffer. The column was washed ,vith 25 mL elution buffer and eluted with a linear gradient from 200 
to 500 roM NaC! in 140 mL elution buffer followed by 25 mL elution buffer containing 500 mM 
NaC!. Fractions containing calpain activity were collected and dialyzed against elution buffer. 
J.l-Calpain. Muscle (250 g) was homogenized in 5 volumes extraction buffer (100 roM Tris/HCl, pH 
8.0, 10 mM EDTA, 0.05% 2-mercaptoethanol [MCE], 2 roM phenylmethylsulfonyl fluoride [pMSFJ). 
After centrifugation (17,700 x gm.x, 1 h, 4°C), the supernatant was filtered through glass wool and 
loaded onto a DEAE-Sepharose Fast Flow column (2.5 x 40 em, 2 mL/rnin, 10 mL/fraction) 
equilibrated with elution buffer. The column was washed with 300 mL elution buffer and eluted with a 
gradient of 0 to 1 M NaC! in 700 mL elution buff~r followed by 100 mL elution buffer containing 1 M 
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NaC!. Calpain-containing fractions, as detected by Western blotting, were collected (2B5 mL), brought 
to O.B M (NH4)2S04 and loaded onto a Butyl-Sepharose 4 Fast Flow column (2.5 x 40 cm, 2 mL/min, 
10 mL/fraction). The column was washed with 200 mL elution buffer with O.B M (NH4)2S04 and 
eluted with a gradient of O.B to 0 M (NH4)2S04 in 500 mL elution buffer followed by 200 mL elution 
buffer. Calpain-containing fractions were collected (275 mL) and loaded onto a Mono Q HR 10/10 
column (1 mL/min, 5 mL/fraction) equilibrated with elution buffer. The column was washed with 25 
mL elution buffer and eluted with a linear gradient from 0 to 1 mM NaC! in 200 mL elution buffer. 
Calpain-containing fractions (10 mL) were collected and loaded on a Reactive Red 120 column (0.5 x 
12 cm, 0.5 mL/min, 2.5 mL/fraction). The column was washed with 30 mL elution buffer containing 
0.5 M NaC!, and eluted with 50 mL elution buffer pH B.3. Calpain containing fractions were collected 
(~7 mL), dialyzed against extraction buffer and concentrated to 3.5 mL using Centriprep 10 
concentrators. 
Calpain assays 
Calpain assays using casein as the substrate were performed according to Koohmaraie (1990). Calpain 
assays using fluorescein isothiocyanate-Iabeled casein (FlTC-casein) were performed according to 
Twining (19B4). Calpain and calpastatin activity was expressed as described by Koohmaraie (1990). 
Calpain activity measured using F1TC-casein was converted to standard calpain attivity units by 
comparison of activities measured with both methods. Thus, the number of fluorescence units in the 
F1TC-casein assay that corresponded to one unit of activity in the standard casein assay was 
determined. 
Characterization of m-calpain 
Calcium-requirement. Salmon m-calpain and ovine m-calpain were dialyzed against elution buffer 
and the activity against casein in the presence of 0 to 1.6 mM free Ca2+ was measured in triplicate. 
Autolysis. salmon m-calpain and ovine m-calpain in elution buffer were incubated at 25°C in the 
presence of 2 mM free Ca2+. An aliquot was taken after 0,1,2,5 and 10 min of incubation and mixed 
with an equal volume of2 X protein denaturing buffer (PDB) [0.12 M Tris/HCI, pH 6.B, 3.4% (w/v) 
SDS, 10% glycerol, 1.67% (vol/vol) MCE, 0.003% bromophenol blue]. 
Specific activity. The activity of salmon m-calpain against casein was compared to that of ovine m-
calpain using recombinant domain Iovine calpastatin. The calpains in elution buffer were incubated 
\vith different amounts of the inhibitor and remaining activity was measured in triplicate. 
Characterization of p-calpain 
Calcium-requirement. Salmon f,l-calpain and ovine f,l-calpain were dialyzed against elution buffer and 
the activity against FITC-casein in the presence of 0 to 0.4 mM free Ca2+ was measured in triplicate. 
Autolysis. Salmon f,l-calpain was incubated at 25°C with or \vithout 10 units of recombinant domain 
1 ovine calpastatin in the presence of2 mM free Ca2+. An aliquot was taken after 0,1,5,10 and 15 
min of incubation and mixed with an equal volume of 2 X PDB. 
Specific activity. The activity of salmon f,l-calpain against F1TC-casein was compared to that of ovine 
f,l-calpain. The relative concentrations of the two calpains were estimated by Western blotting. 
'Western blots were scanned using a Microtek Scanmaker X6 EL (Microtek International Inc., 
Taiwan). Images were stored using Adobe Photoshop version 4 (Adobe Systems Inc., San Jose, Cal., 
U.S.A.). Intensity of the bands was quantified using GeiBlot-Pro image analysis software (Ultra Violet 
Products Ltd., Cambridge, UK). 
Proteolysis of muscle proteins and activity of the calpain system during refrigerated storage of 
muscle 
Proteolysis of muscle proteins. About 20 g of muscle was dipped in a 1 mM NaN3 solution and 
stored for 0, 1,3, or 7 days in closed 50-mL tubes at 5 0C, After storage,S g of the muscle was 
homogenized in three volumes extraction buffer using an ultra-turrax (lKA, Staufen, Germany). After 
centrifugation (1,500 x gm •• , 20 min, 4 0q, an aliquot of the supernatant was mixed with an equal 
volume 2X PDB and stored at -20°C until use. The remaining supernatant was discarded and the 
pellet resuspended in 40 mL elution buffer, centrifuged and the supernatant dicarded. This washing 
procedure was repeated two more times and an aliquot of the fmal suspension of washed myofibriJs 
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was mixed with an equal volume of 2X PDB, heated for 3 min in boiling water and stored at -20°C 
until use. Degradation of muscle proteins during storage was evaluated by SDS-PAGE. Autolysis of Il-
calpain during storage was monitored by Western blotting. Fragmentation of the washed myofibrils 
was evaluated using a phase contrast microscope (Standard microscope 16; Zeiss, Oberkochen, 
Germany) 
Proteolysis of myofibrillar proteins by m-calpain. Washed myofibrils (5 mg/mL), prepared as 
described above from at-death muscle, were incubated with m-calpain (0.5 V/mL) in the presence of 
5 mM CaCh at 25°C. After 0, 2.5, 5, 10, 15,30 and 60 min a 200 ilL aliquot was mixed with 10 ilL 
EDTA/Tris (200 mM, pH 7). Insoluble material was precipitated using an Eppendorf centrifuge. An 
aliquot of the supernatant was mixed with an equal volume of 2X PDB, heated for 3 min in boiling 
water and stored at -20°C until use. The remaining supernatant was discarded and the pellet was 
dissolved in PDB buffer, heated for 3 min in boiling water and stored at _20°C until use. Degradation 
of muscle proteins was evaluated by SDS-PAGE. 
Activity of the calpain system during refrigerated storage of the muscle. Muscle samples (20 g) 
from 4 salmon were stored for 0 or 2 d at 5 0C. After storage, 10 g samples were homogenized in 5 
volumes extraction buffer using an u1tra-turrax and centrifuged (27,000 x gm", 30 min, 4 0q. The 
supernatant was fIltered through g1asswool and the samples were dialyzed overnight against dialysis 
buffer (40 mM Tris/HCI, 5 mM EDTA, pH 7.35, 5 0q. After dialysis the samples were centrifuged 
(27,000 x gmax, 30 min, 4 0q, and the supernatants loaded by gravity onto DEAE-Sepharose Fast 
Flow columns (1.5 x 20 cm) equilibrated with elution buffer. The columns were washed with 150 mL 
elution buffer, and eluted with a gradient of 0 to 700 mM NaC! in 350 mL elution buffer (2 mL/ min, 
5 mL/fraction). Calpain and calpastatin activity was localized using FITC-casein as a substrate. 
Calpastatin activity was tested against ovine m-calpain. Active fractions of the respective components 
of the calpain system were pooled and the pooled activity determined using FITC-casein. 
Preparation of recombinant domain 1 calpastatin 
Recombinant domain 1 calpastatin was used to test the specific activity of the calpains. A eDNA 
fragment corresponding to domain 1 of ovine calpastatin was PCR-amplified using primers containing 
restriction site overhangs. After restriction digestion, the DNA fragment was sub cloned into pGEX-
4T -1 vector. Protease-deficient E. coli strain BL21 was transformed with the recombinant plasmid, 
cultured, and recombinant protein expression was induced as described by Liew and others (1997). 
Cells were harvested by centrifugation, washed twice with ice-cold PBS (0.8% NaC!, 0.02% KCI, 0.1 % 
Na2HP04, 0.02% KH2P04, pH 7.4), and resuspended in one-tenth culture volume of PBS containing 
ImM PMSF. The bacterial suspension was sonicated (5 times, 1 min, 50% power) before addition of 
one-tenth volume of PBS + 10% Triton X-I00. The mixture was gently agitated and clarified by 
centrifugation. Glutathione agarose beads (re-swollen in PBS to a bed volume of 6 mL) were added to 
the supernatant and mixed overnight at 4°C. Beads were collected by centrifugation, washed 3 times 
in 10 volumes PBS + 1% Tween 20, and 3 times \vith PBS alone. One hundred units of thrombin (1 
unit = 0.2 NIH units) was combined with 4 mL PBS and gently mixed with the beads at room 
temperature for 1 h. The supernatant was collected following centrifugation and heated at 95°C for 5 
min. Denatured protein was pelle ted and the protein concentration in the supernatant measured. 
SDS-PAGE, Western blotting and protein determinations 
SDS-PAGE was performed according to Laemmli (1970) and Western blotting was performed 
according to Towbin and others (1979). Protein concentration of samples dissolved in PDB was 
performed according to Karlsson and others (1994). Protein concentration of myofibrillar suspensions 
was determined using the biuret method (Gornall and others 1949). Protein concentration of soluble 
proteins was determined according to Bradford (1976). 
Results and Discussion 
Calpain purification 
Chromatography of the soluble muscle fraction over DEAE-Sepharose revealed the presence of a 
calpain inhibitor which eluted between 0.11 and 0.21 mM NaC!. Calcium dependent proteolytic 
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activity eluted between 0.30 and 0.43 mM NaCl. Subsequent chromatograpy of the proteolytic activity 
resulted in purification of a typical calpain composed of a large subunit of about 80 kDa and a small 
subunit of about 28 kDa (fable 1, Fig. 1). Attempts to purify the inhibitory activity failed. The salmon 
calpain inhibitor did not bind to Blue Sepharose CL-6B which has been shown to be very effective in 
purifying mammalian calpastatin (Geesink and others 1998). Binding of mammalian calpastatin to this 
medium probably involves domain L (Mellgren 1988). The failure of salmon calpastatin to bind to 
Blue Sepharose may indicate that it lacks a domain equivalent to mammalian calpastatin domain L. A 
number of antibodies against mammalian calpains were tested against the purified salmon calpain, but 
none of them reacted. When these antibodies were tested on total soluble salmon muscle proteins, an 
antibody against the large subunit of fl-calpain reacted with a band at 80 kDa. Western blotting \vith 
this antibody against the different stages of the calpain purification revealed that the protein reacting 
with this band co-eluted to a certain extent with the purified calpain on DEAE-Sepharose and 
Reactive Red, but it was separated from the purified calpain after chromatograpy on the Mono Q 
column. However, no activity, other than that of the purified m-calpain, was detected in the fractions 
eluting from the Mono-Q. This result could be explained by: (1) the antibody cross-reacting with a 
protein which was not calpain; (2) the calpain had lost its activity during the purification steps; (3) the 
calpain did not degrade casein; or (4) the level of calpain activity was below the sensitivity of the 
standard casein assay. To resolve some of these possibilities several attempts were made to purify the 
protein using Western blotting as the detection method. A small amount of the protein was eventually 
partially purified (fable 2, Figures 2A and 2B) and, subsequently, identified as a calpain. This 
particular calpain eluted between 0.20 and 35 mM NaCl on a DEAE-Sepharose column. The protease 
did not elute off a phenyl-Sepharose column even if 30% (v Iv) ethylene glycol was included in the 
buffer. This indicates that this particular calpain is more hydrophobic than the mammalian ubiquitous 
calpains. Furthermore, the protein did not bind completely to the Reactive Red column. During 
loading and washing a small amount eluted off the column. 
Calpain characterization 
The calcium requirement of the predominant salmon calpain was slightly lower than that of ovine m-
calpain (Fig. 3), but half-maximal activity was close to 0.5 mM Ca2+ characterizing it as an m-type 
calpain. 
The autolysis pattern of salmon m-calpain differed from that of ovine m-calpain (Fig. 4). 
Compared to ovine m-calpain, autolysis of the large subunit of salmon m-calpain proceeded at a faster 
rate. The small subunit autolyzed to 21 kDa instead of 18 kDa which is typical for mammalian 
ubiquitous calpains. The autolytic products of calpains, as detected by Western blotting, can be used 
as indicators of calpain activation in postmortem muscle (Geesink and Koohmaraie 1999a). 
Unfortunately, none of the available antibodies reacted with salmon m-calpain. This precludes the use 
of Western blotting as a means to evaluate its possible role in postmortem proteolysis in salmon 
muscle. 
Accurate determination of the specific activity of an enzyme requires a virtually pure enzyme, 
and that the purified enzyme retains its activity throughout the purification stages. Because we were 
interested in comparing the specific activity of salmon m-calpain with ovine m-calpain, an alternative 
approach to determining the specific activity was used. Assuming calpastatin binds both calpains to 
the same extent, a difference in specific activity would be evident from a difference in inhibition at a 
given calpastatin concentration. It was found that both calpains were inhibited to a similar extent by 
recombinant domain 1 calpastatin (Fig. 5), indicating that the specific activity of salmon m-calpain 
against casein was similar to that of ovine m-calpain. 
Using the standard casein assay, the partially purified protein that reacted with the fl-calpain 
antibody did not express significant proteolytic activity. However, when this protein was incubated 
\vith Ca2+, it autolyzed and, because autolysis was inhibited by calpastatin (Fig. 6), the protein is 
characterized as calpain. Using a more sensitive assay with FITC-Iabeled casein as a substrate, it was 
established that this calpain did express caseinolytic activity. The calcium requirement of this calpain 
was similar to that of ovine fl-calpain (Fig. 7), characterizing it as a fl-type calpain. Interestingly, the 
autolysis pattern of this calpain also differed from the mammalian form. Autolysis of the large subunit 
of mammalian fl-calpain proceeds through readily discernable 78 and 76 kDa intermediates. These 
intermediates were not evident during autolysis of salmon fl-calpain (Fig. 6). The specific activity of 
salmon fl-calpain was compared to ovine fl-calpain using Western blotting as a means to estimate the 
relative amounts of the respective enzyme (Fig. 8). Using this method, the specific activity of salmon 
fl-calpain against casein was estimated to be 25% of the specific activity of ovine fl-calpain. 
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Evaluation of the role of calpains in proteolysis of salmon muscle proteins 
During 7 days of refrigerated storage of the salmon muscle some degradation of muscle proteins 
occurred as evidenced by the appearance of a 31-kDa breakdown product (Fig. 9). Degradation of 
troponin-T resulting in protein fragments with a molecular weight of about 30 kDa is the most 
reported change in myofibrillar proteins during storage of mammalian muscles (for a review see 
Robson and others 1997). Antibodies against calpain substrates in mammalian muscle (troponin-T, 
desmin and titin) did not react with these proteins in salmon muscle. As a result, it was not possible to 
determine whether the 31-kDa band is a degradation product of troponin-T, or whether desmin and 
titin are also degraded during refrigerated storage of salmon muscle. The slow rate at which the 
suspected degradation product appears, and the relatively low intensity of the band compared to 
mammalian muscles (Koohmaraie and others 1991), suggest that relatively little proteolysis occurs 
during storage of the muscle. In mammalian muscles, postmortem proteolysis results in weakening of 
the myofibrils. As a result, aged meat yields a higher proportion of smaller fragments than fresh meat 
(Davey and Gilbert 1969; Moller and others 1973). During storage of salmon muscle no evident 
increase in fragmentation of the myofibrils upon homogenization was observed (Fig. 10), which 
supports the suggestion that little proteolysis occurred. 
The appearance of the 31-kDa band during storage of salmon muscle could be reproduced 
by incubating salmon myofibrils with salmon m-calpain (Fig. llA). During the incubation several 
degradation products were released from the myofibrils into the soluble fraction (Fig. lIB). 
Incubation of ovine myofibrils and calpain results in a similar release of soluble degradation products, 
many of which have been identified as degradation products of titin (Geesink and Koohmaraie 
1999b). This similarity suggests that titin is a calpain substrate in salmon muscle. 
Western blotting was used to determine whether fl-calpain autolyzed during storage of the 
muscle (Fig. 12). No obvious decrease in the intensity of the band at 80 kDa was observed and none 
of the autolysis products shown in Fig. 6 was detected. This result indicates that the enzyme was not 
activated or that the calpastatin concentration was sufficient to inhibit autolysis to undetectable levels. 
Using a shallow gradient we were able to achieve baseline separation between calpastatin, fl-
calpain and m-calpain on DEAE-Sepharose Fast Flow. Calpastatin, fl-calpain, and m-calpain eluted 
between 80 and 190 mM NaCl, 230 and 300 mM NaCl, and 365 and 450 mM NaCl, respectively. The 
possibility of partial co-elution of the different components of the calpain system was tested by 
heating the fl-calpain containing fractions and assaying for the presence of the heat-stable calpastatin, 
and by Westen blotting of the different fractions against fl-calpain (data not shown). The baseline 
separation between the different components of the calpain system enabled their quantification (Table 
3). In accordance with the results of Sakamoto and others (1985) on carp muscle, relatively little m-
calpain activity was present in salmon muscle compared to mammalian muscles. fl-Calpain activity was 
about 100 times lower than the level of the enzyme in mammalian muscles (Koohmaraie and others 
1991). Calpastatin levels, however, were relatively high and comparable to those found in beef muscles 
(Koohmaraie and others 1991). After 2 days of storage the calpastatin activity was higher (P < 0.05) 
than at death. The reason for this is unclear. It may be due to a difference in extraction efficiency. 
Levels of m-calpain and fl-calpain activity were numerically, but not significantly (p > 0.05), lower at 2 
days post mortem than at death. This result indicates that the activity of both enzymes is relatively 
stable during postmortem storage. 
The low levels of calpain activity and high calpastatin-to-calpain ratio may explain the low 
levels of postmortem proteolysis (Fig. 9) and the virtual absence of fragmentation of the muscle fibers 
during storage (Fig. 10). In mammalian muscles, a comparable, although less extreme, situation is 
observed with the callipyge sheep. Longissimus muscles from these animals contain about twice the 
amount of calpastatin found in animals not expressing this genotype. As a result, little postmortem 
proteolysis and fragmentation of the muscle fibers is observed during postmortem storage of the 
muscles (Koohmaraie and others 1995; Geesink and Koohmaraie, 1999a). 
The results presented here relate to calpain/ calpastatin activities and postmortem proteolysis 
in sexually immature salmon. Compared to sexually immature salmon, the muscle of mature salmon 
has an inferior texture which has been associated with an increase in muscle proteolysis (Stoknes and 
Rustad 1995); however, no notable differences were observed in calcium-independent proteolytic 
activities between muscles from mature and immature salmon. In addition, spawning salmon have a 
very soft texture and high cathepsin Band L activities (Yamashita and Konagaya 1991). It would, 
therefore, be of interest to compare calpain and calpastatin activities of mature and immature salmon 
muscle. 
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TABLES 
Table 1 - Summary of protein and activity yields at each step of the purification of m-calpain 
from salmon muscle. 
Purification step Protein cone. Activity Total activity 
(mg/mL) (units/mg) (units) 
Extract 1 7 2' a 0071" 275' 
DEAE-Seph. 1.33 0.38 275 
Reactive Red 0.177 28.8 240 
Mono Q 0.256 64.2 132 
'Estimates based on activity after DEAE-Sepharose chromatograpy 
Purification 
(fold) 
53.5 
4056 
9042 
Table 2 - Summary of protein yields at each step ofthe purification of ,,-calpain from salmon 
muscle. 
Purification step 
Extract 
DEAE-Seph. 
Butyl-Seph. 
MonoQ 
Reactive Red 
Protein cone. 
(mg/mL) 
7.8 
1.88 
0.30 
0.90 
0.043 
Total protein 
(mg) 
9750 
461 
83 
9 
0.15 
Table 3 - Calpain and calpastatin activities in salmon muscle at death and after two days 
storage at 5 °C (mean + standard deviation; n = 4). 
Item Day 0 
Calpastatin 4.25' (0.76) 
fJ.-Calpain 8. 7x 10.3 (1.0x 1 0-3) 
m-Calpain 0.24 (0.11) 
.bMeans with different superscripts differ (P < 0.05) 
Day 2 
5.95b (0.31) 
5.6xlO-3 (2.1xl0-3) 
0.16 (0.10) 
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FIGURE CAPTIONS 
Figure 1 - Purification of m-calpain from salmon muscle (SDS-PAGE; 12.5% acrylamide). Lanes 1 to 
5: Molecular weight marker, soluble extract (25 J.lg), DEAE-Sepharose Fast Flow (25 J.lg), Reactive 
Red (10 J.lg), Mono-Q (3 J.lg). 
Figure 2 - Partial Purification of J.l-calpain from salmon muscle. A. (SDS-PAGE; 12.5% acrylamide) 
Lanes 1 to 6: Molecular weight marker, soluble extract (25 J.lg), DEAE-Sepharose Fast Flow (25 J.lg), 
butyl-Sepharose (1.5 J.lg), Mono-Q (1.5 J.lg), Reactive Red (1.1 J.lg). B: (Western blot) Lanes 1 to 7: 
Soluble extract, DEAE-Sepharose Fast Flow, butyl-Sepharose, Mono-Q, Reactive Red, Reactive Red 
(amido black stain), molecular weight marker (amido black stain). 
Figure 3 - Comparison of the Ca2+ -requirement of salmon and ovine m-calpain (n = 3; pooled 
standard deviation = 4.2). 
Figure 4 - Autolysis of salmon and ovine m-calpain (SDS-PAGE; 12.5% acrylamide; 3 J.lg/lane). Lanes 
1 to 5: Salmon m-calpain autolyzed for 0,1,2,5 and 10 min at 25°C. Lanes 6 to 10: Ovine m-calpain 
autolyzed for 0, 1,2, 5 and 10 min at 25°C. Molecular weights are indicated on the left side of the gel. 
Figure 5 - Inhibition of salmon and ovine m-calpain by recombinant ovine domain 1 calpastatin. 
Figure 6 - Autolysis of salmon J.l-calpain in the absence Qanes 2 to 5) and presence Qanes 6 to 9) of 
recombinant ovine domain 1 calpastatin for 0, 5, 10 and 15 min. at 25°C (Western blot; 12.5% 
acrylamide gel; 0.5 J.lg/lane). Lane 1: Molecular weight marker (amido black stain). 
Figure 7 - Comparison of the Ca2+ -requirement of salmon and ovine J.l-calpain (n = 3; pooled 
standard deviation = 4.8). 
Figure 8 - Comparison of the specific activities of salmon J.l-calpain Qane 1) and ovine J.l-calpain Qanes 
2 to 8) against FITC-casein using Western blotting as a means to estimate the amount of enzyme. 
Relative activities (%) are indicated below the respective bands. 
Figure 9 - SDS-P AGE (12.5% acrylamide; 30 J.lg/lane) of myofibrillar proteins from salmon muscle 
after 0,1,3 and 7 days postmortem storage at 5°C Qanes 2 to 4, respectively). The arrowhead at the 
right side of the gel indicates the 31-kDa degradation product. Lane 1: Molecular weight marker. 
Figure 10 - Phase micrograph of myofibrils prepared from salmon muscle after 0,1,3 and 7 days 
postmortem storage at 5 0c. 
Figure 11 - SDS-PAGE (12.5% acrylamide) of the insoluble (A; 30 J.lg/lane) and soluble (B) proteins 
after incubation of salmon myofibrils with salmon m-calpain for 0, 2.5, 5, 10, 15,30 and 60 min at 25 
°C (Lanes 2 to 8). Lane 1: molecular weight marker. The arrow on the right indicates the 31 kDa 
degradation product. 
Figure 12 - Western blot (7.5% acrylamide gel) against salmon J.l-calpain in the soluble muscle fraction 
(30 J.lg/lane) after 0, 1,3 and 7 days postmortem storage of the muscle at 5 °C (Lanes 3 to 6). Lanes 1 
and 2 contain molecular weight marker and purified salmon m-calpain (2 J.lg), respectively. 
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